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Abstract 
 
Oesophageal Squamous cell Carcinoma (OSCC) has a poor survival rate and is highly prevalent 
in southern Africa. Cisplatin is the standard therapeutic drug for OSCC, but has poor efficacy 
due to drug resistance and toxicity. Development of therapies that can be used to reduce the 
dose of cisplatin or offer a more effective tumour response is of great importance. Metformin is 
an anti-diabetic drug that has demonstrated anti-proliferative effects in various cancer types. 
Metformin’s potential as a chemotherapeutic drug is highlighted by its low toxicity profile, 
ability to reduce growth factor signalling, and toxic effects against cancer stem cells.  
In this study we combined metformin and cisplatin to find that whilst metformin reduced the 
proliferation of OSCC cell lines, it antagonised the effects of cisplatin. This was attributed to 
increased levels of reduced thiols as a consequence of enhanced glycolysis, which leads to the 
formation of reducing equivalents such as NADPH. Since metformin enhances the intracellular 
reducing potential, we combined metformin with drugs that are activated in reducing 
environments. Two copper bis(thiosemicarbazones), Cu-ATSM and Cu-GTSM, both retained 
their toxicity in the presence of metformin. Disulfiram (DSF), an established anti-alcoholism 
drug, has previously demonstrated chemotherapeutic potential when conjugated to copper 
(Cu-DSF). DSF and Cu-DSF both exerted potent cytotoxic effects against OSCC cell lines which 
were enhanced by metformin. Metformin increased intracellular copper accumulation when 
combined with DSF and we found that DSF perturbed proteasome function, as observed in 
other studies. Furthermore, we identified a novel target of DSF, the lysosome, and found that 
DSF reduces lysosomal pH, which led to increased accumulation of lysosomal protein 
aggregates, thereby inhibiting autophagy in OSCC cell lines.  
Therefore, the co-prescription of metformin and cisplatin is not advised for OSCC treatment. 
However metformin can be effectively combined with DSF, which inhibits multiple protein 
degradation pathways, to offer a novel treatment option for OSCC.  
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Chapter 1: General Introduction and Overview 
1.1. A Brief History of Cancer 
Many people believe that cancer is as old as the human race. However, paleopathological 
evidence has shown formation of haemangioma in the bones of dinosaurs and early 
mammals, which indicates that cancer actually predates the human race (Haddow, 1936). 
The first medical description of cancer can be traced back to Egypt in 3000 BC, where a case 
of breast cancer was described on the Edwin Smith Papyrus (Mould, 2008). Hippocrates 
(460-370 BC) first used the word carcinos or carcinoma to describe cancer, since the 
projections of a metastatic tumour which he observed resembled that of a crab. These 
words were later translated to the Latin word for crab, cancer by the Roman physician, 
Celcus (25-50 BC) (Hajdu, 2011).  
By the 18th century, scientists had begun performing autopsies, which allowed them to 
diagnose and differentiate between cancers that could be removed by surgery and those 
that had metastasized. In the 19th century, development of microscopy allowed scientists to 
better examine cancers and ensure that they were completely removed during surgery 
(Hajdu, 2011). In 1971, US President Richard Nixon signed the National Cancer Act, and 
declared a war on cancer. The hype about cancer at the time convinced society to invest 
their money in cancer research, and more government funding meant that cancer research 
could erupt. However, people had the false notion that cancer could be cured in a matter of 
5 years and very soon after the act was passed, people demanded answers.  
In the 1970’s, technology was not adequate enough to allow for early detection of cancer. 
Research soon shifted toward identifying the causes of cancer and more emphasis was 
placed on cancer prevention. The identification of carcinogens such as tobacco and UV 
radiation raised public awareness campaigns that helped to reduce the onset of cancer. In 
developed countries, policies were created to increase taxes on cigarettes, which led to an 
eventual decline in cancer caused by cigarette smoke. Due to a decline in sales, cigarette 
companies were forced to target foreign markets. As such, less developed countries with 
fewer restrictions on tobacco policies have now become victim to these tobacco giants 
(Doku, 2010).   
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Cancer is one of the leading causes of disease-related death worldwide. Although diseases 
such as HIV, pneumonia and tuberculosis are more frequently diagnosed than cancer in less 
developed countries, cancer-related mortality still prevails in more developed regions. This 
indicates that once healthcare and awareness are improved in less developed countries, and 
deaths due to non-communicable diseases such HIV and tuberculosis are reduced, cancer 
will still pose a severe threat. Factors such as genetic predisposition, nutrition and diet 
further highlight the importance of region-specific cancer research. Improving research and 
technology will bring humanity closer to finding a solution to this age-old disease.  
1.2. Oesophageal Squamous Cell Carcinoma 
1.2.1. Oesophageal Squamous Cell Carcinoma in Southern Africa 
There are two major histological subtypes of oesophageal cancer, adenocarcinoma and 
squamous cell carcinoma, which differ in their aetiology and epidemiology (Pickens & 
Orringer, 2003). Risk factors associated with adenocarcinoma include Barrett’s oesophagus 
and gastroesophageal reflux. Oesophageal squamous cell carcinoma (OSCC) is associated 
with excessive tobacco and alcohol consumption, low nutrient intake and DNA methylation 
induced by nitrosamines originating from dietary nitrates and nitrites (Stoner & Gupta, 
2001).  
Adenocarcinoma is more prevalent in developed regions, whereas OSCC generally occurs 
more frequently in developing regions, with the exception of China. The frequency of OSCC 
in sub-Saharan Africa is the second highest in the world, where age standardised incidence 
rates are 6.4 per 100 000 in men and 4.6 per 100 000 in women (Arnold et al., 2015) (Figure 
1.1).  According to the South African National Cancer Registry, there is a higher frequency of 
oesophageal cancer in black people compared to other races, which suggests that there may 
be a genetic predisposition (National Health Laboratory Service, 2008). Studies in Asian 
populations suggest that genetic polymorphisms do influence OSCC occurrence (Kuroki et 
al., 2002; Hao et al., 2004). Genome sequencing in an African cohort would be required to 
determine whether genetic factors correlate with increased incidence of OSCC in African 
populations.  
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Figure 1.1: Age-standardized incidence rates for oesophageal cancer based on region, 
subtype and sex. Statistics based on those collected from the International Agency for 
Research on Cancer (IARC) show that the incidence rate of oesophageal squamous cell 
carcinoma in sub-Saharan Africa is the second highest in the world. Of the two 
subtypes squamous cell carcinoma (SCC) is more prevalent than adenocarcinoma (AC) 
in sub-Saharan Africa. The frequency of oesophageal cancer is also higher in males 
compared to females. (Arnold et al., 2015) 
Another motivating factor for OSCC research in South Africa is the fact that mortality rates 
are particularly high for this cancer. Based on information obtained from the interactive IARC 
global cancer statistics website, there are approximately 3868 new cases of oesophageal 
cancer and 3557 deaths due to oesophageal cancer in South Africa per annum (Ferlay et al., 
2013). These staggeringly high mortality rates may be attributed to late detection and a lack 
of cost effective treatment options. This further emphasises the need for improved 
treatment options that are affordable in less developed countries.   
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1.2.3. Stages of Oesophageal Squamous Cell Carcinoma 
Treatment of an OSCC patient is decided based on the stage at which the cancer is detected. 
There are five stages by which oesophageal cancer is graded (Figure 1.2). Differences 
between these stages are characterised by the depth of invasion, the degree of lymph node 
metastasis and the degree of differentiation.  
 
 
 
 
 
 
 
Figure 1.2: Stages of Oesophageal Cancer.  Stage 0, a high grade dysplasia is present, 
but does not spread beyond the mucosa. Stage I – the tumour invades the lamina 
propia and penetrates the submucosa. Stage IIA – the tumour invades the muscle and 
adventitia layers but there are no signs of lymph node metastasis. Stage IIB – the 
tumour invades muscle and adventitia layers and metastasis is detected in 1-2 regional 
lymph nodes. Stage III – the tumour has invaded neighbouring structures and 
metastasis can be detected in 3-6 neighbouring lymph nodes. Stage IV – the tumour 
has invaded adjacent structures and metastasized to lymph nodes and distant organs. 
(Bhaijee & Akhtar, 2013) 
Chemotherapeutic drugs most commonly prescribed for OSCC in South Africa include 
cisplatin, 5-fluorouracil and mitomycin C. These drugs are often combined with each other 
and with radiation and surgery to offer more potent effects against the cancer. At present, 
the primary treatment option for OSCC is surgical resection which is often combined with 
chemotherapy and radiotherapy to offer a more effective treatment, although the 
therapeutic approach used depends on the stage of the cancer. For stage 0 and stage I 
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lesions that do not penetrate into the submucosal layer, there is a slim chance of lymph 
node metastasis. In these cases the conventional and often curative therapy is endoscopic 
resection (Higuchi et al., 2009). An improved outcome was shown in a clinical trial where 
patients with stage 0 oesophageal cancer were treated with cisplatin and 5-fluorouracil 
combined with radiation compared to radiotherapy alone (Herskovic et al., 1992). However 
there are still debates about whether this is more successful than surgery. For  stage I lesions 
that penetrate further into the submucosal layer, endoscopic resection is followed by 
chemoradiotherapy to prevent local relapses (Higuchi et al., 2009).  
Due to post-operative complications, in stage II and stage III lesions that have not yet 
invaded neighbouring structures, pre-operative chemoradiotherapy is first applied in order 
to reduce tumour size followed by surgical resection (Higuchi et al., 2009). Pre-operative 
chemotherapy was compared to post-operative chemotherapy with cisplatin and 5-
fluorouracil, and the former was shown to be more successful as overall survival rates were 
higher (Igaki et al., 2008). Post-surgical survival is poor for patients with stage III lymph node 
metastasis or stage IV distal metastatic cancer. For this reason, chemoradiotherapy without 
surgery is used to improve 5 year survival rates or as a palliative option. Three year survival 
rates were improved in stage III and stage IV OSCC patients receiving 5-FU combined with 
cisplatin and radiation (Ohtsu et al., 1999).  
The importance of chemotherapeutic drugs for OSCC treatment is stressed by their frequent 
prescription in combination chemotherapy as well as in multi-modal therapies involving 
radiation and surgery. Cisplatin is a first-line drug used for OSCC treatment and was 
investigated in the present study. The mechanism of action of cisplatin in cancer and modes 
of resistance will be described further.  
 
 
 
 6 
 
 
1.2.4. Cisplatin – Mode of Action, Resistance and Side Effects 
Barnett Rosenburg discovered the anti-proliferative effects of cisplatin while investigating 
the effects of electrical current on E. coli growth in ammonium chloride buffer. E. coli were 
exposed to electrical currents from a platinum electrode and began to appear elongated and 
growth was stunted. The hydrolysis products of platinum in this buffer led to the formation 
of cisplatin (cis-diamminedichloroplatinum(II) complex), which was soon discovered to be 
the cause of altered morphology in E. coli (Alderden, Hall & Hambley, 2006). A method for 
the rapid synthesis of cisplatin was described in 1970 (Dhara, 1970) and cisplatin was 
approved for the treatment of cancer by the U.S. Food and Drug Administration (FDA) in 
1978.  
Cisplatin enters the cell either by passive diffusion or active transport (Figure 1.3). A linear 
correlation between cisplatin dose and accumulation suggested that the drug might enter 
the cell via passive diffusion. However, combinations of glycolysis and oxidative 
phosphorylation inhibitors that reduce ATP levels impaired cisplatin entry, which suggested 
that some of the drug enters the cell via energy dependent transport (Andrews et al., 1988). 
Transporters that have been implicated in cisplatin uptake include the copper transporter 
(Ctr1) and the organic cation transporters (OCTs) (Ishida et al., 2002; Ciarimboli et al., 2005). 
Knockout studies of transporters such as Ctr1 did not completely abolish the effects of 
cisplatin, suggesting that cisplatin enters the cell via multiple modes (Ishida et al., 2002).  
Upon entry into a cancer cell, cisplatin causes DNA damage, which leads to apoptosis via the 
DNA damage response (Figure 1.3). Cisplatin is administered intravenously and, as the 
chloride ion concentration in the bloodstream is high, this prevents the displacement of 
cisplatin chloride ions. Since the intracellular chloride ion concentration is much lower, 
either one or both of the chloride ions are replaced with water upon cisplatin entry into cells 
(Alderden, Hall & Hambley, 2006). The hydrolysis products of cisplatin are highly reactive 
and this forms the basis for its anti-proliferative effects. Purine bases on DNA are particularly 
susceptible to cisplatin, which causes DNA damage by forming both intrastrand and 
interstrand DNA cross-links. Cisplatin DNA-adduct formation triggers the binding of DNA 
damage response proteins to DNA. If DNA damage is too extensive to repair, apoptosis is 
triggered via DNA damage response pathways (Siddik, 2003).  
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Figure 1.3: Cisplatin Mode of Entry, Action and Resistance. Cisplatin enters the cell by 
passive diffusion or active transport via transporters such as the copper transporter 
(Ctr1). Due to the lower intracellular chloride concentration, cisplatin is hydrolysed to 
its highly reactive form. It then reacts with DNA to form cross-links. This triggers 
apoptosis due to excessive DNA damage. Cisplatin also reacts with intracellular thiols 
such as glutathione and metallothionine and can be targeted for export by glutathione 
S-conjugate (GS-X) pumps. Cisplatin can also be directly removed from the cell by the 
active transporters, ATP7A and ATP7B.  
Two major factors that contribute to cisplatin resistance are reduced formation of cisplatin 
DNA adducts and increased repair of DNA damage. Reduced cisplatin DNA binding can be 
caused by reduced drug accumulation and altered drug sequestration. Reduced intracellular 
accumulation of cisplatin can be caused by reduced influx and increased efflux of the drug. 
Mutations or altered expression of transporter proteins such as Ctr1, involved in cisplatin 
uptake, can lead to reduced drug uptake (Song et al., 2004). Extracellular pH and osmolarity 
may be involved in modulating cisplatin entry via passive diffusion (Andrews et al., 1987). 
The copper exporters, ATP7A and ATP7B are also involved in the export of cisplatin. Over-
expression of ATP7A has been associated with resistance to cisplatin (Samimi et al., 2004).   
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Intracellular thiols such as glutathione and metallothionine can bind to cisplatin and 
sequester the drug in the cytoplasm. Glutathione, metallothionine and thiol-containing 
proteins bind to the central platinum atom of cisplatin, thus preventing the formation of 
cisplatin DNA-adducts. Elevated glutathione and metallothionine levels have been highly 
correlated with cisplatin resistance in numerous cancer types, including oesophageal cancer 
(Andrews, Murphy & Howell, 1987; Godwin et al., 1992; Hishikawa et al., 1997). Similarly, 
increased activity of the glutathione S-conjugate (GS-X) pump has been correlated with 
reduced cisplatin accumulation and increased glutathione levels, indicating that reduced 
drug accumulation is partly due to increased export via GS-X pumps (Kurokawa et al., 1995).  
Nucleotide excision repair (NER) can confer resistance to cisplatin whereas DNA mismatch 
repair can increase cisplatin sensitivity. Cisplatin-DNA adducts can be removed  by NER 
proteins and cells deficient in these proteins were shown to be more sensitive to cisplatin 
than their non-deficient counterparts (Lee et al., 1993). Additionally, enhanced expression of 
NER proteins have been detected in cisplatin-resistant tumour cell lines (Dabholkar et al., 
1994). Reduced expression of mismatch repair proteins allows for DNA synthesis machinery 
to overlook cisplatin-DNA adducts and continue synthesising DNA; the down-regulation of 
mismatch repair genes has been observed in cell lines resistant to cisplatin (Aebi et al., 
1996).  
The Fanconi anaemia (FA) pathway has also been shown to play a significant role in the 
repair of DNA cross-links and alterations in this pathway can alter susceptibility to cisplatin 
(Romick-Rosendale et al., 2013). FA gene products form an FA complex that is involved in the 
repair of DNA interstrand cross-links (Deans & West, 2011). Numerous proteins that have 
been shown to increase breast cancer susceptibility, including the BRCA family, are also 
members of the FA family of proteins. Mutations in these genes leading to non-functional 
products promote cancer formation, but also improve sensitivity to DNA cross-linking agents 
such as cisplatin as these cell types are deficient in their ability to repair interstrand cross-
links (Romick-Rosendale et al., 2013). However, cells that have fully functional FA gene 
products are more resistant to cisplatin (Siddik, 1998).   
Another major factor contributing to poor cisplatin efficacy is the harsh side-effects of the 
drug. Common side effects of cisplatin include pain, mild hearing loss, swelling and general 
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weakness. Cisplatin resistance by tumour cells leads to the prescription of higher doses or 
prolonged chemotherapy in order to improve the anti-cancer effects. However, patients 
treated with high doses of cisplatin can suffer from severe nephrotoxicity. Cisplatin is 
administered intravenously, and apart from having more potent effects on proliferating cells, 
it is not a targeted treatment. The organic cation transporters have been associated with 
cisplatin uptake. Studies show that the OCT2 isoform, which is mainly expressed in the 
kidney, is involved in cisplatin uptake. As such, the expression of OCT2 in kidney cells is 
associated with cisplatin-mediated nephrotoxicity  (Ciarimboli et al., 2005).  
Cisplatin accumulation in renal cells results in numerous toxic events. It impairs renal 
excretion due to increased accumulation in tubules, alters the uptake and metabolism of 
substrates that are involved in regular kidney function, and causes increased calcium levels 
and mitochondrial swelling. This results in increased ROS levels which leads to necrotic cell 
death of kidney cells. Altogether, cisplatin induced nephrotoxicity alters the histology of 
kidneys and impairs renal function (Yao et al., 2007). This impedes the prescription of high 
doses of cisplatin for cancer therapy. Therefore, resistance to cisplatin and lack of drug 
specificity highlights the need for more targeted and less harmful therapies for OSCC.  
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1.3. Emerging Therapies for Oesophageal Squamous Cell 
Carcinoma 
1.3.1. Potential Drugs for Oesophageal Cancer Treatment 
The drugs currently prescribed for oesophageal cancer lack in their ability to effectively 
reduce the size of late stage tumours. There is a need for more effective chemotherapeutic 
options that can be combined with surgery for stage II and III tumours and drugs that offer 
better palliation for non-resectable tumours. Various new drugs are now being tested for the 
treatment of oesophageal cancer in pre-clinical studies as well as clinical trials. These include 
monoclonal antibodies, receptor tyrosine kinase inhibitors, angiogenesis inhibitors and drugs 
that target metabolic pathways.  
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase which has an 
extracellular ligand binding domain and an intracellular region containing a tyrosine kinase 
domain. When a ligand binds to the receptor, this results in dimerization and 
autophosphorylation of the intracellular kinase domain. Activation of EGFR triggers a 
signaling cascade that leads to cell survival, proliferation and angiogenesis. EGFR is 
upregulated in 71-88% of oesophageal cancers, including OSCC (Ozawa et al., 1987; Laskin & 
Sandler, 2004). Another member of the epidermal growth factor receptor family, HER2, has 
also been reported to be upregulated in 30% of OSCC cases and expression is associated 
with poor prognosis (Sato-Kuwabara et al., 2009; Zhan et al., 2012).  HER2 is a binding 
partner for other members of the same family of growth factor receptors.  
Monoclonal antibodies targeted at EGFR and HER2, as well as receptor tyrosine kinase 
inhibitors, are now being developed and tested for cancer therapy. Cetuximab is a 
monoclonal antibody targeted at EGFR. It is currently prescribed for the treatment of 
colorectal cancer and ongoing trials are assessing its use in combination with other drugs 
and radiation for metastatic colorectal cancer (Cutsem et al., 2009). Cetuximab did not have 
significant effect as a monotherapy for oesophageal cancer treatment, however phase II 
clinical trials for its use in combination with other drugs are ongoing (De Vita et al., 2011). 
Trastuzumab (Herceptin) is a monoclonal antibody targeted at HER2. Antibody-mediated 
apoptotic cell death occurred in OSCC cell lines with various degrees of HER2 expression 
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treated with Herceptin, and levels of cell death correlated with the degree of HER2 
expression (Mimura, Kono, Hanawa, Kanzaki, et al., 2005). Early studies have shown that the 
combination of Cetuximab and Herceptin is effective against OSCC cell lines that over-
express both EGFR and HER2. However, this did not correlate with receptor expression 
levels, suggesting that other mechanisms may be involved in the anti-proliferative effects of 
these drugs (Kawaguchi et al., 2007).  
Monoclonal antibodies and tyrosine kinase inhibitors both target receptor tyrosine kinases in 
different ways. Whereas monoclonal antibodies bind to the extracellular domain and inhibit 
ligand binding, tyrosine kinase inhibitors prevent ATP binding to the intracellular domain to 
block catalytic activity of the receptor. The receptor tyrosine kinase inhibitors, Gefitinib and 
Erlotinib, have recently been tested in phase II clinical trials in combination with 
chemoradiotherapy for the treatment of oesophageal cancer. However, no significant 
benefit was shown with Gefitinib, and only partial benefit with Erlotinib (Rodriguez et al., 
2010; Ilson et al., 2011). Another target for treatment is angiogenesis, the process required 
by tumours to sustain growth by modifying the surrounding vasculature. Vascular 
endothelial growth factor (VEGF) is frequently overexpressed in many cancers including 
oesophageal cancer. Bavacizumab is a monoclonal antibody targeted at VEGF, and acts to 
block angiogenesis. Some benefit was shown when Bevacizumab was combined with 
cisplatin and Irinotecan for the treatment of gastroesophageal junction adenocarcinoma 
(Shah et al., 2006). There is no evidence of the effects of this drug on OSCC.  
Although many of the targeted therapies described above have shown some therapeutic 
benefit, the cost of these drugs make it near to impossible to implement in resource-poor 
countries where OSCC is prevalent, such as South Africa. HER2 is frequently over-expressed 
in breast cancer and Herceptin has been approved by the South African Oncology 
Consortium for the treatment of breast cancer. In 2006, a South African Attorney, Lisa 
Metzer won a case against Discovery for breach of contract. Discovery was liable to pay for a 
year's supply of Herceptin for 8 patients who were to be treated once every three weeks. 
The treatment cost was R450 000 per patient, and Discovery had argued that it was 
unfeasible to pay these high prices as they would have to increase monthly premiums of 
other insurers in order to cover the costs. Since then, medical aid schemes have changed 
their policies so that they require co-payment for Herceptin, which is unaffordable by most 
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people (Independent Online News - South Africa, 2006). It is therefore crucial to find more 
effective anti-cancer agents that are affordable in less developed countries such as South 
Africa.  
Over the past few years, there has been growing interest in cancer cell metabolism and its 
potential as a target for cancer therapy. Fatty acid synthase (FAS) inhibitors have been 
considered for oesophageal cancer treatment due to the high expression of FAS in this 
cancer type (Nemoto et al., 2001). However, these drugs are still at the pre-clinical stage and 
more research is required before they can be developed into a prescribed drug. More 
recently, there has been heightened interest in the use of metformin for oesophageal cancer 
treatment. Metformin is an anti-diabetic drug with an established clinical profile. This drug is 
the topic of investigation for this project and will be described in detail.  
1.3.2. Metformin – From Anti-Diabetic to Chemotherapeutic Drug 
The use of metformin (dimethyl biguanide hydrochloride) can be traced as far back as 
medieval Europe, when Galega officinalis was used as a herbal medicine for the treatment of 
diabetes like symptoms. In the late 1800’s, it was discovered that G. officinalis was rich in 
guanidine and in 1918 this compound was shown to reduce glucose levels in animals. 
However, due to the toxicity of guanidine, attention shifted to a second compound found in 
the plant, galegine (isoamylene guanidine) (Bailey & Day, 2004). Once the structure of 
galegine was determined, analogues of the compound were soon developed.  
Metformin, a galegine analogue synthesised in Dublin in 1922, was shown to have glucose 
lowering effects in people and was much less toxic than guanidine and galegine (Shenfield, 
2013). Due to the development of insulin for diabetes treatment, attention toward 
biguanide research waned, and it was not until the 1950’s that research in this field 
continued. In 1957, Jean Sterne published research where he proposed using metformin for 
diabetes treatment under the name “Glucophage”. At the same time, two analogues that 
were slightly more potent than metformin, phenformin and buformin, were also 
synthesised. But these were retracted by 1970 due to an increased risk of lactic acidosis and 
cardiac mortality (Bailey & Day, 2004). Metformin did not show severe side-effects like its 
counterparts, which led to commercialisation of the drug.  
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Metformin is now the first line drug prescribed for the treatment of type II diabetes and is 
also prescribed for insulin resistance and metabolic syndrome (American Diabetes 
Association, 2014). Common side effects of metformin include mild gastrointestinal upset 
such as diarrhoea, stomach pain and loss of appetite and rare side effects include breathing 
difficulties, cramps, skin problems and lactic acidosis (Datapharm, 2014). A meta-analysis 
showed that  metformin-associated lactic acidosis mainly occurred in individuals suffering 
from renal impairment or those who had overdosed (Stades et al., 2004).  
The glucose lowering effects of metformin have been attributed to reduced intestinal 
absorption of glucose, reduced hepatic gluconeogenesis and increased glucose uptake and 
utilization by muscle cells (Cusi, Consoli & DeFronzo, 1996; Hundal et al., 2000). Additionally, 
metformin causes reduced insulin secretion from pancreatic β-cells and may therefore 
reduce pancreatic insulin secretion (Leclerc et al., 2004). Diabetes is associated with a higher 
risk of cancer, which may be attributed to higher circulating glucose levels and increased 
expression of insulin and insulin-like growth factor receptors on the surface of cancer cells 
(Giovannucci et al., 2010).  
In 2005, a role for metformin in cancer became evident when a case control study showed 
that metformin was associated with a lower risk of cancer in diabetic patients (Evans et al., 
2005). It was also shown that diabetic patients suffering from breast cancer who were 
treated with metformin and neoadjuvant chemotherapy had higher pathological complete 
response rates than diabetics not treated with metformin and non-diabetic breast cancer 
patients, who also received neoadjuvant chemotherapy (Jiralerspong et al., 2009). 
Numerous cohort studies and randomized controlled trials have since shown that metformin 
can reduce the risk of breast, colorectal, liver, lung and pancreatic cancers (Emami Riedmaier 
et al., 2013). In vitro research has shown that metformin reduces the growth of numerous 
cancer cell lines including breast, ovarian and endometrial cancer and it induced apoptosis in 
pancreatic cancer cells (Gotlieb et al., 2008; Alimova et al., 2009; Kisfalvi et al., 2009). More 
interestingly, metformin was shown to target breast cancer stem cells that are frequently 
resistant to chemotherapy (Hirsch et al., 2009). Therefore metformin may be able to 
enhance the response of tumours to current chemotherapeutic agents by targeting a 
different cell population within the tumour microenvironment.  
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Due to its well-established tolerance profile, there are many clinical trials currently 
investigating the use of metformin for cancer therapy. Metformin as a monotherapy is being 
tested for the treatment of non-diabetic patients suffering from early stage cancer, including 
breast and endometrial cancer (NCT01101438 and NCT01205672). Metformin is being 
combined with other chemotherapeutic drugs and radiotherapy to treat metastatic cancer 
of the head and neck or lung (NCT01333852 and NCT02115464). Metformin is also being 
tested as a pre-surgical therapy for cancers including breast and prostate cancer 
(NCT00930579 and NCT01433913). Clinical trials for the use of metformin to treat 
oesophageal cancer are currently focused on adenocarcinoma as this is the more prevalent 
subtype in western countries (NCT01447927 and NCT01465113).  
A meta-analysis of cohort studies testing the effects of metformin on cancer in diabetic 
patients showed that cancer-related mortality was reduced by at least 20%. However, 
randomised controlled trial data did not show a significant benefit of metformin (Noto et al., 
2012). This indicates that the anti-proliferative effects of metformin may be dependent on 
cancer type, which highlights the importance of investigating the effects of metformin on 
each cancer type in order to determine whether it may or may not be useful.  
Although metformin is widely prescribed for the treatment of diabetes and is now being 
tested for cancer therapy, a direct target of the drug has not been identified. Metformin is 
known to reduce systemic glucose and insulin levels. This alone however, cannot be the 
reason for its anti-cancer effects as other glucose lowering agents are not as effective as 
metformin against cancer in diabetic patients (Soranna et al., 2012). Studies have shown that 
metformin promotes phosphorylation and activation of the AMP-activated protein kinase 
(AMPK) (Zhou et al., 2001). This kinase plays a central role in metabolic regulation at the 
whole-body and cellular levels. The roles of metformin and AMPK in metabolic regulation in 
cancer will be discussed further.   
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1.4. Targeting Cancer Cell Metabolism 
1.4.1. Altered Metabolism is an Emerging Hallmark of Cancer 
Growing tumours are able to maintain enhanced cell proliferation and are able to survive 
nutrient deprivation and hypoxia. In order to maintain their phenotype, cancer cells must 
reprogram their metabolic activities in order to cope with the requirements of sustained 
proliferation in the absence of a regular nutrient and oxygen supply. In order to provide for 
the basic needs of rapidly proliferating cells, cancer cell metabolism is altered in a way that 
increases ATP generation, increases macromolecular biosynthesis and there is tightened 
maintenance of an altered redox state. As such, regulation of essential macromolecules such 
as carbohydrates, lipids, amino acids and nucleic acids is altered in cancer.  
Altered metabolism in cancer was first described by Otto Warburg, who showed that cancer 
cells are more reliant on glycolysis for energy production than oxidative phosphorylation, 
even in the presence of oxygen (Warburg, 1956). Warburg proposed that cancer cells have 
mitochondrial defects that impair their ability to break down glucose by oxidative 
phosphorylation. However, more recent studies indicate that many cancer cell lines have 
functional mitochondria and still preferentially select glycolysis as opposed to oxidative 
phosphorylation for their metabolic demands (Moreno-Sánchez et al., 2007; Frezza & 
Gottlieb, 2009).  
Glycolysis is a much less efficient form of energy production compared to oxidative 
phosphorylation. However, glycolytic degradation may better provide for the biosynthetic 
requirements of proliferating tumour cells by providing carbon based precursors required for 
nucleotide, lipid and protein synthesis. The high energy demands of proliferating cells may 
be compensated for by extremely high rates of glycolysis observed in cancer cells 
(DeBerardinis et al., 2008). As such, glycolysis is more efficient in catering for the needs of 
growing tumours than oxidative phosphorylation. This type of metabolic reprogramming is 
crucial for tumour progression, and is now regarded as an emerging hallmark of cancer 
(Hanahan & Weinberg, 2011).  
Taking this into consideration, these deregulated metabolic pathways may serve as 
alternative targets for cancer chemotherapy. Therapies that have been used to target a 
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single rate-limiting step of these metabolic pathways, such as glucose mimetics or 
hexokinase inhibitors, have shown some benefit but were not cytotoxic. There is now a shift 
toward designing drugs or drug combinations that have multiple targets in a metabolic 
pathway to offer a more effective chemotherapeutic approach (Moreno-Sánchez et al., 
2010). 
1.4.2. Metformin and the AMPK Signaling Pathway 
The adenosine monophosphate (AMP) activated protein kinase (AMPK) is an energy sensing 
molecule involved in metabolic regulation (Hardie, 2005). AMPK is involved in metabolic 
regulation as it activates pathways that produce energy and inhibits pathways that consume 
energy. AMPK phosphorylates numerous targets involved in carbohydrate, lipid and protein 
metabolism and also plays a role in the cell cycle by promoting senescence (Carling, 2004). A 
role for AMPK in cancer became apparent when studies identified LKB1 (liver kinase B1) as 
the major AMPK kinase (Hawley et al., 2003). LKB1 is a well-known tumour suppressor gene, 
inactivation of which leads to Peutz-Jeghers syndrome (Hemminki et al., 1998). Peutz-
Jeghers syndrome is a disease that results in the onset of intestinal hamartomous polyps and 
is highly associated with the onset of colorectal and gastro-intestinal cancers later in life 
(Volikos et al., 2006). LKB1 may also be involved in familial predisposition to breast cancer 
(Chen & Lindblom, 2000). Two other less investigated kinases, CaMKK and TAK1, have also 
been shown to phosphorylate AMPK (Hurley et al., 2005; Momcilovic, Hong & Carlson, 
2006). 
In 2001, Zhou et al. first showed that metformin promoted the activation of AMPK (Zhou et 
al., 2001). The exact mechanism responsible for increased AMPK phosphorylation in 
response to metformin is yet to be determined (Rena, Pearson & Sakamoto, 2013). Some of 
the interactions between metformin and the AMPK signalling pathway are outlined in Figure 
1.4. It is hypothesised that metformin promotes AMPK activation by increasing the AMP:ATP 
ratio. Metformin has been shown to inhibit complex I of the mitochondrial electron 
transport chain (El-Mir et al., 2000). This abrogates adequate proton gradient formation that 
is required to drive ATP synthesis by complex V, thus causing an increase in the AMP:ATP 
ratio. Complex I inhibition prevents the oxidation of NADH to NAD+, which is required as a 
cofactor in the tricarboxylic acid (TCA) cycle. A reduction in TCA flux reduces mitochondrial   
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Figure 1.4: Metformin and its Interactions with the AMPK Signaling Pathway. 
Metformin exerts whole body effects by inhibiting hepatic glucose secretion and 
insulin secretion by pancreatic β cells. It exerts direct cellular effects upon entry via 
organic cation transporters. Metformin inhibits complex I of the mitochondrial 
respiratory chain which results in an increase in the AMP:ATP ratio, this promotes 
AMPK phosphorylation by an upstream kinase such as LKB1. Upon activation, AMPK 
promotes GLUT4 translocation to the plasma membrane which facilitates glucose 
uptake and glycolysis. AMPK promotes cell cycle arrest by inhibiting cyclin D1 and also 
promotes p53 stabilisation. AMPK and metformin inhibit protein synthesis and 
promote autophagy via inhibition of the mTOR signaling cascade. 
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oxidative phosphorylation and further impairs ATP production (Luengo, Sullivan & Heiden, 
2014). AMP binding promotes AMPK phosphorylation by upstream kinases, therefore, 
metformin indirectly activates AMPK due to an increase in the AMP:ATP ratio. AMPK can 
also be activated in response to low glucose levels (Laderoute et al., 2006). 
Upon activation, AMPK phosphorylates multiple downstream targets involved in the 
degradation of macromolecules such as carbohydrates, lipids and proteins. AMPK plays a 
direct role in glycolysis by promoting translocation of the GLUT4 transporter to the plasma 
membrane, thus enabling glucose entry into the cell (Figure 1.5). AMPK activation also 
promotes transcription of the GLUT4 and GLUT1 genes (Kurth-Kraczek et al., 1999; Zheng et 
al., 2001). AMPK further promotes glycolysis by activating 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (PFKFB3), thus increasing fructose 2,6-bisphosphate 
levels (Marsin et al., 2000).  
AMPK promotes cell senescence by halting cell cycle progression at the G1/G0 stage. Cell 
division and progression of the cell cycle is an energy consuming processes that must be 
slowed down to allow a cell to conserve energy. AMPK is involved in regulation of the cell 
cycle as it was shown to block G1-S transition via phosphorylation of p53Ser15 (Jones et al., 
2005). Cell cycle progression is tightly regulated by cyclins and cyclin dependent kinases. 
Cyclin D1 is involved in the transition from G1 to S-phase. Metformin-induced activation of 
AMPK was shown to block cell cycle progression and reduce cyclin D1 levels in breast cancer 
cells (Zhuang & Miskimins, 2008).  
AMPK also inhibits protein synthesis by suppressing mammalian target of rapamycin (mTOR) 
complex 1 formation. The mTORC1 complex is a kinase that couples growth factor signaling 
with amino acid availability in order to regulate cell growth. Growth factor stimuli such as 
insulin receptor activation trigger the Akt signaling pathway, which promotes activation of 
mTORC1 via a Rag GTPase. There are various downstream targets of mTORC1, one of them is 
the ribosomal protein S6 kinase (p70S6K), which plays an important role in ribosomal 
biogenesis and nascent protein synthesis (Ma & Blenis, 2009). Inhibition of mTOR by AMPK 
leads to an inhibition of p70S6KThr389 phosphorylation and hence protein synthesis, which is 
essential for tumour growth, is also reduced.  
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AMPK and mTORC1 play an important role in regulating autophagy. AMPK activates a 
mammalian autophagy initiating kinase (Ulk1), whereas phosphorylation of Ulk1 by mTORC1 
leads to inhibition of autophagy initiating complex formation (Kim et al., 2011). In addition, 
mTORC1 exerts a second level of control over autophagy by inhibiting other members of the 
autophagy initiating complex such as mATG13. Autophagy has mixed roles in cancer 
progression as turnover of old proteins and organelles can be useful for cell survival by 
replenishing pools of amino acids required for protein synthesis. On the other hand, over-
induction of autophagy can lead to cell death by apoptosis (Morselli et al., 2009).  
1.4.3. AMPK Independent Effects of Metformin 
In addition to the AMPK-dependent effects of metformin described above, there is growing 
evidence that metformin also exerts AMPK independent effects. A recent study showed that 
the effects of metformin in cancer may be attributed to reduced energy charge due to 
impaired mitochondrial function (Andrzejewski et al., 2014). Metformin has been shown to 
inhibit complex I of the mitochondrial respiratory chain (El-Mir et al., 2000). Inhibition of 
complex I hampers electron transfer and disrupts the proton gradient required for ATP 
production. This leads to an increase in the intracellular AMP:ATP ratio. Although there is 
still debate about whether complex I is a direct target for metformin, there is a consensus 
that metformin leads to an increase in the AMP:ATP ratio and as such, alters energy charge 
in the cell. Apart from AMPK activation, reduced ATP levels may have a range of other 
effects.   
Metformin also inhibits a second mitochondrial enzyme, glycerol-phosphate dehydrogenase 
(Madiraju et al., 2014), which is involved in shuttling NADH from the cytosol into 
mitochondria. NADH is utilized as a cofactor by complex I, hence inhibition of mitochondrial 
glycerol-phosphate dehydrogenase, along with complex I, impairs mitochondrial NADH 
oxidation and further disrupts electron transfer and ATP production (Luengo, Sullivan & 
Heiden, 2014). Reduced ATP production by mitochondrial oxidative phosphorylation led to 
higher levels of aerobic glycolysis in response to metformin treatment in breast cancer cells 
(Andrzejewski et al., 2014).  
Metformin can reduce glucose levels independent of AMPK activation. Glucagon is a peptide 
hormone produced by pancreatic cells and is involved in promoting hepatic gluconeogenesis. 
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ATP is required for the synthesis of cyclic AMP (cAMP), a second messenger required for 
glucagon signaling (Miller et al., 2013). Reduced ATP levels prevent cAMP production via 
adenylyl cyclase and therefore glucagon signaling is impaired. Reduced glucagon signaling 
reduces hepatic gluconeogenesis, and as such, metformin can reduce systemic glucose levels 
in the absence of AMPK. Metformin was shown to reduce gluconeogenesis in hepatocytes 
that lacked AMPK or LKB1 (Foretz et al., 2010).  
Metformin blocks cell cycle progression and inhibits mTOR activity in the absence of AMPK. 
Cell cycle progression was blocked in prostate cancer cells that lacked AMPK in response to 
metformin. This was associated with a decrease in cyclin D1 levels (Ben Sahra et al., 2008). 
Mouse embryonic fibroblasts that expressed mutant AMPK or AMPK double-knockout cells 
showed reduced p70S6K phosphorylation, indicative of reduced mTORC1 signaling in 
response to metformin (Kalender et al., 2010). This was dependent on the presence of Rag 
GTPases. Therefore, mTORC1 inhibition can occur independently of AMPK activation in a Rag 
GTPase dependent manner.  
The hypothesis that metformin exerts its effects through a reduction of energy charge is now 
gaining more favour. Although metformin has been shown to inhibit complex I, the 
mechanism by which this occurs is still not known, and a direct target for metformin is yet to 
be identified. It would be of great benefit to elucidate the exact molecular mechanism by 
which metformin acts as this would help determine which cancers may be more susceptible 
to the drug. For now, more rigorous in vitro and in vivo testing is still required to determine 
which cancers metformin may be most effective against.  
 
1.4.4. Redox Regulation in Cancer 
Reactive oxygen species (ROS) are a group of highly reactive oxygen containing molecules 
and mainly include the superoxide free radical, O2
•-, singlet oxygen, 1O2, the hydroxyl free 
radical, OH•
-
, and hydrogen peroxide, H2O2. ROS play a role in cell signaling due to oxidation 
of protein kinases and phosphatases. High ROS levels have been shown to promote genomic 
instability and contribute to tumourigenesis (Fruehauf & Meyskens, 2007). For these 
reasons, antioxidants are considered to be beneficial for cancer therapy. Although elevated 
 21 
 
 
ROS levels are a feature of many cancers and promote tumourigenesis, excessive ROS levels, 
above the tumour inducing threshold, can exert chemotherapeutic effects by promoting 
cancer cell death (Cairns, Harris & Mak, 2011). This forms the basis of using ionizing radiation 
for cancer therapy which increases ROS levels above this threshold and in turn leads to 
apoptosis of cancer cells (Wang & Yi, 2008). 
Mitochondria are the main producers of intracellular ROS.  Damage to mitochondrial DNA 
has been shown to impair electron transport, as increased intracellular OH•
-
 levels have 
been observed in osteosarcoma cells. Rotenone is known to inhibit complex I of the 
mitochondrial respiratory chain and it has been shown to increase intracellular OH•
-
 levels 
(Indo et al., 2007). However, rotenone has also been shown to reduce ROS production in 
isolated mitochondria by impairing reverse electron flux through complex I. Similar to 
rotenone, metformin has been shown to hamper reverse electron flux and ROS production 
in isolated mitochondria, but not to the same extent as rotenone (Batandier et al., 2006). 
This suggests that metformin inhibits complex I in a manner slightly different to rotenone, 
and the exact mechanism by which metformin inhibits complex I is not yet known. Studies 
have shown that metformin reduced ROS production in bovine aortic endothelial cells but its 
effects on ROS production in cancer cells are still poorly defined (Ouslimani et al., 2005).  
Intracellular ROS levels are tightly regulated by anti-oxidant molecules such as glutathione, 
thioredoxin, superoxide dismutase and peroxidases (Scherz-Shouval & Elazar, 2011). The 
glutathione anti-oxidant defence system is a major intracellular pathway for ROS 
detoxification. Glutathione can exist in either a reduced (GSH) or oxidised (GSSG) state and 
pools of GSH are replenished due to the activity of glutathione reductase. Glutathione 
reductase uses NADPH as a cofactor which is oxidised to NADP+. Glucose-6-phosphate (G-6-
P) produced during the first step of glycolysis can be shunted into the pentose phosphate 
pathway (PPP). This replenishes NADPH pools as it utilises NADP+ as a cofactor for the 
conversion of G-6-P to 6-phosphogluconolacton via glucose-6-phosphate dehydrogenase 
(Sattler & Mueller-Klieser, 2009). Therefore, increased shunting of glycolytic intermediates 
into the PPP provides the NADPH required for glutathione reduction and increased glycolysis 
contributes to a more reducing intracellular environment.  
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Considering that cancer cells have increased levels of glycolysis, drugs such as metformin 
which increase glycolytic flux could enhance the reducing potential of cancer cell lines by 
increasing NADPH or GSH levels. It would be of value to consider combining metformin with 
drugs that are activated in reducing environments for cancer treatment. We have shown 
that metformin increases the reducing potential of OSCC cell lines (Damelin et al., 2014). We 
also effectively combined metformin with disulfiram and copper bis(thiosemicarbazones) 
which are cytotoxic agents activated in reducing environments. The combination of 
metformin and reductively activated drugs with chemotherapeutic potential, may offer a 
novel approach to OSCC treatment that is both effective and affordable.  
 
 
 
  
 23 
 
 
1.5. Reductively Activated Drugs for Cancer Therapy 
1.5.1. Copper bis(thiosemicarbazones) 
The bis(thiosemicarbazone), glyoxal bis(thiosemicarbazone) (GTSM) was first synthesised by 
Neuberg et al. in 1909 (Neuberg, Neimann & Salkowski, 1909). However, commercially 
available glyoxal used in its synthesis at the time contained impurities such as formaldehyde, 
glycoaldehyde and glyoxilic acid, which could yield toxic thiosemicarbazone products during 
synthesis. The preparation of this compound was improved in 1958 and was shown to have 
anti-cancer effects (French et al., 1958). A marked reduction in DNA synthesis and mild 
reductions in protein and RNA synthesis were identified as the mechanism responsible for 
the anticancer effects of bis(thiosemicarbazones) (Sartorelli & Booth, 1967). French and 
Freedlander showed that GTSM and various other bis(thiosemicarbazone) derivatives 
improved survival of Sarcoma 480 mice when administered orally, but not when 
administered via intra-peritoneal injection (French & Freedlander, 1960). It was 
hypothesised that the anti-cancer effects of these compounds may be dependent on their 
metal chelating properties (French et al., 1958).  
Whilst bis(thiosemicarbazones) showed a potential benefit in vivo, initial studies showed 
that the doses required for anti-cancer effects in vitro were particularly high, which may 
have been due to low copper content in culture medium (Petering, Buskirk & Underwood, 
1964). A cupric chelate of kethoxal bis(thiosemicarbazone) synthesised in the late 1960’s 
was shown to be more toxic and also prolonged the life-span of mice bearing sarcoma 
(Sartorelli & Booth, 1967). However, kethoxal bis(thiosemicarbazone) had also been shown 
to bind to numerous metabolites, including proteins, in higher animals (Underwood et al., 
1959). Therefore, numerous analogues of the bis(thiosemicarbazones) have been 
synthesised and investigated. Many of these analogues resulted in moderate to severe 
weight loss in mice. Additionally Cu-GTSM, which was shown to exert beneficial effects 
against tumour bearing mice, is insoluble in aqueous media, resulting in drug accumulation 
at the site of injection (French et al., 1958). These effects, along with heightened interest in 
cisplatin for cancer therapy, led to a decline in interest and research on the 
bis(thiosemicarbazones).  
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Copper bis(thiosemicarbazone) research was renewed in the late 1980’s, this time to be 
applied as a radiopharmaceutical for positron emission tomography (PET) (Green, 
Klippenstein & Tennison, 1988). In  1997, Fujibayashi et al. first proposed the use of copper 
diacetyl-bis(4-methyl-3-thiosemicarbazone) (64Cu-ATSM) as a radiopharmaceutical 
(Fujibayashi et al., 1997). 64Cu-ATSM showed promise as it was easily distributed and 
penetrated the brain and heart, it showed selectivity for hypoxic tissue and was easily 
cleared from the blood pool (Fujibayashi et al., 1997). More recent reports documenting 
some of the mechanisms responsible for hypoxia selectivity of Cu-ATSM and comparing 
these effects to other copper bis(thiosemicarbazones) have allowed research on these drugs 
to progress to clinical trials (Xiao et al., 2008; Paterson & Donnelly, 2011).  
Renewed interest in copper bis(thiosemicarbazone) research for radiopharmaceuticals has 
prompted further studies on the use of these agents for cancer therapy. 64Cu-ATSM is 
currently undergoing clinical trials for use as an imaging agent for cancer detection 
(NCT00794339). This highlights the fact that Cu-ATSM is tolerated by humans and that it 
targets hypoxic cancer tissues. Further studies will be required to confirm whether it can be 
tolerated for longer periods of time that are effective for cancer therapy. The rationale 
behind using Cu-ATSM as a chemotherapeutic agent is that it may serve to deliver excess 
amounts of copper to hypoxic tissue leading to cell death due to heavy metal toxicity. 
Palanimuthu et al. recently synthesised a number of new bis(thiosemicarbazone) complexes. 
The glyoxal-based copper bis(thiosemicarbazones) were more toxic than Cu-ATSM and 
resulted in a better tumour response (Palanimuthu et al., 2013). However, these analogues 
were not targeted or specific to cancer tissue. More studies are required to elucidate their 
molecular mechanism of action and to determine whether new analogues can be derived to 
offer better anti-tumour effects with reduced toxicity.  
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1.5.2. Disulfiram 
Disulfiram (tetraethylthiuram disulphide) was first synthesised in 1881 by M. Grodzki, a 
chemist in Berlin, but received little attention back then (Kragh, 2008). It was introduced in 
the rubber manufacturing process to accelerate the vulcanising process in the early 1930’s. 
In 1937, a physician at a rubber manufacturing plant, E. E. Williams, first noticed that factory 
workers exposed to disulfiram experienced unpleasant symptoms upon alcohol consumption 
and voluntarily abstained from alcohol (Suh et al., 2006). Between 1940 and 1945 in 
Denmark, Erik Jacobsen and Jens Hald conducted research on disulfiram and noticed that 
disulfiram caused an unpleasant reaction to alcohol (Kragh, 2008). Tetraethylthiuram 
monosulfide (Sulfiram) was shown to be effective in the treatment of scabies, which is a skin 
infection caused by the mite Sarcoptes scabiei (Gordon & Seaton, 1942). Disulfiram was also 
used to treat domestic animals for scabies and intestinal worms in the early 20th century. 
Jacobsen and Hald discovered that the effects of disulfiram in the treatment of scabies and 
intestinal worms were due to the formation of disulfiram-copper chelates, as lower life 
forms rely on copper rather than iron for oxygen transport. In trying to purify disulfiram 
contaminated with copper, the group figured out a method to improve drug absorption. 
Jacobsen and Hald patented this method for the preparation of disulfiram under the name 
“Antabuse” in 1952 (Kragh, 2008).  
The prescription of disulfiram (DSF) for alcohol abuse promoted pharmacological research 
on its biochemical mechanism of action, which showed that there are a number of 
metabolites of disulfiram. Upon ingestion, disulfiram is partly reduced to 
diethyldithiocarbamate (DDC), which is unstable in acidic solutions and rapidly converts to 
carbon disulphide and diethylamine. Alternatively, DDC is a strong metal chelating molecule, 
which rapidly forms a complex with cupric ions to form a bis(diethyldithiocarbamato) copper 
complex (Cu(DDC)2). Cu(DDC)2 is acid stable and hydrophobic, hence easily absorbed along 
the gastrointesintal tract. Upon entry into the bloodstream, DSF and Cu(DDC)2 are reduced 
to DDC, which can be further metabolised to diethyldithiomethylcarbamate (Me-DDC) and 
the glucuronic acid of DDC. Me-DDC is converted to diethylthiomethylcarbamate (Me-DTC) 
by oxidative desulfuration mediated by microsomal p450 mono-oxygenases. Me-DTC is 
involved in the disulfiram-ethanol reaction as it inhibits mitochondrial aldehyde 
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dehydrogenase leading to accumulation of acetaldehyde and the harsh side effects of DSF in 
the presence of alcohol (Johansson, 1992). 
During early stages of investigation, high doses of disulfiram were prescribed (2000-3000 mg 
per day) which led to psychosis in some patients (Martensen-Larson, 1951). The dose was 
then reduced to a more tolerable 500-2000 mg per day, however this led to the deaths of 4 
patients who had consumed large amounts of alcohol (Jacobsen, 1952). Today, the 
recommended daily dose is 250 mg, and should not exceed 500 mg. In the presence of 
alcohol, a severe disulfiram ethanol reaction results, causing facial flushing, throbbing in the 
head and neck, headache, nausea, vomiting, sweating, thirst, chest pain, palpitations, 
dyspnea, hyperventilation, tachycardia, confusion, arrhythmias, and convulsions (Elenbaas, 
1977). However, in the absence of alcohol, the side effects of disulfiram are mild, and 
include drowsiness, headache, skin rash and impotence. Hepatotoxicity occurs in 
approximately 1 in 30 000 patients treated with disulfiram, but can be reversed if treatment 
with disulfiram is stopped upon first signs of liver damage (Chick, 1999). As such, liver 
function is strictly monitored and patients receiving disulfiram are educated on the potential 
signs and symptoms of liver disease.  
The first evidence for the use of disulfiram in cancer was in 1974, when Lee Wattenberg 
showed that disulfiram suppressed the formation of benzopyrene or 
dimethylbenzanthracene induced gastric tumours in Sprague-Dawley rats (Wattenberg, 
1974). Wattenburg later showed that disulfiram also prevented the formation of 
dimethylhydrazine induced neoplasias of the large intestine in mice (Wattenberg, 1975). 
Considering that mice were treated with tumour supressing agents either prior to or during 
treatment with the tumour-inducing agent, it was difficult to tell from these findings alone 
whether disulfiram could reduce the size of a pre-existing tumour. In the 1980’s, it was 
shown that disulfiram potentiated the effects of various anti-cancer agents in mice (Hacker 
et al., 1982; Valeriote & Grates, 1989). However, little was known about the mechanism of 
action of disulfiram against cancer at the time. 
Many studies have now been conducted toward elucidating a mechanism for the anti-cancer 
effects of disulfiram. Collectively, these studies demonstrate that disulfiram exerts a variety 
of effects in cancer cells, which impacts on at least three cancer hallmarks. Disulfiram has 
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been shown to induce apoptosis in a variety of cancer cell lines, reduce angiogenesis and 
also reduce tumour invasiveness and metastasis (Chen et al., 2001, 2006; Shiah et al., 2003; 
Cho et al., 2007). Apoptosis induction in response to disulfiram treatment is attributed to 
DNA damage as a result of increased ROS levels and inhibition of NFκB, which has been 
associated with increased inflammation and tumour survival (Yip et al., 2011). Furthermore, 
disulfiram altered DNA transcriptional regulation by inhibiting supercoiling activity of DNA 
topoisomerases and also inhibits DNA methyltransferase 1 (Yakisich et al., 2001; Lin et al., 
2011). In the majority of the above-mentioned cases, the effects of disulfiram were copper 
dependent.  
The role of copper in disulfiram induced toxicity is two-fold. Firstly, disulfiram may act as a 
copper delivery agent. Increased intracellular copper levels can lead to cell death due to 
heavy metal toxicity. Copper is also a redox active metal, delivery of this metal into cells 
promotes oxidative stress and leads to cell death (Stefan et al., 1995). Secondly, disulfiram 
may alter cell function by chelating intracellular copper. Chelation of intracellular copper can 
inhibit the activity of Cu/Zn superoxide dismutase, this promotes oxidative stress, inhibits 
angiogenesis and may lead to cell death (Marikovsky et al., 2002). In addition, disulfiram and 
other copper-binding agents have been shown to inhibit proteasome activity. Protein 
degradation is essential to replenish amino acid pools required for de novo protein synthesis 
and cell division. As such, proteasome inhibition is associated with reduced tumour growth 
and cell proliferation, further highlighting the chemotherapeutic potential of disulfiram 
(Daniel et al., 2005; Rajkumar et al., 2005; Chen et al., 2006; Wickström et al., 2007).  
There are a number of phase I clinical trials that are ongoing or have been recently 
completed for the use of disulfiram alone or in combination with standard chemotherapy or 
chemoradiotherapy to treat individuals with various cancer types. These include solid 
tumours of the liver, non-small cell lung cancer, prostate cancer, metastatic melanoma and 
glioblastoma (NCT00742911, NCT00312819, NCT01118741, NCT00256230, NCT01907165). 
While results from these clinical trials are keenly awaited, in vitro and mouse studies on the 
effects of disulfiram in cancer show promising evidence for its repurposing as a 
chemotherapeutic agent. Further studies are still required in order to elucidate a direct 
cellular target for disulfiram.   
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1.6. Aim and Objectives 
Aim 
To investigate the anti-proliferative effects of metformin on oesophageal squamous cell 
carcinoma cell lines and determine whether its combination with other anti-cancer agents 
can offer novel combination chemotherapeutic strategies.  
Objective 1 
To determine the effects of metformin on OSCC cell proliferation and the AMPK signalling 
pathway 
1.1. Determine the effects of metformin on OSCC cell proliferation by direct cell counts.   
1.2. Assess the stage of the cell cycle after metformin treatment by flow cytometry.   
1.3. Assess changes in phospho-AMPKαThr172 levels in response to metformin treatment by 
western blotting.  
1.4. Assess changes in phospho-p70S6KThr389 levels in response to metformin treatment by 
western blotting.  
 
Objective 2 
To investigate the effects of metformin on cisplatin mediated cytotoxicity in OSCC cell lines. 
2.1. Determine the effects of metformin in combination with cisplatin on OSCC cytotoxicity 
by MTT assay.  
2.2. Determine whether metformin alters cisplatin DNA adduct formation by quantifying 
platinum in DNA by inductively coupled plasma mass spectrometry (ICP-MS).  
2.3. Assess the effects of metformin on glycolysis levels by quantifying lactate secreted into 
cell culture medium after metformin treatment.  
2.4. Determine whether metformin alters intracellular reduced thiol levels based on 
monobromobimane fluorescence.  
2.5. Determine whether modulation of intracellular thiols alters the effects of metformin 
on cisplatin-mediated cytotoxicity.  
2.6. Assess whether metformin alters the reducing potential of OSCC cells by MTT assay. 
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Objective 3 
To investigate the effects of metformin in combination with drugs activated in reducing 
environments as novel combination chemotherapeutic strategies for OSCC. 
3.1. Evaluate the effects of metformin combined with DSF, Cu-ATSM or Cu-GTSM on OSCC 
cytotoxicity by MTT assay.   
3.2. Determine whether DSF, Cu-ATSM and Cu-GTSM exert copper mediated DNA damage 
based on their ability to alter plasmid DNA supercoiling.  
3.3. Determine whether metformin combined with DSF, Cu-ATSM or Cu-GTSM alters 
intracellular copper levels by ICP-MS.  
3.4. Determine whether DSF, Cu-ATSM or Cu-GTSM, with or without metformin alters 
lysosomal acidity based on acridine orange fluorescence.  
3.5. Determine whether copper modulation alters the effects of DSF.  
3.6. Determine the effects of DSF with or without metformin on protein degradation by 
quantifying total ubiquitin and LC3-B levels by western blotting. 
3.7. Evaluate the effects of DSF and metformin on autophagosome formation by 
transmission electron microscopy.  
3.8. Determine the effects of DSF with or without metformin on proteasome activity based 
on cleavage and fluorescence of succinyl-Leu-Leu-Val-Tyr-amido methylcoumarin (Suc-
LLVY-AMC). 
3.9. Compare the effects of disulfiram with analogues that have lower hydrolysis rates on 
OSCC cytotoxicity by MTT assay.  
3.10. Assess the effects of DSF analogues on lysosomal acidity by acridine orange 
fluorescence.  
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1.7. Synopsis 
Chapter 2: Characterising the Anti-Proliferative Effect of Metformin in OSCC 
Cell Lines 
Oesophageal squamous cell carcinoma (OSCC) is a highly aggressive cancer with a poor 
survival rate. The poor survival rate may be attributed to a lack of cost-effective 
chemotherapeutic strategies for this cancer. We hope to find effective chemotherapeutic 
drugs that are also affordable for the treatment of OSCC. Metformin is a widely prescribed 
anti-diabetic drug that shows chemotherapeutic potential, and is also affordable.   
In this chapter, we show that metformin inhibits the proliferation of OSCC cell lines as fewer 
cells were present after 10 mM metformin treatment for 24 hours compared to untreated 
controls. Flow cytometry assessment with propidium iodide staining showed that cells 
accumulated at the G1/G0 stage of the cell cycle in response to metformin, suggesting that 
the drug halts cell cycle progression. Metformin treatment was associated with increased 
phosphorylation and activation of AMPK, evaluated by western blotting. There was also a 
reduction in the phosphorylation of p70S6 kinase which is inhibited by AMPK, thus proving 
that AMPK signalling is increased in the presence of metformin.   
These results show that metformin halts OSCC cell proliferation, and as such may potentially 
be used to halt tumour progression. However, the treatment was not cytotoxic and would 
have to be combined with more potent drugs in order to offer an effective 
chemotherapeutic strategy.  
Chapter 3: Metformin Negatively Alters the Effects of Cisplatin in OSCC Cell 
Lines 
Cisplatin is currently the first-line drug prescribed for OSCC treatment. However, cisplatin 
resistance is a pitfall associated with frequent therapy and the prescription of high doses. 
The combination of metformin and cisplatin has shown both positive and negative effects, 
depending on cancer type (Gotlieb et al., 2008; Janjetovic et al., 2011; Lesan et al., 2014). 
We sought to determine the effects of metformin on cisplatin mediated cytotoxicity in OSCC 
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cell lines. Furthermore, we investigated the mechanisms responsible for the effects of 
metformin and cisplatin when combined.  
Cytotoxicity was evaluated using the MTT assay to calculate the drug concentration required 
for 50% cell death (LC50). Metformin-cisplatin treated cells displayed higher LC50 values 
versus cisplatin treatment alone, suggesting that metformin negatively alters the effects of 
cisplatin in these cell lines. Platinum levels in DNA quantified by inductively coupled plasma 
mass spectrometry indicated that protective effects of metformin are attributed to reduced 
cisplatin-DNA adduct formation. Metformin also increased glycolytic rates in these cell lines, 
which suggested that it could modulate the glutathione redox defence system. We 
quantified levels of reduced low-molecular weight thiols based on monobromobimane 
fluorescence, which was higher in cells treated with metformin. This indicates that 
metformin increases the levels of reduced thiols in these cell lines. Increased thiols are a 
plausible explanation for the negative effects of metformin on cisplatin mediated 
cytotoxicity as treatment with N-acetyl-L-cysteine, a glutathione pre-cursor, also negatively 
altered the effects of cisplatin. Glutathione depletion by buthionine sulfoximine blocked the 
protective effects of metformin on cisplatin mediated toxicity. Increased levels of 
intracellular thiols suggested that metformin could alter the redox state of these cells. 
Reducing potential was higher in the presence of metformin, as indicated by its ability to 
reduce MTT.  
Metformin reduced cisplatin cytotoxicity by reducing DNA adduct formation. This occurred 
due to altered drug sequestration or increased drug export by intracellular thiols such as 
glutathione. For these reasons, metformin should not be combined with cisplatin for OSCC 
treatment. Extra caution must be heeded in the case of cancer patients that also suffer 
diabetes. Interestingly, metformin increased the reducing potential of OSCC cell lines, which 
suggests that it may work well when combined with cytotoxic agents that are activated in 
reducing environments.  
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Chapter 4: Metformin has a positive effect on anti-cancer agents which are 
activated in reducing environments 
The effects of metformin in combination with Cu-ATSM, Cu-GTSM and disulfiram on OSCC 
cytotoxicity were investigated. These drugs were chosen as they are activated in reducing 
environments. Disulfiram showed the most promising response, and therefore the 
mechanisms of toxicity were further investigated. Disulfiram has been shown to inhibit 
proteasomal function. Therefore, the effects of this drug in combination with metformin on 
protein degradative pathways were further investigated.  
Cu-ATSM or Cu-GTSM both exerted toxicity toward OSCC cell lines at particularly low doses 
and this was not altered in the presence of metformin. Metformin enhanced the cytotoxic 
effects of DSF. This indicated that metformin can be combined with these drugs for OSCC 
treatment. DSF is the most promising agent for potential application as an anti-cancer drug 
as it is FDA approved and has a well-established low toxicity profile. Our findings corroborate 
other studies which show that the effects of DSF are significantly enhanced as copper levels 
are increased, which indicate that copper plays a significant role in the mechanism of action 
of this drug. The DSF-copper complex, Cu-DSF, has been shown to inhibit proteasome 
activity. We found that DSF and Cu-DSF treatment led to a significant increase in the 
accumulation of ubiquitinated proteins, but only partially inhibited proteasome function. 
This suggested that DSF could be involved in inhibiting other pathways of protein 
degradation. We showed that DSF still exerted cytotoxic effects without additional copper 
and after copper depletion. We therefore hypothesised that the hydrolysis products of DSF 
may be involved in its toxic effects, and that diethylamine may accumulate in lysosomal 
vesicles, reduce their acidity and inhibit autophagy. We proved this by showing that DSF 
treatment reduced lysosomal acidity as indicated by acridine orange staining. We also 
showed that cells treated with DSF or Cu-DSF had increased levels of LC3B-II and electron 
microscopy showed an accumulation of protein aggregates in autolysosomes. This indicated 
that DSF inhibited autophagy in OSCC cell lines.  
Therefore, metformin enhanced the effects of DSF, which indicates that these drugs can be 
used in combination for OSCC therapy. DSF owes its anticancer effects to the inhibition of 
multiple protein degradation pathways.   
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Chapter 2: Characterising the Anti-Proliferative Effect 
of Metformin on OSCC Cell Lines 
2.1. Introduction  
Metformin is a widely prescribed anti-diabetic drug that has recently demonstrated 
chemotherapeutic potential (Evans et al., 2005). It has been shown to inhibit the 
proliferation of numerous cancer cell lines including breast, prostate, endometrial, ovarian, 
melanoma, glioma, pancreatic and colon cancers (Zakikhani et al., 2006; Buzzai et al., 2007; 
Isakovic et al., 2007; Ben Sahra et al., 2008; Wang et al., 2008; Cantrell et al., 2010; Rattan et 
al., 2011; Tomic et al., 2011). In addition, metformin was cytotoxic towards glioma cells and 
melanoma cell lines (Isakovic et al., 2007; Wang et al., 2008; Tomic et al., 2011). Since 
metformin is already FDA approved for the treatment of diabetes and has a well-established 
tolerance profile, numerous clinical trials are being conducted to elucidate whether 
metformin can be used for cancer therapy. There is extensive evidence supporting the anti-
proliferative effects of metformin; however, an exact molecular mechanism of action for 
metformin in cancer is still not known. Although metformin was shown to reduce the 
proliferation of many cancer cell types, the effects of metformin on OSCC were undefined at 
the beginning of this study. Kobayashi et al. have recently shown that metformin inhibits the 
proliferation of Japanese derived OSCC cell lines (Kobayashi et al., 2013).  
Reduced cell proliferation in response to metformin is associated with cell cycle arrest. 
Metformin induces cell cycle arrest at the G1/G0 stage with a concomitant reduction in 
cyclin D1 levels in breast cancer cells (Ben Sahra et al., 2008; Alimova et al., 2009). In order 
to acquire replicative immortality, cancer cells must bypass the G1/S checkpoint to allow cell 
cycle progression. Cyclin D1 regulates G1 to S phase transition partly by repressing the E2F 
transcription factor (Figure 2.1). E2F promotes the expression of genes required for the 
transition from G1 to S phase (Tashiro, Tsuchiya & Imoto, 2007). Cyclin D1 is also a member 
of a complex that sequesters and blocks the action of cyclin dependent kinase (CDK) 
inhibitors, p27kip and p21cip. The CDK inhibitors bind to and inhibit cyclin E which promotes 
G1-S cell cycle progression (Zhuang & Miskimins, 2008). Therefore, inhibition of cyclin D1 
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leads to release of these CDK inhibitors, which then sequester cyclin E and halt cell cycle 
progression.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Metformin interacts with the AMPK and mTOR signalling pathways 
leading to reduced cell proliferation.  Metformin inhibits the cell cycle via the AMPK 
or mTOR signalling pathways and independent of these pathways via cyclin D1. 
Metformin activates AMPK. AMPK promotes p53 activation which is associated with 
increased levels of the cyclin-dependent kinase inhibitor, p21cip, and therefore 
inhibits cell cycle progression. Metformin has been shown to reduce cyclin D1 
expression independent of AMPK. This leads to elevated levels of p27kip and p21cip, 
which inhibit cell cycle progression. Cyclin D1 also promotes the action of eukaryotic 
initiation factor, E2F, which is inhibited in the presence of metformin. Metformin can 
inhibit mTORC1 via Rag GTPases, REDD1 or via AMPK. Inhibition of mTORC1 leads to 
reduced levels of p70S6K and increased levels of 4E-BP, which results in reduced cell 
growth proliferation. Metformin can therefore inhibit cell cycle progression via 
numerous routes.   
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AMPK is linked to reduced cell proliferation due to its role in inhibiting mTOR at various 
levels and its involvement in promoting p53Ser15 phosphorylation which leads to activation of 
p21cip (Imamura et al., 2001). Metformin induced G1/G0 stage cell cycle arrest in prostate 
cancer cells and was associated with reduced cyclin D1 expression and elevated p27kip levels. 
However, AMPK knockdown in those cell lines did not alter the effects of metformin on cell 
proliferation, which indicates that AMPK is not fully required for the growth inhibitory 
effects of metformin (Ben Sahra et al., 2008).  
In addition to p53-dependent effects, the anti-proliferative effects of metformin, in breast 
cancer cells, have also been found to be AMPK dependent but not dependent on p53. AMPK 
activation has been shown to be associated with down-regulation of cyclin D1, and increased 
binding of p27kip and p21cip to cyclin E, which is required for G1-S phase transition. These 
effects were shown to be AMPK-dependent, as treatment with the AMPK inhibitor, 
compound C, reduced the anti-proliferative effects of metformin  (Zhuang & Miskimins, 
2008). Although compound C has been widely used as an AMPK inhibitor, it has also been 
shown to exert AMPK-independent effects, which raises questions about the use of this 
agent as a specific AMPK inhibitor (Vucicevic et al., 2014). Metformin has also been shown to 
inhibit cell cycle progression after siRNA mediated knockdown of AMPK, which indicates that 
metformin can halt cancer cell proliferation irrespective of its AMPK or p53 status (Ben Sahra 
et al., 2011).  
Metformin and AMPK have been shown to inhibit mammalian target of rapamycin (mTOR) 
signalling. There are two major complexes containing mTOR, mTOR complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2), which play a role in promoting cell growth and proliferation 
in response to growth factors, nutrients, energy and stress. Due to the fact that mTOR 
signalling is upregulated in numerous cancers, inhibition of mTOR has been considered for 
cancer therapy (Chan, 2004). Two main proteins activated by mTORC1 and have growth 
promoting effects due to their roles in protein translation are the 70kDa ribosomal protein 
S6 kinase (p70S6K) and eukaryotic translation initiation factor 4E (eIF4E) binding protein-1 
(4E-BP1) (Hara et al., 1998). Downstream mTORC1 signalling is dependent on recruitment of 
three complex members to mTOR, the rapamycin-sensitive adaptor protein of mTOR 
(raptor), the G protein β-subunit-like protein (GβL) and the proline-rich Akt substrate 40 kDa 
(PRAS40). Upon activation, p70S6K regulates ribosomal protein translation and ribosome 
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biogenesis. Phosphorylation of 4E-BP1 by mTORC1 leads to the release of eIF4E which is 
required for translation of mRNA encoding proteins required for G1 to S phase transition 
such as cyclin D1 (Bjornsti & Houghton, 2004). Inhibition of mTORC1 results in G1 phase cell 
cycle arrest.  
Phosphorylation of p53Ser15 by AMPK was also shown to activate the phosphatase and tensin 
homologue (PTEN) which consequently inhibits PI3K-AKT signalling by inhibiting the 
conversion of PIP2 to PIP3 (Levine et al., 2006). PTEN is mutated in numerous cancers 
including brain, breast, prostate cancer, bladder, lung and renal carcinomas, and is one of 
the most frequently mutated genes in cancer (Li, 1997; Guertin & Sabatini, 2005). This 
further emphasises requirement of enhanced mTOR signalling by cancer cells. Interestingly, 
metformin was shown to inhibit mTORC1 independent of AMPK or TSC2, in a Rag GTPase 
dependent manner (Kalender et al., 2010). Metformin also promoted mTORC1 inhibition by 
activating REDD1 (regulated in development and DNA damage responses 1), and these 
effects are dependent on p53 (Ben Sahra et al., 2011). However, the mechanism by which 
REDD1 inhibits mTORC1 is still largely unknown.  
In this chapter, we aimed to determine the effects of metformin on OSCC cell proliferation. 
Metformin treatment reduced proliferation and halted cell cycle progression at the G1/G0 
stage in these cell lines. Preliminary findings indicated that mTOR levels were particularly 
high in these cell lines and did not seem to be altered in the presence of metformin. 
Metformin treatment was associated with increased phosphorylation of AMPK and 
inhibition of p70S6K in the three cell lines tested. 
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2.2. Methods 
The three human oesophageal squamous cell carcinoma (OSCC) cell lines used in this study, 
WHCO1, WHCO5 (Veale & Thornley, 1989) and SNO (Bey et al., 1976) were originally derived 
from moderately differentiated tumour. Since OSCC has been shown to have a higher 
prevalence amongst the black male population, these cell lines are an ideal model for the 
target population as they are derived from males of African descent. The effects of 
metformin on cell proliferation were investigated by determining cell viability and stage of 
the cell cycle in the absence and presence of metformin. We also aimed to determine 
whether the effects of metformin on cell proliferation were attributed to alterations in 
metabolic regulation by assessing levels of P-AMPKαThr172 and P-p70S6KThr389. All reagents 
used in this study were purchased from Sigma-Aldrich, unless otherwise specified.   
2.2.1. Cell Culture 
All cell lines used in this study were a kind gift from Professor Robin Veale. Cells were 
cultured in medium made of three parts Dulbecco’s Modified Eagle’s Medium (DMEM) to 
one part Hams F12 supplemented with 10% foetal calf serum (FCS) (Highveld Biological) and 
maintained in a humid incubator at 37 °C with 5% carbon dioxide. Cells were routinely sub-
cultured when 70-90% confluence was reached by removing culture medium, rinsing cells 
three times in 1 x PBS (137 mM NaCl; 2.7 mM KCl; 10 mM Na2HPO4; 2 mM KH2PO4, pH 7.2, 
autoclaved), followed by the addition of 1.2 ml Trypsin:EDTA (0.25% Trypsin: 0.02% EDTA in 
Hanks’ Balanced Salt Solution) for 2-5 min at 37 °C. Approximately 300 µl of the cell 
suspension was re-suspended in 8 ml fresh culture medium for maintenance of the cell line. 
Culture medium was replaced 24 hour after seeding and every second day thereafter.  
2.2.2. Evaluation of Cell Proliferation with Trypan Blue Staining 
To determine the effects of metformin on OSCC cell proliferation, untreated and metformin 
treated cells were counted and compared. Cells were equally seeded in 24-well plates (4 x 
104 cells/well) and allowed to settle for 24 hours. Cells were then treated with 10 mM 
metformin for a further 24 hours, or culture medium was replaced for all untreated controls. 
After treatment, cells were trypsinized for 5-10 min at 37 °C, and trypsin was inactivated by 
re-suspending cells in 2 volumes culture medium. The cell suspension was then added to an 
 38 
 
 
equal volume of Trypan blue (0.2% in 1 x PBS, filter sterilized), mixed for 2 min and counted 
using a haemocytometer slide. Counts were used to calculate cell concentration (cells/ml) 
and total number of cells per well, values were represented as an average (n = 3 ± SD).  
2.2.3. Cell Imaging by Microscopy 
An equal number of cells were seeded per well (200 000 cells/well) on autoclaved glass 
cover-slips in 6-well plates. After 48 hours, cells were treated with 10 mM metformin for 24 
hours or cells were incubated in fresh culture medium for 24 hours in the case of untreated 
cells. Following treatment, glass coverslips with adhered cells were rinsed in 1 x PBS, placed 
cell side down on glass slides and immediately viewed with an Olympus BX63 microscope. 
Images were captured at 10 x magnification in bright-field.  
2.2.4. Flow Cytometry for Cell Cycle Evaluation 
Propidium iodide (PI) stained DNA in OSCC cells were assessed by flow cytometry in order to 
determine the stage of the cell cycle in OSCC cell lines (Liu et al., 2001). Cells were evenly 
seeded in 10 cm cell culture dishes and after 24 hours they were treated with 10 mM 
metformin for a further 24 hours, or medium was replaced for untreated controls. 
Additionally, cells deprived of serum for 8 hours were used as positive controls for G1/G0 
cell cycle arrest. Treated cells were rinsed in 1 x PBS three times, removed by trypsinisation 
for 5 min, two volumes fresh culture medium was added to block the effects of trypsin. Cells 
were counted on a haemocytometer slide, and approximately 3 x 106 cells were centrifuged 
at 3000 rpm for 10 min, culture medium was removed and cells were re-suspended in 500 µl 
1 x PBS prior to analysis. The DNA Prep Reagent Kit (Beckman Coulter) was used for cell cycle 
analysis.  An equal volume of DNA prep LPR lysis solution was added to cells and vortexed for 
10 sec to permeabilize cell membranes. DNA prep stain solution composed of PI and RNAse 
was then added to each sample and vortexed for a further 5 sec to facilitate DNA binding of 
PI. Cell suspensions were then passed through the BD LSRFortessa™ cell analyser (BD 
Biosciences), excited with a 488nm laser and detected with a 584/42nm band pass emission 
filter. The data was used to create DNA histograms using FlowJo v10 software and the 
percentage of cells in the G0/G1, S, and G2/M phase of the cell cycle were calculated (n = 3 ± 
SD).  
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2.2.5. Western Blot for AMPK and p70S6 Kinase 
Western blotting was used to detect AMPKα, phospho-AMPKαThr172, p70S6K and phospho-
p70S6KThr389 levels in the absence and presence of metformin in OSCC cell lines. Following 
treatment, cytoplasmic proteins were extracted and quantified using the Bradford assay.  
Proteins were resolved by sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis 
(SDS-PAGE), with a 5% stacking gel and 10% resolving gel. Proteins were then transferred 
onto nitrocellulose membranes, blocked and rinsed. Membranes were then incubated in 
primary antibodies (1 in 1000 in 5% BSA made up in 1 x TBS/T) of interest followed by 
incubation in the goat anti-rabbit IgG horse-radish peroxidase-linked secondary antibody 
(SantaCruz, sc-2004) (1/2000 in 5% fat-free milk powder made up in 1 x TBS/T). Bands were 
detected after exposure to chemiluminescent substrates with X-ray film.  Full descriptions of 
these steps are detailed below.  
2.2.5.1. Protein Sample Preparation 
2.2.5.1.1. Treatment and Collection of Cells 
Cells were evenly seeded in 100 mm cell culture dishes, after 24 hours they were treated 
with 10 mM metformin for 24 hours or medium was replaced for untreated controls. After 
treatment, cells were harvested and kept on ice throughout the procedure. Cells were rinsed 
in 5 ml ice cold 1 x PBS three times, scraped in 1 ml 1 x PBS and collected in 1.5 ml 
microcentrifuge tubes. Tubes were centrifuged at 4300 x g for 10 min at 4 °C to pellet cells, 
excess 1 x PBS was removed and cells were stored at -70 °C until required.  
2.2.5.1.2. Preparation of lysates containing cytoplasmic proteins 
Frozen cell pellets were lysed in ½ x radio-immunoprecipitation (RIPA) buffer (25 mM Tris-
HCl, pH 8.0; 75 mM NaCl; 0.05% SDS; 0.5% Triton X-100; 0.25% sodium deoxycholate) 
containing inhibitors. Each of the following inhibitors were added per 1 ml RIPA buffer 
immediately before use: 10 µl phenylmethylsulfonylfluoride (1 mM stock solution dissolved 
in ethanol); 1 µl leupeptin (10 µM stock); 10 µl sodium orthovanadate (1 mM stock); 20 µl 
sodium fluoride (10 mM stock). Approximately 80-100 µl RIPA buffer was added to each cell 
pellet, samples were incubated on ice and vortexed every 5 min at high speed for 20 min to 
facilitate lysis of the cell membrane. Cytoplasmic fractions were used as all proteins 
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investigated exist in the cytoplasmic compartment. Samples were centrifuged at 9600 x g for 
5 min at 4 °C to remove cell debris and nuclei. Aliquots of the supernatants containing 
cytoplasmic protein fractions were stored at -70 °C for further analysis.  
2.2.5.1.3. Protein concentration estimation  
Proteins were quantified using the method by Bradford (Bradford, 1976). For the microplate 
assay, standard solutions of bovine serum albumin (BSA) in the linear range of 9 – 75 µg/ml 
were prepared. Cell lysates from test samples with unknown concentrations were diluted by 
a factor of 1/100 or 1/200, blank solutions were made up of the corresponding dilutions of ½ 
x RIPA buffer. 160 µl of each solution was added per well in triplicate on a 96-well plate and 
40 µl of Bio-Rad protein dye reagent concentrate was added to each sample (Bio-Rad). 
Samples were mixed by pipetting and absorbance readings at 595 nm were recorded using 
the MULTISKAN GO microplate reader (ThermoScientific). Absorbance values for BSA 
standard solutions were plotted against their respective concentrations and a linear 
trendline was fitted to data using MS Excel. Concentrations of unknown protein solutions 
were determined from equation of the standard curve.  
2.2.5.2. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
The Mini-PROTEAN® Tetra Cell system (Bio-Rad 165-800) was used for SDS-PAGE. Two glass 
plates, one with a 1 mm spacer were sandwiched against each other in a gel cassette. A 10% 
resolving gel and a 5% stacking gel were prepared as detailed in Table 2.1. Ammonium 
persulfate (APS) and tetramethylethylenediamine (TEMED) were added immediately before 
the solution was poured between the glass plates and a layer of distilled water was poured 
over the resolving gel to prevent evaporation. The resolving gel was allowed to set for 30 
min, excess water overlay was then removed and a layer of stacking gel with freshly added 
APS and TEMED was poured above the resolving gel with a comb and allowed to set for a 
further 30 min. The SDS-PAGE gel and glass plates were then removed from the cassette and 
assembled with the gasket in the running tank. Running buffer (192 mM Glycine, 25 mM Tris 
pH 8.8; 0.1 % SDS) was poured between the electrode assembly and into the mini tank. 
Protein samples were then loaded onto the gel.  
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Table 2.1: Resolving gel and stacking gel recipes for SDS-PAGE.  
 Resolving Gel (10 ml) Stacking Gel (5 ml) 
 10% 12% 14% 5% 7% 
ddH20 4 ml 3.3 ml 2.63 ml 3.4 3.1 ml 
29:1 Acryl/Bisacryl 3.3 ml 4.0 ml 4.7 ml 830 µl 1.2 ml 
Tris (1.5M pH 8.8) 2.5 ml 2.5 ml 2.5 ml 630 µl 630 µl 
10% SDS 100 µl 100 µl 100 µl 50 µl 50 µl 
10% APS 100 µl 100 µl 100 µl 50 µl 50 µl 
TEMED 5 µl 4 µl 4 µl 4 µl 3 µl 
 
Proteins samples were prepared by first adding 3 parts protein to 1 part 4x loading buffer 
(40% glycerol; 240 mM Tris-HCl pH 6.8; 8% SDS; 0.04% bromophenol blue, 5% β-
mercaptoethanol) in microcentrifuge tubes. Samples were placed in boiling water for 5 min 
before loading equal amounts of protein (µg) per well. The PageRulerTM prestained protein 
ladder (Fermentas) was used as a molecular weight marker. Proteins were separated by 
electrophoresis at a constant current of 25 mA per gel till the dye front had reached the 
bottom of the gel (±60 min). The regions of gel containing antigens of interest were cut out 
and prepared for electrophoretic transfer. Excess pieces of gel were stained in Coomassie 
blue gel staining solution (3 mM Coomassie blue (Merck); 50 % methanol; 10 % acetic acid) 
for 1 hour and de-stained by incubating in destain solution (10 % acetic acid; 10 % methanol) 
overnight with shaking at 60 rpm at room temperature.  
2.2.5.3. Electrophoretic Transfer 
Proteins were transferred from the gel onto nitrocellulose with the Bio-Rad Mini Trans-Blot® 
Electrophoretic Transfer Cell (Bio-Rad 170-3930) system. SDS-PAGE gels and nitrocellulose 
membranes were sandwiched between four sheets of filter paper and two fibre pads. The 
electrode module was set up such that the gel was closer to the negative electrode and 
nitrocellulose was closer to the positive electrode. The electrode module was placed in a 
tank with an ice pack and immersed in transfer buffer (192 mM glycine; 25 mM Tris; 20% 
methanol; pH 8.3). A current of 300 mA was passed through the system for 2.5 hours in a 4°C 
cold room, the current was then stopped and nitrocellulose membranes were removed and 
rinsed in distilled water prior to blocking.  
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2.2.5.4. Blocking, Antibody Binding and Detection 
Nitrocellulose membranes were blocked in 5% fat-free milk powder made up in 1 x TBS/T (20 
mM Tris-HCl pH 7.6; 137 mM NaCl; 0.01 % Tween-20) for 1 hour at room temperature with 
gentle agitation at 60 rpm. After blocking, membranes were washed in three changes of 1 x 
TBS/T with shaking at 120 rpm for 5 min each time and then incubated in primary antibody. 
All primary antibodies used were purchased from Cell Signaling Technology unless otherwise 
specified. In this chapter rabbit anti-AMPKα (#2532), rabbit anti-phospho AMPKα (Thr172) 
(#2531), rabbit anti-p70S6K (#2708), rabbit anti-phospho p70S6K (Thr389) (#9234) and β-
actin (Santa Cruz, sc-130656) were used. Nitrocellulose membranes were incubated in 
primary antibodies diluted in 5% bovine serum albumin (BSA) in 1 x TBS/T (1/1000) overnight 
at 4 °C. Excess antibody was removed by washing membranes in cold 1 x TBS/T five times for 
5 min per wash at 120 rpm, and membranes were incubated in secondary antibody (Santa 
Cruz, sc2004) for 1 hour at room temperature. Membranes were washed in cold 1 x TBS/T 
five times for 5 min per wash to remove excess secondary antibody. Excess secondary 
antibody was removed by washing membranes in cold 1 x TBS/T five times for 5 min per 
wash at 120 rpm prior to antibody detection.  
Bands were detected using the SuperSignal® West Pico Chemiluminescent Substrate Kit 
(Thermo Scientific). Equal volumes of stable peroxide solution and luminol/enhancer 
solution were mixed and layered on the surface of nitrocellulose containing proteins for 5 
min. Membranes were dabbed on paper towel to remove excess liquid, then covered in cling 
film and blue X-ray film was used to detect bands. X-ray film was then placed in developing 
solution (6.4 M metol; 0.6 M sodium sulphite; 80 mM hydroquinone; 45 mM sodium 
carbonate; 34 mM potassium bromide), rinsed in water and then placed in fixer solution (0.8 
M sodium thiosulphate; 0.2 M sodium metasulphite) and rinsed in water once again. Bands 
were scanned with a GS-800 calibrated densitometer (Bio-Rad, 170-7980) and quantified 
using LabWorks 3.0 software.  
2.2.8. Statistical Analysis 
Results are expressed as means ± SD and statistical significance was calculated using a paired 
Student’s t-test on MS Excel 2007. In all cases, p-value stars represent the following:  
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p ≤ 0.001 *** 
p ≤ 0.01 ** 
p ≤ 0.05  * 
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2.3. Results 
2.3.1. Metformin Reduces OSCC Cell Proliferation and Promotes Cell 
Accumulation at the G1/G0 stage  
Metformin has been shown to reduce proliferation of various cancers. We aimed to 
determine whether metformin could also reduce proliferation of South African derived OSCC 
cell lines. Studies in mice show that metformin accumulates in tissues at concentrations 
several fold higher than blood circulating conditions, tissue accumulating concentrations are 
reported to be between 1 – 10 mM metformin (Martin-Castillo et al., 2010). Early studies in 
our laboratory showed that 10 mM metformin had the most promising effects on inhibition 
of cell proliferation with minimal toxicity. Therefore, the clinically attainable concentration 
of 10 mM metformin was used throughout this study. Direct cell counts indicated that OSCC 
cell proliferation was significantly reduced after 24 hour treatment with 10 mM metformin 
compared to untreated controls with a reduction of 18% in WHCO1, 32% in WHCO5 and 33% 
in SNO cell lines (Figure 2.2). Images of cells treated with metformin clearly depict the 
reduction in cell growth compared to untreated cells (Figure 2.3).  
 
 
 
 
 
 
 
Figure 2.2: Metformin reduces OSCC cell proliferation.  Cells were counted after 
treatment with 10 mM metformin for 24 hrs (red bars) or no treatment (blue bars). 
Cell numbers were represented as a percentage of untreated controls. The graph 
indicates that there were significantly fewer cells present after metformin treatment 
compared to cells that received no treatment for WHCO1, WHCO5 and SNO cell lines 
(n=3±SD).  
* ** ** 
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Figure 2.3: Cells are less confluent after treatment with metformin.  Images of 
untreated cells or 10 mM metformin treated cells were captured at 10X 
magnification under normal light using the Olympus BX63 microscope. (A) WHCO1 
untreated, (B) WHCO1 metformin, (C) WHCO5 untreated, (D) WHCO5 metformin, (E) 
SNO untreated, (F) SNO metformin.  
A B 
C D 
E F 
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The inhibitory effects of metformin on cell proliferation have been partly attributed to 
accumulation of cells at the G1/G0 stage of the cell cycle (Zhuang & Miskimins, 2008; Tomic 
et al., 2011). Flow cytometric evaluation of PI stained cells show OSCC cell accumulation at 
the G1/G0 stage of the cell cycle was higher after treatment with 10 mM metformin for 24 
hours in WHCO1, WHCO5 and SNO cell lines (Figure 2.4). A concomitant reduction in S-phase 
and G2/M phase cells was also observed. Pooled data for replicates are shown in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Metformin promotes cell accumulation at the G1/G0 stage.  PI 
fluorescence per cell was measured in (A) WHCO1, (B) WHCO5 and, (C) SNO cell lines 
that were untreated (left), 10 mM metformin for 24 hr treated (centre), or deprived 
of foetal calf serum for 8 hrs (right). Metformin halted cell cycle progression at the 
G1/G0 stage. Results for a single set of data are depicted.  
 
A 
Untreated Metformin Serum Deprived 
 
B 
 
C 
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Table 2.2: Metformin increases the proportion of cells in the G1/G0 stage and reduces 
proportion in G2/M and S stages of the cell cycle (n=3±SD).  
 
† Stars represent P-value significance for metformin treatment compared to untreated 
cells or serum deprived cells compared to untreated cells.  
 
There was a significant increase in the proportion of cells in the G1/G0 stage and a reduction 
in G2/M and S stage cells with metformin treatment. This result therefore supports other 
studies that have also shown increased accumulation of cells in the G1/G0 stage of the cell 
cycle in response to metformin treatment (Buzzai et al., 2007; Tomic et al., 2011). AMPK 
activation and inhibition of p70S6K as a result of hampered mTOR signalling may contribute 
to the effects of metformin on OSCC cell lines. We next evaluated the effects of metformin 
on these two members of these signalling pathways as their regulation plays a key role in cell 
growth or growth inhibition.  
 
  
Cell line Stage Cell Proportion (%) 
  
Untreated Metformin † Serum Deprived † 
WHCO1 
G1/G0 50.5 ± 0.7% 61.6 ± 1.2% *** 55.2 ± 0.8% *** 
S 24.6 ± 1.1% 17.4 ± 0.9% *** 20.0 ± 2.0% * 
G2/M 24.4 ± 0.5% 21.1 ± 1.9% * 23.4 ± 1.6% ns 
WHCO5 
G1/G0 52.5 ± 2.3% 64.0 ± 1.9% ** 62.0 ± 2.0% ** 
S 21.2 ± 0.7% 17.8 ± 0.3% ** 18.5 ± 2.9% ns 
G2/M 26.1 ± 2.7% 18.2 ± 1.7% ** 18.4 ± 0.4% * 
SNO 
G1/G0 67.5 ± 2.5% 80.4 ± 1.7% ** 76.5 ± 2.6% ** 
S 16.1 ± 0.7% 9.9 ± 2.4% * 11.4 ± 1.4% ** 
G2/M 16.3 ± 2.5% 11.2 ± 1.8% * 12.1 ± 1.7% * 
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2.3.2. Metformin increases phospho-AMPKThr172 levels  
Metformin mediated cell cycle arrest at the G1/G0 stage was shown to be dependent on 
AMPK in breast cancer cells (Zhuang & Miskimins, 2008). AMPK has also been shown to 
inhibit the mTOR signalling pathway, which may contribute reduced cell proliferation 
(Bolster et al., 2002). The effects of metformin on AMPK in OSCC cell lines was evaluated by 
determining levels of P-AMPKαThr172 and comparing these to total AMPKα levels in untreated 
and metformin treated cells. There was a slight increase in total AMPK levels with metformin 
treatment in OSCC cell lines. A significant increase in P-AMPKThr172 levels were observed 
presence of metformin in all three OSCC cell lines tested (Figure 2.5).  
 
 
 
 
 
 
 
Figure 2.5: Metformin increases P-AMPKαThr172 levels in OSCC cell lines.  Cytoplasmic 
protein extracts from OSCC cells that were untreated or 10 mM metformin treated for 
24 hrs were used in the detection of P-AMPKαThr172, total AMPKα and β-actin levels by 
western blotting. Relative optical densities indicate levels of P-AMPKαThr172 compared 
to total AMPKα relative to their respective untreated controls. P-AMPKαThr172 levels 
were higher in metformin treated cells (red bars) compared to untreated controls 
(blue bars) in WHCO1, WHCO5 and SNO cell lines.  
 
 
 
P-AMPKα
Thr172
   
  
  
AMPKα 
β-actin 
** ** ** 
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2.3.3. Metformin reduces phospho-p70S6KThr389 levels  
Signalling via the mTORC1 pathway is upregulated in many cancers and activation of its 
downstream targets promotes cell growth and proliferation (Zoncu, Efeyan & Sabatini, 
2011). Activation of mTOR promotes protein synthesis and cell growth by activating p70S6K, 
which promotes translation of proteins required for ribosomal biogenesis (Wullschleger, 
Loewith & Hall, 2006). Therefore, the mTOR-p70S6K signalling axis promotes cell growth and 
proliferation. Metformin was shown to directly inhibit p70S6K activity in breast cancer cells 
(Vazquez-Martin, Oliveras-Ferraros & Menendez, 2009). Additionally, activation of AMPK 
suggested that the mTOR-p70S6K signaling axis could be inhibited in the presence of 
metformin. We investigated the effects of metformin on p70S6K activity in OSCC cell lines 
and as expected, we found that metformin reduced P-p70S6KThr389 in the OSCC cell lines 
(Figure 2.6). Total p70S6K were not significantly altered in the presence of metformin.  
 
 
 
 
 
 
 
Figure 2.6: Metformin reduces P-p70S6KThr389 levels in OSCC cell lines.  Cytoplasmic 
protein extracts from OSCC cells that were untreated or 10 mM metformin treated for 
24 hrs were used in the detection of P-p70S6KThr389, total p70S6K and β-actin levels by 
western blotting. Relative optical densities were expressed as P-p70S6KThr389 compared 
to p70S6K with respect to corresponding untreated controls. P-p70S6KThr389 levels 
were significantly lower in metformin treated cells (red bars) compared to untreated 
controls (blue bars) in WHCO1, WHCO5 and SNO cell lines.  
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2.4. Discussion 
We have shown that metformin reduces the proliferation of OSCC cell lines. This was 
attributed to cell accumulation at the G1/G0 stage of the cell cycle. Reduced proliferation is 
a promising result as it suggests that metformin could be used to halt OSCC progression prior 
to surgical resection for early stage cancer. Metformin treatment also resulted in increased 
activation of AMPK and inhibition of mTOR signalling as indicated by reduced p70S6K 
phosphorylation. The AMPK and mTOR signalling pathways play critical roles in the cells 
response to nutrient deprivation and stress. Both AMPK and mTOR signalling pathways are 
frequently deregulated in cancer as cancer cells must bypass the ability to sense nutrient 
deprivation yet retain the ability to promote cell proliferation. Increased AMPK activation 
and inhibition of mTOR by metformin may serve as means to normalise signalling via these 
pathways and promote cell senescence.  
We show in this study that metformin increased AMPK activation in OSCC cell lines. 
However, we cannot confirm whether AMPK is required for the anti-proliferative effects of 
metformin from these findings alone. The anti-proliferative effects of AMPK are partly 
attributed to p53-mediated activation of p21cip (Motoshima et al., 2006). However the 
proliferation of SNO cells, which harbour a mutated p53, was still significantly reduced and 
AMPK was also activated in response to metformin (Fanucchi & Veale, 2009). This indicates 
that p53 activation via AMPK signalling may not play a significant role in the anti-
proliferative effects of metformin in OSCC cell lines. Western blot evaluation of P-p53Ser15 
levels could be used to confirm the involvement of p53 in metformin-induced cell cycle 
arrest. AMPK activation is also associated with inhibition of the mTOR signalling pathway and 
inhibition of mTOR-p70S6K signalling may play a prominent role in the anti-proliferative 
effects of metformin in these cell lines. Further evaluation of the expression levels of other 
components of this pathway such as p27kip and p21cip, cyclin D1, E2F, REDD1 and 4E-BP will 
allow for a better understanding of the way metformin alters these pathways in OSCC.  
We found that metformin inhibited p70S6K in OSCC cell lines. Protein translation is critical 
for cell survival and proliferation, p70S6K is of critical importance as it plays a role in 
promoting the translation of proteins required for ribosomal biogenesis (Bjornsti & 
Houghton, 2004). Inhibition of p70S6K in response to metformin may therefore be central to 
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its anti-proliferative effects. Previous studies indicate that metformin can inhibit mTOR 
independently of AMPK (Kalender et al., 2010; Ben Sahra et al., 2011). Further investigations 
would be required to determine whether p70S6K inhibition is dependent on or occurs 
independently of AMPK in OSCC cell lines. Inhibition of p70S6K with metformin in breast 
cancer cells was associated with reduced levels of the Her2 receptor (Vazquez-Martin, 
Oliveras-Ferraros & Menendez, 2009). Her2 is up-regulated in many cancers including OSCC 
and over-expression of this growth factor receptor is associated with poor prognosis 
(Mimura, Kono, Hanawa, Mitsui, et al., 2005). Therefore, inhibition of p70S6K is a promising 
effect that can be harnessed for chemotherapy.  
Metformin reduced OSCC cell proliferation, but was not toxic at 10 mM, which has been 
shown to be the highest clinically achievable concentration (Martin-Castillo et al., 2010). It is 
possible that transient exposure to higher doses of metformin may exert cytotoxic effects 
that could be exploited for cancer therapy. However, these doses are not clinically 
achievable via oral administration. Additionally, the side-effects of this type of 
administration are not yet known and further studies are required to determine whether 
this type of application will be effective with in vivo studies. Drug administration via non-
conventional routes such as intravenous injection, topical ointments for skin cancer or 
suppositories for rectal cancer may potentially be used to obtain higher drug concentrations 
at the site of the cancer (Menendez et al., 2014). We have proven that metformin reduces 
OSCC cell proliferation at a dose that is clinically achievable and this corresponds with a 
recent study investigating the effects of metformin on OSCC cell lines (Kobayashi et al., 
2013). To exploit the anti-proliferative effects of metformin for cancer therapy, it can be 
combined with cytotoxic agents in order to offer a more effective therapeutic response.  
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Chapter 3: Metformin Negatively Alters the Effects of 
Cisplatin in OSCC Cell Lines 
 
3.1. Introduction 
Cisplatin is one of the most widely prescribed chemotherapeutic drugs and is used for the 
treatment of many different cancers including oesophageal, non-small cell lung, breast, 
cervical, stomach and bladder cancers (Griffiths et al., 2011; Kitagawa et al., 2012; Koo et al., 
2012; Lee et al., 2012; Paz-Ares et al., 2012; Byrski et al., 2014). Cisplatin has been used since 
the 1980’s either as a monotherapy or combination therapy agent for the treatment of OSCC 
(Leichman, 1989). Despite its widespread use, cisplatin can lead to severe renal toxicity 
which is a clinical limitation and major setback to continued treatment or the prescription of 
high doses. For this reason, there is an ongoing search for drugs that can enhance the anti-
cancer effects of cisplatin or reduce cisplatin-induced toxicity (Pinzani et al., 1994). Over 
3000 analogues of cisplatin have been synthesised. Of these, only carboplatin showed 
benefit over cisplatin with regards to its toxicity profile, but was less effective in terms of 
tumour response (Weiss & Christian, 1993; Stewart, 2007). In addition to renal toxicity, 
many patients treated with cisplatin acquire resistance to the drug (Perez, 1998).  
Cisplatin resistance occurs when cancer cells continue to survive in the presence of the drug. 
Cisplatin exerts cytotoxic effects by forming covalent bonds with nitrogen atoms on DNA 
bases. These platinum-DNA adducts hamper DNA replication and promote activation of DNA 
damage response pathways (Jamieson & Lippard, 1999). Alterations in DNA damage 
response signalling can therefore contribute to cisplatin resistance. Mutations in DNA 
damage recognition machinery allow cancer cells to by-pass DNA damage check-points and 
continue to proliferate, whereas over-induction of DNA damage response pathways leads to 
increased repair of platinum-DNA adducts. Both of these effects contribute to cisplatin 
resistance. Conversely, mutations in DNA repair pathways can enhance the sensitivity to 
cisplatin due to reduced repair of platinum-DNA adducts (Basu & Krishnamurthy, 2010). 
Aside from alterations in DNA damage signalling, cisplatin resistance can also be caused 
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when there is reduced cisplatin entry into the nucleus due to altered drug sequestration or 
increased drug export.  
Although DNA binding is thought to be the primary mechanism by which cisplatin exerts 
cytotoxic effects, only a small percentage of cisplatin that enters the cell binds to DNA. This 
may be explained by cross reactivity of cisplatin with other cell components such as RNA, 
proteins, membrane phospholipids and cytoskeletal microfilaments (Gonzalez et al., 2001). 
Platinum-RNA adducts can also disrupt cellular processes that involve the RNA to which it 
binds (Hostetter, Osborn & DeRose, 2012). In addition to its high affinity for nitrogen atoms, 
cisplatin can also form covalent bonds with sulfhydryl groups, such as those in cysteine 
containing proteins. DNA-protein cross-links mediated by cisplatin have been implicated in 
DNA synthesis inhibition (Chválová, Brabec & Kaspárková, 2007). Cisplatin treatment leads to 
the collapse of the cytoskeleton due to it binding thiols in tubulin and to proteins that 
interact with cytoskeletal components (Köpf-Maier & Mühlhausen, 1992). Cisplatin, in its 
aquated form, can also bind to phosphatidylserine moieties of the plasma membrane, which 
may disrupt downstream signalling by membrane proteins (Speelmans et al., 1996). 
Although many of these alternative targets of cisplatin could contribute to its anti-cancer 
effects, they may also act to sequester cisplatin in the cytoplasm and limit its interaction 
with DNA, thereby limiting its cytotoxicity.  
Binding of cisplatin to intracellular thiols such as glutathione (GSH), metallothionein or 
thioredoxin is a major factor that contributes to cisplatin resistance. Increased glutathione 
levels correlated with cisplatin resistance in ovarian cancer cell lines, along with elevated 
levels of γ-glutamylcysteine  synthetase, which is required for GSH synthesis (Godwin et al., 
1992). Conversely, over-expression of glutamate cysteine ligase, also required for GSH 
synthesis, increased cisplatin sensitivity in small-cell lung cancer cell lines and this was 
attributed to up-regulation of the copper transporter which is involved in cisplatin uptake 
(Chen et al., 2008). A plausible mechanism for cisplatin resistance was discovered when it 
was shown that cytoplasmic GSH can bind to cisplatin and target the drug for export via 
glutathione-S conjugate (GS-X) pumps in leukaemia cells (Ishikawa & Ali-Osman, 1993). This 
leads to reduced cisplatin-DNA binding and therefore promotes drug resistance. Cisplatin is 
also able to bind with the cysteine-rich protein, metallothionein, which is involved in heavy 
metal detoxification. Higher levels of metallothionein were correlated with cisplatin 
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resistance in ovarian cancer cell lines (Andrews, Murphy & Howell, 1987). Another redox 
active small protein, thioredoxin, also reduced cisplatin sensitivity when it was over-
expressed in bladder and prostate cancer cell lines (Yokomizo et al., 1995). The level of 
intracellular reduced thiols or thiol containing anti-oxidant molecules may therefore play an 
important role in resistance to cisplatin.  
The primary function for intracellular GSH is the detoxification of reactive oxygen species 
(ROS) and GSH levels are maintained via the reducing potential of NADPH (Figure 3.1). The 
ratio of reduced glutathione (GSH) to oxidised glutathione (GSSG), respectively, is reported 
to be between 100:1 and 300:1 (Dooley et al., 2004). The pentose phosphate pathway (PPP) 
links glycolysis to the GSH redox system. NADP+ is converted to NADPH during reactions 
catalysed by glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate 
dehydrogenase (6PGD), thus providing NADPH which is required for the reduction of GSSG 
(Mehta, Mason & Vulliamy, 2000).  
Metformin promotes glycolysis as increased lactate levels have been observed in diabetic 
patients treated with metformin and higher amounts of glycolytic intermediates were found 
in livers of metformin treated rats (Owen, Doran & Halestrap, 2000). Increased levels of 
glycolysis can also promote PPP flux as glucose-6-phosphate (G6P), produced during the first 
step of glycolysis, can be shunted into the PPP for the production of ribose-5-phosphate 
which is essential for DNA replication. This leads to increased NADPH production which 
promotes the reduction of GSSG to GSH, contributing to a further increase the intracellular 
reducing potential. These effects of metformin on GSH metabolism may therefore impact on 
cisplatin mediated cytotoxicity.  
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Figure 3.1: Relationship between glucose metabolism and the glutathione 
regulation.  G6P produced during the first step of glycolysis can be shunted into the 
PPP. NADP+ is utilised as a co-factor during the oxidative reactions of the PPP, thus 
providing NADPH which is subsequently utilised for the reduction of GSSG to GSH. 
GSH plays an important role in ROS detoxification, and increased GSH also 
contributes to cisplatin resistance.  Hexokinase, HK; glucose-6-phosphate 
dehydrogenase, G6PDH,  6-phosphogluconolactonase, 6PGL; 6-phosphogluconate 
dehydrogenase, 6PGD; ribulose-5-phoshate isomerase, Ru5PI; nicotinamide adenine 
dinucleotide phosphate, NADP; nicotinamide adenosine dinucleotide phosphate, 
NADPH; reduced glutathione, GSH; oxidised glutathione, GSSG; glutathione 
reductase, GR; glutathione peroxidase, GPx.  
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There are numerous studies that have evaluated the effects of metformin combined with 
cisplatin for cancer therapy and these have shown both positive and negative effects. 
Metformin enhanced the effects of cisplatin in ovarian cancer cell lines and ovarian cancer 
xenografts (Gotlieb et al., 2008; Rattan et al., 2011). Metformin also augmented cisplatin 
cytotoxicity in melanoma cells, but it reduced cisplatin toxicity in glioma, neuroblastoma and 
leukaemia cell lines (Janjetovic et al., 2011). Metformin was also shown to enhance the 
effects of cisplatin in lung cancer cell lines, independent of the AMPK signalling pathway and 
via a pathway that interfered with ROS generation (Lin et al., 2013). A recent study showed 
that metformin antagonised the effects of cisplatin in gastric cancer cell lines, and this was 
shown to involve Akt upregulation (Lesan et al., 2014). Therefore, it is evident that the 
effects of metformin combined with cisplatin may differ depending on the cancer type. 
In this chapter, we investigated the effects of metformin in combination with cisplatin on 
OSCC cytotoxicity. We found that metformin decreased the cytotoxic effects of cisplatin and 
was associated with reduced platinum-DNA adducts. Metformin also increased glycolysis 
and the reducing potential of OSCC cell lines. We show that metformin increased 
intracellular thiols and that excessive thiols contribute to cisplatin resistance in OSCC cell 
lines. Therefore, metformin should not be combined with cisplatin for OSCC therapy.  
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3.2. Methods 
3.2.1. Cytotoxicity Assessment by MTT assay 
The effects of metformin on cisplatin mediated toxicity in OSCC cell lines were measured 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay. Cells 
were evenly seeded (7500 cells per well) in 96-well plates and allowed to settle. On the 
following day they were either treated with 10 mM metformin for 24 hours or medium was 
replaced for cells that did not receive metformin. This was followed by treatment with 
cisplatin (linear range 0 – 400 µM) for a further 48 hours, either in the presence or absence 
of 10 mM metformin.  
Following treatment, cell culture medium was removed and replaced with 100 µl of 0.5 
mg/ml MTT solution diluted in culture medium and incubated at 37 °C for 1.25 hrs. This 
allowed for the reduction of MTT to formazan by viable cells. After incubation, 80 µl of the 
MTT solution was removed, 20 µl was left in the well to ensure formazan crystals were not 
disturbed, 100 µl dimethyl sulfoxide (DMSO) was then added per well to dissolve formazan 
crystals. Plates were incubated at 37 °C for 5 minutes, followed by 10 min of shaking in the 
dark at room temperature.  
Absorbance readings at 570 nm were recorded using the MULTISKAN GO microplate reader 
(n = 3 ± SD). Raw absorbance values expressed as a percent of the control, indicative of cell 
viability, were plotted against drug concentration. SigmaPlot 11.0 was used fit sigmoidal 
dose response curves to the data and to calculate the lethal drug concentration required for 
50% cell death (LC50) for each drug treatment.   
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3.2.2. Platinum Content in DNA Quantified by Inductively Coupled 
Plasma Mass Spectrometry (ICP-MS)  
The cytotoxic action of cisplatin is mainly attributed to its ability to form cisplatin-DNA 
adducts. In order to determine whether metformin alters cisplatin-DNA adduct formation, 
total genomic DNA was extracted from OSCC cells and platinum content in DNA was 
quantified by inductively coupled plasma mass spectrometry (ICP-MS). OSCC cells were 
treated with LC30 concentrations of cisplatin for 48 hours either with or without prior 
exposure to 10 mM metformin for 24 hours.  
Cells were harvested and collected as previously described (section 2.2.5.1.1.) and genomic 
DNA was immediately isolated using a phenol: chloroform extraction method. Cells in 50 µl 
1x PBS were resuspended in 450 µl genomic lysis buffer (10mM Tris pH 8; 100mM EDTA pH8; 
autoclaved; 0.5% SDS in nuclease-free water) and incubated at 37 °C for 1 hour. Proteinase K 
(Fermentas, EO0491) was added to a final concentration of 100 µg/ml and samples were 
incubated at 50 °C for 2 hours with swirling every 20 min in order to degrade proteins. An 
equal volume of 25:24:1 phenol: chloroform: isoamyl alcohol was added to each sample, 
vortexed on medium speed for 5 sec and then centrifuged at 12 500x g for 20 min at room 
temperature to allow for phase separation. The upper aqueous phase was removed into a 
clean tube and the previous step was repeated. An equal volume of 24:1 chloroform: 
isoamly alcohol was then added to remove excess phenol and samples were centrifuged at 
12 500x g for 20 min at room temperature once again.  
Two volumes of 100% ethanol and a tenth of the volume of 3M sodium acetate (pH 5.2) was 
added to each sample in order to precipitate DNA. Samples were gently mixed and 
incubated at -20 °C for 24 hours. Samples were centrifuged at 10 000x g for 5 min at 4 °C to 
pellet DNA precipitate, and pellets were resuspended in 70% ethanol in order to wash DNA. 
After centrifugation to collect DNA, excess ethanol was removed, and pellets were dried and 
resuspended in nuclease-free water. DNA solutions were quantified using the NanoDrop 
spectrophotometer (Thermo Scientific, ND1000).  
For ICP-MS, equal amounts of DNA (40 µg) were hydrolysed in 1% HNO3 at 70°C for 24 hours 
and analysed for platinum content on an Agilent 7700 ICP-MS  (n = 3 ± SD). ICP-MS was 
performed as a charged service by Riana Rossouw at Stellenbosch University. The instrument 
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was optimised for sensitivity and low oxides. Analysis was done in no-gas mode, and the 
instrument was calibrated for platinum analysis using National Institute of Standards and 
Technology traceable standards.  
3.2.3. Lactate Quantification for Evaluation of Glycolysis 
Glycolysis levels were determined by quantifying lactate secreted in culture medium by the 
lactate dehydrogenase assay (Cowley et al., 2004). During the conversion to lactate to 
pyruvate via lactate dehydrogenase, NAD+ is utilized as a cofactor which results in NADH 
release at a rate that is directly proportional to the concentration of lactate. NADH strongly 
absorbs light at 340 nm whereas NAD+ does not. Cells were either not treated or treated 
with 10 mM metformin for 24 hours after which culture medium and cells were collected. 
Cells were counted as described in section 2.2.2. For lactate quantification, 50 μl of culture 
medium was added to 950 μl glycine-hydrazine buffer (640 mM glycine, 640 mM hydrazine, 
4.8 mM NAD+, 16 U/ml lactate dehydrogenase, pH 9.2) and incubated at 37°C for 2 minutes. 
NADH was then quantified spectrophotometrically at 340 nm and values corrected for cell 
number (n = 3 ± SD).  
3.2.4. MTT Assay to Determine Reducing Potential in the Presence of 
Metformin 
The effect of metformin on the reducing potential of OSCC cell lines was measured using the 
MTT assay. Cells were evenly seeded in 96-well plates (8500 cells/well) and allowed 24 hours 
to settle. Cells were then treated with 10 mM metformin for a further 24 hours or medium 
was replaced for untreated controls. For the MTT assay, cells were treated with 100 µl of a 
0.5 mg/ml MTT solution made up in cell culture medium for 1 hour. Once the precipitate had 
formed, 80 µl of the supernatant was removed from each well to ensure that the formazan 
precipitate was not disturbed and 100 µl dimethyl sulfoxide (DMSO) was added per well in 
order to dissolve formazan. Plates were incubated at 37 °C in the dark for 5 min, followed by 
15 min shaking at room temperature. Absorbance values at 570 nm were recorded using the 
Multiskan GO microplate spectrophotometer (Thermo Scientific, 51119200). Absorbance 
values were corrected against live cells counted from replicate wells using Trypan blue 
exclusion as described in section 2.2.2.  
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3.2.5. Low Molecular Weight Thiol levels Determined by 
Monobromobimane Fluorescence 
Cisplatin can bind to intracellular thiols which reduces its efficacy due to altered drug 
sequestration and reduced DNA binding. Metformin was shown to increase reducing 
potential in OSCC cell lines, and the intracellular redox state is tightly controlled by the thiol 
redox defence system. We hypothesised that metformin contributes to cisplatin resistance 
by modulating intracellular thiols. Monobromobimane was used to quantify levels of 
reduced low molecular weight thiols determined by the fluorescence of thiol-bimane 
adducts.  
Cells were evenly seeded in 10 cm culture dishes and allowed 24 hours to settle. They were 
then treated with 10 mM metformin for 24 hours or medium was replaced for untreated 
controls. Cells were then treated with 0.3mM monobromobimane made up in DMSO for 10 
min and harvested as previously described. Cells were lysed in triple detergent lysis buffer 
(50 mM Tris–HCl, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate), then 
centrifuged at 10 000x g for 5 min to remove cell debris and 100 µl of the resulting 
supernatants were used in the assay.  
Samples were analysed using the Ascent multi-well plate fluorimeter (Thermo Scientific) at 
excitation/emission wavelengths of 360/460 nm. Fluorescence readings were corrected 
against cell number (n = 3 ± SD) for cells seeded in parallel dishes that were counted using 
trypan blue exclusion as described in section 2.2.2.    
3.2.6. The Effect of Glutathione Depletion by Buthionine Sulfoximine 
on Cisplatin Toxicity 
We showed that metformin increased intracellular thiols in OSCC cell lines. Glutathione is 
the major intracellular thiol and may play a role in the negative effects of metformin on 
cisplatin cytotoxicity. In order to determine whether the observed increase in thiols in 
response to metformin treatment negatively alters the effects of cisplatin, cytotoxicity of 
cisplatin or metformin and cisplatin was assessed during glutathione (GSH) depletion by 
buthionine sulfoximine (BSO). BSO acts to deplete GSH by inhibiting γ-glutamyl cysteine 
ligase, which is required for GSH synthesis (Griffith, 1982).  
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An equal number of cells were seeded (7500 cells per well) in a 96-well plate and allowed 18 
hours to settle. They were then treated with 10 mM metformin for 18 hours or 10 mM 
metformin combined with 0.4 mM BSO for 18 hours; followed by the addition of 12 fold 
dilutions of cisplatin (400 – 0 µM) for 36 hours. Control cells were untreated, treated with 10 
mM metformin or treated with metformin and BSO for the entire duration. Cytotoxicity was 
then evaluated using the MTT assay as described in section 3.2.1 (n = 3 ± SD).  
3.2.7. The Effect of Thiol Repletion with N-acetyl-L-cysteine on 
Cisplatin Toxicity 
In order to confirm that increased thiols contribute to cisplatin resistance in OSCC cell lines, 
the effects of increased intracellular thiols on the cytotoxicity of cisplatin was determined 
using the MTT assay. N-acetyl-L-cycteine (NAC) is a cell permeable cysteine derivative that 
was used to increase intracellular thiol pools. Cytotoxicity assays were performed as 
previously described (section 3.2.1.). Cells were evenly seeded at 7500 cells/well, after 24 
hours they were treated with 10 mM NAC for 24 hours or replaced with fresh culture 
medium. They were then treated with a cisplatin or 10 mM NAC and cisplatin for a further 
48 hours and the MTT assay was performed.   
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3.3. Results 
3.3.1. Metformin increases resistance to cisplatin in OSCC cell lines by 
reducing platinum-DNA adduct formation. 
In chapter 1 we showed that metformin exerts anti-proliferative effects on OSCC cell lines, 
but it was not cytotoxic at the concentration used. We combined metformin with cisplatin 
and evaluated cytotoxicity in OSCC cell lines. MTT assay data indicated that metformin 
reduced the toxic effects of cisplatin on OSCC cell lines (Figure 3.2) as LC50 values were 
higher when 10 mM metformin was combined with cisplatin (Table 3.1). This indicates that 
metformin negatively alters the response to cisplatin in OSCC cell lines. The percentage 
increase in LC50 for metformin cisplatin treatment compared to cisplatin alone was 77 ± 6% 
for WHCO1, 128 ± 65% for WHCO5 and 173 ± 38% for SNO.  
 
 
 
 
 
 
 
Figure 3.2. Cytotoxicity curves indicate that metformin causes resistance to 
cisplatin.  Cells were treated with 18 fold dilutions of cisplatin (CDDP) for 48 hrs or 
pre-treated with 10 mM metformin (Met) for 24 hrs followed by 48 hr co-treatment 
with metformin and cisplatin. A) MTT assay data expressed as a percent of respective 
controls are depicted on the graphs and sigmoidal dose response curves were fitted 
to the data (n=3 ± SD).  
 
  CDDP  CDDP + Met   
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Table 3.1: Metformin antagonises the cytotoxicity of cisplatin.  LC50 values were higher 
when metformin was combined with cisplatin compared to cisplatin alone (n=3 ± SD), which 
confirms that metformin promotes cisplatin resistance.  
 
 
 
 
 
 
Although resistance to cisplatin is not desirable from a chemotherapeutic perspective, it was 
important to determine the mechanisms responsible for the altered susceptibility to 
cisplatin in the presence of metformin as both these drugs are already being prescribed for 
the treatment of cancer and diabetes. Diabetes is associated with an increased risk of cancer 
and as such, it is possible that these drugs may be co-prescribed to individuals suffering from 
both cancer and diabetes. By determining the mechanisms of metformin-induced cisplatin-
resistance, it may also be possible to identify other cancer types that could become cisplatin-
resistant.  
Since cisplatin primarily exerts cytotoxic effects by forming platinum-DNA adducts, we 
quantified platinum levels in DNA extracted from cells treated with cisplatin alone or 
metformin combined with cisplatin. Platinum content in DNA was lower when metformin 
was combined with cisplatin compared to cisplatin alone in all three OSCC cell lines tested 
(Figure 3.3). There was a 19 ± 0.9% decrease in the WHCO1 cell line, a 14 ± 0.4% decrease in 
the WHCO5 cell line and a 27 ± 4.9% decrease in the SNO cell line.  
 
 
 
 
 LC50 (µM CDDP) 
 
WHCO1 WHCO5 SNO 
CDDP 70.88 ± 13.80 11.68 ± 3.62 11.01 ± 1.62 
CDDP + Met 126.02 ± 26.57 28.03 ± 15.81 28.16 ± 3.37 
P-value 0.009 0.075 0.001 
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Figure 3.3: Metformin reduces platinum-DNA adduct formation.  Cells were treated 
with cisplatin alone for 48 hours or pre-treated with 10 mM metformin for 24 hours 
followed by treatment with 10 mM metformin combined with cisplatin for 48 hours. 
Platinum content in genomic DNA extracted from these samples were quantified by 
ICP-MS. Results showed that platinum levels were significantly lower when metformin 
was combined with cisplatin compared to cisplatin alone (n=3 ± SD). Therefore, 
metformin reduces cisplatin toxicity by inhibiting platinum-DNA adduct formation.  
 
ICP-MS data indicates that the addition of metformin led to a reduction in the formation of 
platinum-DNA adducts in OSCC cell lines. Therefore, metformin antagonized the effects of 
cisplatin by inhibiting its primary mechanism of cytotoxicity. We hypothesised that reduced 
formation of platinum-DNA adducts in the presence of metformin may be attributed to 
reduced drug entry into the nucleus due to altered drug sequestration. Due to the thiol 
binding properties of cisplatin, we investigated whether metformin may increase the pool of 
reduced thiols which contribute to cisplatin resistance.  
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3.3.2. Metformin promotes glycolytic flux and increases the reducing 
potential of OSCC cell lines.  
Enhanced glycolysis contributes to the glucose lowering effects of metformin in diabetes and 
may also be responsible for the increased serum lactate levels observed in diabetic patients. 
Increased glycolysis has been observed in prostate cancer cells treated with metformin (Ben 
Sahra, Laurent, et al., 2010). Enhanced glycolysis contributes to increased PPP flux, and this 
may alter the intracellular redox state due to alterations in the NADP+/NADPH ratio. Lactate 
levels serve as a marker of glycolysis. Hence lactate secreted into cell culture medium after 
OSCC cell lines were treated with metformin were quantified. Metformin treatment resulted 
in higher lactate secretion, indicative of increased glycolysis in OSCC cell lines (Figure 3.4).  
 
 
 
 
 
 
 
Figure 3.4: Metformin increases glycolysis levels as determined by medium lactate 
levels.  Lactate and NAD+ are converted to pyruvate and NADH in the presence of 
LDH. Lactate levels in culture medium of cells that were not treated or treated with 
10 mM metformin for 24 hrs are indicated by NADH absorbance values at 340 nm. 
Absorbance values were corrected against cell number and represented above, 
untreated (blue bars); metformin (red bars) (n=3±SD). Increased lactate secreted by 
OSCC cell lines after metformin treatment show that metformin increases glycolysis.  
 
Next, we determined whether metformin could alter the reducing potential of OSCC cell 
lines as G6P shunted into the PPP can contribute to an increase in the NADPH/NADP+ ratio, 
which would consequently increase the reducing potential of OSCC cell lines. The 
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intracellular reducing environment was determined based on the ability of OSCC cell lines to 
reduce MTT to formazan in the absence or presence of metformin. We found that 
metformin increased the intracellular reducing environment in all three OSCC cell lines 
(Figure 3.5) 
 
 
 
 
 
 
 
Figure 3.5: Metformin increases reducing equivalents in OSCC cell lines.   Reducing 
potential was measured in OSCC cell lines in the absence and presence of 10 mM 
metformin for 24 hrs by quantifying the reduction of MTT to formazan. Absorbance 
values (590 nm) of formazan produced by cells were corrected for cell number to 
represent total reducing equivalents per x 104 cells. Data indicated that metformin 
treated cells had a higher reducing potential than untreated cells (n=3±SD). 
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3.3.3. Modulation of intracellular thiols by metformin contributes to 
cisplatin resistance. 
Metformin increased glycolytic flux and also increased the reducing potential of OSCC cell 
lines. We hypothesised that increased glycolysis may increase PPP flux and NADPH levels 
which fuels the reduction of GSSG to GSH. This contributes to cisplatin resistance by 
reducing cisplatin-DNA binding due to altered drug sequestration or increased export 
(Ishikawa & Ali-Osman, 1993).  
Levels of reduced intracellular thiols after 24 hour treatment with 10 mM metformin were 
quantified and compared to that of untreated controls. Metformin increased intracellular 
reduced thiol levels as monobromobimane fluorescence was higher in metformin treated 
samples (Figure 3.6). For each cell line, fluorescence per 1 x 104 cells in untreated and 
metformin treated cells, respectively, were WHCO1 - 4.3 ± 0.13 and 8.8 ± 0.28; WHCO5 – 5.4 
± 0.36 and 9.3 ± 0.27; SNO – 6.5 ± 0.18 and 11.8 ± 0.62. We concluded that increased levels 
of intracellular reduced thiols may alter the sequestration of cisplatin which reduces the 
formation of platinum-DNA adducts and contributes to cisplatin resistance in OSCC cell lines.  
 
 
 
 
 
 
Figure 3.6: Metformin increases the level of reduced low molecular weight thiols in 
OSCC cell lines. Untreated (blue bars) and 10 mM metformin treated cells (red bars) 
were treated with 0.3 mM monobromobimane for 10 min and fluorescence was 
recorded (excitation 360 nm/emission 460 nm). Cells exhibited higher fluorescence in 
the presence of metformin indicating higher levels of reduced molecular weight thiols.   
0 
2 
4 
6 
8 
10 
12 
14 
WHCO1 WHCO5 SNO 
Lo
w
 m
o
le
cu
la
r 
w
e
ig
h
t 
th
io
ls
 
(f
lu
o
re
sc
e
n
ce
 3
6
0
n
m
/4
6
0
n
m
) 
   
   
   
 
p
er
 1
0
4
 c
e
lls
  
Untreated 
10mM Met 24hr 
** ** ** 
 68 
 
 
In order to confirm that thiols were involved in the mechanism of resistance to cisplatin in 
the presence of metformin, we sought to determine the effects of buthionine sulfoximine 
(BSO) on cisplatin and metformin. We considered using BSO as it inhibits synthesis of the 
major intracellular thiol, glutathione (GSH). Cytotoxicity was evaluated in cells treated with 
cisplatin only, cisplatin plus BSO, cisplatin and metformin or cisplatin and metformin plus 
BSO. We found that thiol depletion blocked the protective effects of metformin on cisplatin 
chemotoxicity (Figure 3.7). Predictably, thiol depletion enhanced toxicity of cisplatin as lower 
LC50 values were observed.  
LC50 values for cisplatin and metformin combined with BSO were much lower compared to 
cisplatin and metformin without BSO. In fact, LC50 values for metformin and cisplatin 
therapy combined with BSO were very similar to that of cisplatin alone, which shows that 
GSH is involved in the metformin-induced cisplatin resistance. Glutathione depletion 
completely abolished the chemoprotective effects of metformin when combined with 
cisplatin, which indicates that glutathione plays a significant role in metformin induced 
cisplatin resistance.   
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Figure 3.7: Cisplatin resistance in the presence of metformin is reversed by 
glutathione inhibition.  Cells were treated with 0-400µM CDDP for 36 hrs; 0.4 mM BSO 
plus CDDP; 10 mM metformin and CDDP; or 0.4 mM BSO, 10 mM metformin and CDDP. 
Cytotoxicity was then evaluated using the MTT assay. A) MTT assay curves display the 
effects of the various drug combinations on OSCC cell lines. B) LC50 values were 
expressed as a percentage of cisplatin alone and depicted on the graph. As expected, 
BSO enhanced the toxicity of CDDP alone. LC50 values for BSO, metformin and CDDP 
treatment were reduced to similar levels as CDDP alone which indicates that BSO 
abolished metformin induced cisplatin resistance in OSCC cell lines.  
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In order to confirm that increased levels of intracellular thiols is a plausible mechanism of 
resistance to cisplatin in OSCC cell lines, higher levels of intracellular thiols were induced 
with N-acetly-L-cysteine (NAC) and the effects of this treatment on cisplatin-mediated 
cytotoxicity was measured with the MTT assay. Cells treated with NAC combined with 
cisplatin exhibited higher LC50 values compared to cells treated with cisplatin only, as seen 
by the considerable rightward shift in toxicity curves for NAC treated cells (Figure 3.8). The 
percentage change in LC50 compared to cisplatin alone is represented in Table 3.2. As 
expected, NAC increased LC50 values in OSCC cell lines.  
 
 
 
 
 
 
 
 
Figure 3.8: Increased thiols promote cisplatin resistance in OSCC cell lines. 
Cytotoxicity was evaluated by MTT assay in cells treated with 0-400 µM CDDP, CDDP 
plus 10 mM metformin or CDDP plus 10 mM NAC. LC50 values were higher when CDDP 
was combined with 10 mM NAC. MTT assay graphs depict a rightward shift in orange 
curves compared to purple curves. Metformin and NAC both increase LC50 values with 
regard to CDDP, indicating that increased intracellular thiols contribute to cisplatin 
resistance and metformin induced CDDP resistance may be due to increased thiols. 
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Table 3.2: Percentage change in LC50 values indicate that cisplatin-induced toxicity is 
reduced in the presence of NAC.  NAC reduced cisplatin induced toxicity by 3- to 12-fold in 
OSCC cell lines, which indicates that higher levels of intracellular thiols are a major factor 
contributing to cisplatin resistance. Metformin also caused resistance to cisplatin, but to a 
lower extent than NAC alone.  
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CDDP 100 ± 1.2 100 ± 12.8 100 ± 4.5 
CDDP + 10 mM Met 145 ± 13.2 147 ± 2.5 174 ± 5.0 
P-Value 0.011  0.015 5 x 10-5 
CDDP + 10 mM NAC 591 ± 71.6 1253 ± 317.8 380 ± 23.7 
P-Value 0.003 0.013 0.002 
 
The significant reduction in cisplatin-mediated toxicity proves that intracellular thiols play a 
major role in cisplatin resistance in these OSCC cell lines. Metformin did not reduce the toxic 
effects of cisplatin to the same extent as NAC, which is expected as the cysteine based 
molecule contains a thiol group. Metformin did, however increase the levels of low 
molecular weight reduced thiols in OSCC cell lines. Therefore, increased levels of reduced 
thiols provides a valid explanation for the reduced toxicity of cisplatin in the presence of 
metformin.  
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3.4. Discussion 
We show in this chapter that metformin diminished the cytotoxic effects of cisplatin in OSCC 
cell lines. Studies by Janjetovic et al. support this finding as they showed that metformin 
antagonized the toxicity of cisplatin in numerous other cancer cell lines (Janjetovic et al., 
2011). They suggested that reduced toxicity of cisplatin occurred because metformin 
treatment results in hyper-activation of Akt independent of AMPK. Hyperactivation of Akt is 
known to promote tumour survival and stimulate glycolysis (Elstrom et al., 2004). 
Additionally, complex I inhibition by metformin could lead to reduced oxidative 
phosphorylation, which increases the AMP:ATP ratio and up-regulates glycolysis via AMPK 
(Ben Sahra, Marchand-Brustel, et al., 2010). We showed that metformin also increased 
glycolysis in OSCC cell lines. Increased glycolysis can provide G6P which fuels the PPP and 
promotes the reduction of NADP+ to NADPH. NADPH also acts as a co-factor for the 
reduction of glutathione, and this promotes resistance to cisplatin.  
Studies have shown that ovarian cancer cell lines that have increased GSH levels are highly 
resistant to cisplatin (Godwin et al., 1992). Cell lines isolated from cisplatin-resistant patients 
also displayed elevated GSH, however, increased GSH did not correlate with cisplatin-
resistance in all cancer types as some cell lines that display cisplatin resistance do not have 
increased GSH levels (Kelland, 1993). Other thiol containing molecules such as 
metallothionein and thioredoxin are also associated with cisplatin resistance (Andrews, 
Murphy & Howell, 1987; Yokomizo et al., 1995). We showed that metformin increased levels 
of low molecular weight reduced thiols in OSCC cell lines and this contributes to cisplatin 
resistance.  
We concluded that GSH plays an important role in metformin induced cisplatin resistance as 
co-treatment with BSO abolished metformin induced cisplatin resistance. GSH depletion 
enhanced the toxicity of cisplatin and increased thiol levels achieved by treatment with NAC 
negated the effects of cisplatin in OSCC cell lines. This result provides conclusive evidence in 
support of the hypothesis that metformin negatively alters the cytotoxic effects of cisplatin 
by increasing the levels of intracellular reduced thiols. Although this finding is not beneficial 
from a cancer treatment perspective, it is important to report that caution should be used if 
these drugs are co-prescribed for diabetes and cancer.  
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Increased levels of reduced thiols and glycolysis in response to metformin also support our 
finding that metformin increases the reducing potential of OSCC cell lines. Although 
metformin did not work well with cisplatin, its anti-proliferative effects make it an attractive 
drug for use with other chemotherapeutic drugs. We have shown that metformin does not 
significantly alter the effects of mitomycin C, which is also commonly prescribed for OSCC in 
South Africa (Damelin et al., 2014). Preliminary data from our laboratory also indicate that 
metformin does not enhance the effects of 5-fluorouracil, which is also prescribed for OSCC. 
Given the fact that metformin inhibits the proliferation of OSCC cell lines, and that it is less 
toxic than most currently prescribed chemotherapeutic drugs, it is a promising agent for the 
treatment of OSCC. Since we showed that metformin increased the reducing potential of 
OSCC cell lines, we aimed to determine whether it would work well in combination with 
drugs that are activated in reducing environments.  
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Chapter 4: Metformin promotes the effects of anti-
cancer agents which are activated in reducing 
environments  
 
4.1. Introduction 
We have proven that metformin exerts chemostatic effects in OSCC cell lines and other 
studies have shown that it has cytotoxic effects against cancer stem cells (Hirsch et al., 2009; 
Song et al., 2012). Due to its low toxicity profile, as evidenced by its frequent prescription for 
diabetes and the fact that it has demonstrated chemotherapeutic potential, metformin is a 
promising agent for the treatment of OSCC. Whilst we have shown that metformin induces 
cisplatin resistance (Damelin et al., 2014), we determined that metformin increased the 
reducing potential in OSCC cell lines. For this reason, the effects of metformin in 
combination with reductively activated drugs on OSCC cell lines will be evaluated in this 
chapter. The drugs tested include two copper bis(thiosemicarbazones), diacetyl 
bis(thiosemicarbazonato) copper(II)  (Cu-ATSM) and glyoxal bis(thiosemicarbazonato) 
copper(II) (Cu-GTSM), and disulfiram (DSF).  
4.1.1. Copper Bis(thiosemicarbazones) 
Bis(thiosemicarbazones) are biologically active tetradentate ligands that chelate transition 
metals such as Cu(II). Chelates of these coordination complexes have a neutral charge and 
are therefore lipophyllic and membrane permeable (Paterson & Donnelly, 2011). Copper 
bis(thiosemicarbazones) exert toxic effects primarily by promoting intracellular copper 
accumulation. When copper bis(thiosemicarbazones) enter a cancer cell, cupric ions (Cu2+) 
are reduced to cuprous ions (Cu1+), which become trapped and accumulate within the cell 
resulting in cytotoxic effects due to general copper toxicity and DNA damage. The cuprous 
ions are easily re-oxidised in normal cells due to the higher oxygen content, unlike tumour 
cells which are often hypoxic and this adds to the tumour specificity of copper 
bis(thiosemicarbazones) (Palanimuthu et al., 2013). Copper accumulation results in cell 
poisoning due to inhibition of DNA synthesis and oxidative phosphorylation as well as the 
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oxidation of thiols to form disulfides (Paterson & Donnelly, 2011). Cupric ions exert DNA 
damage by binding to DNA bases and cycling between cupric and cuprous states in the 
presence of reducing agents such as ascorbic acid and glutathione, this promotes the 
formation of hydroxyl free radicals, an additional factor contributing to DNA damage 
(Samuni et al., 1983). 
Cu-ATSM is a promising anti-cancer agent as it is tolerated in vivo and shows hypoxia 
selectivity. Due to it hypoxia selectivity, 64Cu-ATSM is currently undergoing clinical trials 
(NCT00794339) to be used as an imaging agent in positron emission tomography to detect 
hypoxic regions in tumours (Vāvere & Lewis, 2007). Tumour hypoxia is a characteristic 
feature of highly aggressive solid tumours and increased hypoxia is associated with drug 
resistance and resistance to radiotherapy. Over-expression of the hypoxia-inducible 
transcription factor, which is activated in response to hypoxia, is a prognostic feature of 
OSCC and correlates with the stage and severity of the cancer (Ping et al., 2014). Therefore, 
Cu-ATSM may show beneficial anti-cancer effects toward OSCC. Cu-GTSM has been shown to 
induce cell cycle arrest, followed by apoptosis in a neuroblastoma cell line (Bica et al., 2011). 
Both Cu-ATSM and Cu-GTSM and other bis(thiosemicarbazones) have been shown to exert 
anti-cancer effects by inhibiting DNA and RNA synthesis (Palanimuthu et al., 2013). These 
effects are likely due to bis(thiosemicarbazone) mediated inhibition of uridine and thymidine 
incorporation into RNA and DNA, respectively (Bhuyan & Betz, 1968). The effects of copper 
bis(thiosemicarbazones) in OSCC have not been previously characterised and therefore, they 
were investigated in this study.  
4.1.2. Disulfiram 
DSF is a member of the dithiocarbamate family of drugs and is a heavy metal chelating agent 
with particularly high affinity for copper (Johansson, 1992). DSF can be metabolised to 
various hydrolysis products (Figure 4.1). Upon reduction, DSF is broken down to its 
monomer, diethyldithiocarbamate (DDC). DDC is unstable and readily breaks down to form 
diethylamine and carbon disulfide. Two molecules of DDC can combine with copper to form 
the more stable bis(diethyldithiocarbamato)copper(II) (Cu(DDC)2) complex. DSF can also 
directly chelate copper to corm the copper disulfiram (Cu-DSF) complex.  
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DSF is approved by the FDA for treatment of alcoholism, it does not have any notable side 
effects in the absence of alcohol and has demonstrated anti-cancer effects at doses much 
lower than those currently prescribed for the treatment of alcohol abuse (Chen et al., 2006). 
In vitro studies suggest that the anti-cancer effects of DSF are dependent on copper as Cu-
DSF exerted high levels of cytotoxicity toward glioblastoma cell lines, whereas DSF alone did 
not show any effective cytotoxic response (Liu et al., 2012). On the other hand, an in vivo 
study indicated that while copper enhanced the effects of DSF, an effective 
chemotherapeutic response toward neuroblastoma and glioblastoma xenografts in nude 
mice was observed without additional copper (Rae et al., 2013). DSF was shown to reduce 
the growth of breast tumours in vivo, but did not exert harmful effects toward normal breast 
tissue (Daniel et al., 2005). Cancer tissues have been shown to have elevated copper levels 
and this may partly explain why DSF exerts potent cytotoxicity toward malignant cells, but 
not toward normal cells (Rizk & Sky-Peck, 1984). High copper levels are associated with 
increased angiogenesis which is a hallmark of cancer and is contributes to tumour 
progression (Brewer, 2001). DSF has been shown to inhibit angiogenesis, which is another 
factor contributing to its anti-cancer effects (Shian et al., 2003).  
Numerous copper-binding compounds such as 8-hydroxyquinoline and chloroquine have 
been shown to act as proteasome inhibitors and inducers of apoptosis (Daniel et al., 2007). 
Protein degradation is required for the recycling of old, damaged or unused proteins and in 
the regulation of short-lived proteins such as those which play a role in cell cycle regulation. 
As such, protein degradation is essential for cell survival and proliferation. Cancer cells have 
been shown to have increased proteasomal activity and an increased reliance on autophagy 
(Chen & Madura, 2005; O’Donovan, O’Sullivan & McKenna, 2014). As such, proteasome 
inhibition is known to be an important target for cancer therapy and this has led to the 
advent of proteasome targeting drugs, such as bortezomib which target the proteasome 
(Nencioni et al., 2006). DSF and its analogue, pyrrolidine dithiocarbamate, have both been 
shown to inhibit proteasome activity in breast cancer cells, but only when complexed with 
copper (Daniel et al., 2005; Chen et al., 2006). Interestingly, these compounds did not inhibit 
proteasome function in normal breast cancer cells (Daniel et al., 2005). We have shown in 
this study that another analogue of DSF, di-N-propyl dithiocarbamate also inhibits 
proteasome activity. The proteasome is a promising target for cancer therapy and inhibition 
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of proteasome activity by DSF is considered to be one of the major mechanisms contributing 
to its anti-cancer effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Disulfiram, its metabolites and analogues.  DSF is reduced to form 
DDC, which can be further reduced to form diethylamine and carbon disulfide. DSF 
can bind copper directly to form the Cu-DSF complex, alternatively, two molecules 
of DDC can combine to chelate copper to form the Cu(DDC)2 complex. The effects 
of DSF were compared to two thiuram disulfide analogues, DPTD and TTD. The 
monomeric structures of these molecules are also represented.  
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4.1.3. Protein Degradation Pathways 
There are two major pathways known to mediate protein degradation in eukaryotic cells, 
the ubiquitin-proteasome system (UPS) and lysosomal proteolysis (summarised in Figure 
4.2). The UPS is responsible for the degradation of 80-90% of proteins in eukaryotic cells 
such as regulated, short-lived, and damaged proteins. It involves the attachment and ATP 
dependent activation of ubiquitin, a 76 amino acid polypeptide, to an activating enzyme, E1. 
Activated ubiquitin is then transferred to a conjugating enzyme, E2, and then to the target 
protein via an E3 ubiquitin ligase. This leads to the formation of a polyubiquitin chain on the 
substrate, which is then recognised and targeted for degradation by the 26S proteasome 
(Lilienbaum, 2013). The target substrate then unfolds and is cleaved by the protesomal 
enzymes which include two trypsin-like, two chymotrypsin-like and two caspase-like 
proteolytic sites that each recognise and cleave proteins at specific amino acid sequences 
(Heinemeyer et al., 1997). Substrates are cleaved into short peptides of 3 - 25 amino acids in 
length. Studies have shown that copper binding agents such as disulfiram, pyrrolidine 
dithiocarbamate, clioquinol and 8-hydroxyquinoline act as proteasome inhibitors when they 
are in complex with copper and that these agents are able to induce apoptosis in tumour 
cells known to contain elevated copper levels (Daniel et al., 2005).  
Lysosomes are organelles that are involved in the degradation of proteins and other 
macromolecules (Figure 4.2). These membrane enclosed structures contain hydrolytic 
enzymes which are active in an acidic pH. The intralysosomal pH is maintained at 4.6 - 5.0 by 
a proton pumping ATPase in the lysosomal membrane. Lysosomes receive and degrade 
macromolecules from the autophagic, endocytic, phaogocytic and secretory pathways.  
(Luzio, Pryor & Bright, 2007). Although lysosomes are responsible for the degradation of 
fewer proteins than the UPS, they are active in most cells and are involved in multiple 
proteolytic pathways which include macroautophagy, chaperone mediated autophagy, 
microautophagy and endocytosis (Dice, 2007).  
Macroautophagy is initiated in response to environmental stresses such as nutrient 
deprivation, hypoxia, radiation or anti-cancer drug treatment. This triggers activation of 
AMPK and inhibition of mTOR, which promotes the formation of an autophagy (ATG) protein 
complex. The complex then binds to a portion of membrane believed to originate from the 
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endoplasmic reticulum and promotes the formation of an isolation membrane. The isolation 
membrane then elongates to form a phagophore, this process involves the ATG5-ATG12 
complex and microtubule light chain protein (LC3). During macroautophagy, pro-LC3 is  first 
cleaved at its C-terminus to form LC3-I followed by conjugation with the lipid 
phosphotidylethanolamine (PE) moiety to form LC3-II (Mizushima, Yoshimori & Levine, 
2010). The phagophore then engulfs target substrates such as old or unused proteins and 
organelles. Once the vesicle closes to form the autophagosome and the ATG complex is 
released, the autolysosome fuses with a lysosome and the contents of this acidic vesicular 
organelle (AVO) including LC3 are degraded (Yang & Klionsky, 2010).  
Chaperone mediated autophagy is activated during long term starvation. During this process, 
substrate proteins are directed to the lysosome by a molecular chaperone complex. The 
chaperone complex then recognises and binds to a receptor on the lysosomal membrane 
followed by import and degradation of the substrate in the intralysosomal lumen (Dice, 
2007). Microautophagy can be selective or non-selective and is involved in the degradation 
of cytosolic components containing proteins as well as membrane enclosed organelles such 
as peroxisomes, mitochondria and nuclei. Microautophagy is distinct from other autophagic 
pathways as it involves invagination of the lysosomal membrane followed by engulfment 
and scission of the vesicle (Mijaljica, Prescott & Devenish, 2014). In addition to the 
autophagic pathways, substrates are also targeted to the lysosome via the endosomal 
pathway.  Extracellular proteins such as hormones and receptor proteins are absorbed into 
the cytoplasm and form an endosome. Endosomes may enfold and engulf other vesicles to 
form a multivesicular body which then fuses with a lysosome resulting in the degradation of 
its components (Dice, 2007). These pathways highlight the importance of lysosomes in the 
recycling and effective turnover of both proteins and organelles.  
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Figure 4.2: Protein degradation pathways.  The ubiquitin proteasome system is 
involved in the degradation of approximately 90% of intracellular proteins. Other 
proteins and macromolecules are degraded by lysosomal hydrolytic enzymes. 
Numerous pathways are involved in targeting proteins and organelles for 
degradation by lysosomal hydrolases. These include the autophagic pathways, 
macroautophagy,  microautophagy and chaperone mediated autophagy as well as 
the endosomal pathway.  
In this chapter, we aimed to determine whether metformin can be combined with drugs 
activated in reducing environments to offer a novel therapeutic strategy for OSCC. We 
evaluated the effects of these drug combinations on OSCC cytotoxicity. DSF is a well-
established drug that has potential to enter into phase II clinical trials for cancer therapy as it 
is already approved for the treatment of alcoholism and as such, we investigated the 
mechanisms responsible for the anti-proliferative effects of DSF. Identifying these 
mechanisms will be useful for the identification of diagnostic markers that can be used to 
differentiate between individuals who are likely to respond to this treatment and those who 
are not. We hypothesised that DSF exerted cytotoxic effects toward OSCC cell lines by 
impairing the function of both proteasomal and lysosomal protein degradation pathways.   
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4.2. Methods 
4.2.1. Synthesis of Compounds 
The bis(thiosemicarbazones, diacetyl-bis(4-methylthiosemicarbazone) (ATSM) and glyoxal-
bis(4-methylthiosemicarbazone) (GTSM) were synthesised by Dr. Leonard H. Damelin 
according to the method of French et al. (French et al., 1958; Damelin et al., 2014). Two 
analogues of disulfiram, dipyrrolidine thiuram disulfide (DPTD) and tetrapropyl thiuram 
disulfide (TTD) were also synthesised by Dr. Leonard H. Damelin as previously described 
(Cramer, 1935). Copper conjugates of each compound were synthesised by reacting 100 µl 
of a 50 µM solution of each drug, prepared in DMSO, with 2.5 µl of 2M copper chloride 
(CuCl2). Structure of these compounds were assessed by NMR which was conducted by Dr. 
Amanda L. Rosseau.  
ATSM: 1H NMR (500 MHz, DMSO) 11.74 (2H, s, 2 × CH=N), 8.48 (2H, d, J = 4.2, 2 × NH), 7.72 
(2H, s, 2 × NH), 2.96 (6H, d, J = 4.4, 2 × CH3); 13C NMR (126 MHz, DMSO) 177.55 (2 × C= S), 
140.02 (2 × C=N), 30.89 (2 × CH3).  
GTSM: 1H NMR (500 MHz, DMSO) 10.20 (2H, s, 2 × NH), 8.36 (2H, d, J = 4.1, 2 × NH), 3.02 (6H, 
d, J = 4.5, 2×CH3), 2.20 (6H, s, 2 × CH3); 13C NMR (126 MHz, DMSO) 178.47 (2 × C= S), 147.95 
(2 × C=N), 31.18 (2 × CH3), 11.64 (2 × CH3). 
DPTD: 1H NMR (500 MHz, DMSO-d6) δ 3.86 (dt, J = 61.6, 7.0 Hz, 1H), 2.03 (dt, J = 73.0, 6.9 Hz, 
1H); 13C NMR (126 MHz, DMSO-d6) δ 187.71, 57.43, 51.40, 26.63, 24.21. 
TTD: 1H NMR (500 MHz, DMSO-d6) δ 3.89 (dt, J = 10.1, 4.9 Hz, 1H), 1.78 (dq, J = 87.4, 7.6 Hz, 
1H), 0.92 (dt, J = 57.1, 7.4 Hz, 2H); 13C NMR (126 MHz, DMSO-d6) δ 192.10, 58.88, 54.89, 
21.73, 19.49, 11.42. 
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4.2.2. Cytotoxicity Assessment of Metformin Combined with DSF, Cu-
ATSM or Cu-GTSM 
In order to determine the effects of metformin in combination with drugs that are activated 
in reducing environments, cells were first pre-treated with 10 mM metformin for 24 hours 
followed by combination therapy with metformin and ATSM, Cu-ATSM, GTSM, Cu-GTSM, 
DSF or Cu-DSF for a further 48 hours. MTT assays were then performed as described in 
section 3.2.1.  
The dependence on copper for the cytotoxic effects of DSF was evaluated by reacting copper 
with DSF in 0.25:1, 0.5:1 and 1:1 molar ratios, respectively. Cells were seeded as described in 
section 3.2.1, and after 48 hours they were treated with DSF or each of the above-
mentioned compounds for 48 hours. Cytotoxicity was assessed using the MTT assay as 
described.  
To confirm the role of copper in the mechanism of action of DSF, cytotoxicity was assessed 
after intracellular copper was depleted with the cell impermeable Cu2+ chelator, 
bathocuproine disulfonic acid (BCS) (Furuta et al., 2002). Once settled, cells were pre-treated 
with 10 mM metformin for 24 hours followed by treatment with DSF or DSF and 200 µM BCS 
for a further 48 hours. MTT assays were then conducted as described in section 3.2.1 in 
order to determine the concentration of DSF required for 50% cell death.  
Cytotoxicity of DSF was compared to two DSF analogues, DPTD and TTD. These analogues 
have lower hydrolysis rates and therefore, are not metabolised to the same extent as DSF. 
Briefly, cells were equally seeded in 96-well plates and allowed 24 hours to settle. Cells were 
then pre-treated with metformin for 24 hours, followed by treatment with DSF, DPTD, TTD 
or their respective copper conjugates, in the absence or presence of metformin for 48 hours. 
MTT assays were then conducted as described in section 3.2.1.  
4.2.3. Microscopic Imaging of Disulfiram Treated Cells  
The effects of DSF on cell morphology were captured using bright-field microscopy. Cells 
were equally seeded on glass coverslips in 6-well plates. After 48 hours, cells were treated 
with 10 mM metformin or treated with LC50 concentrations of DSF or Cu-DSF with or 
without metformin for 24 hours. Coverslips were rinsed in 1 x PBS, placed with the cell 
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surface down on glass slides, and images were immediately captured with the Olympus BX63 
microscope in bright-field at 10X magnification.  
4.2.4. Assessing Plasmid DNA Damage Due to Redox Cycling of Copper  
The pBR322 plasmid in JM109 E. coli cells stored in glycerol at -70 °C, were placed into LB 
broth containing 100 μg/ml ampicillin and incubated at 37 °C overnight with shaking at 220 
rpm. Plasmid DNA was isolated using the ZyppyTM Plasmid Miniprep Kit (Zymo Research) for 
use in the experiment. For the assay, 100 ng pBR322 was incubated with 50 μM of the drug 
of interest in the absence of presence of 0.6 mM ascorbic acid. Stock solutions (0.5 mM) of 
each of the following drugs were prepared for use in the assay, metformin, metformin-
copper chloride, DSF, Cu-DSF, DSF-metformin, Cu-DSF-metformin. Reaction components 
were added to 10 μl 2 x assay buffer (100 mM Tris-HCl (pH 7.2); 36 mM NaCl) and made up 
to a final volume of 20 μl with nuclease-free water. Samples were incubated at 37 °C for 1 
hour and reactions were stopped by the addition of quench buffer (0.25% bromophenol 
blue, 50% glycerol, 0.5 mM EDTA). Samples were immediately loaded onto a 1% agarose gel 
containing ethidium bromide, and resolved at constant 100V for 1 hour. Images were 
captured under UV light using the Bio-Rad Gel Doc Imaging System and QuantityOne 
Software.  
 
4.2.5. Determining Intracellular Copper Accumulation by ICP-MS 
ICP-MS was used to quantify total intracellular copper levels as previously described (Price et 
al., 2011). Cells were seeded in 10 cm dishes and treated with metformin, DSF or metformin 
and DSF, as previously indicated. Additionally, the effects of the copper depleting agent, 
bathocuproine disulfonic acid (BCS) on intracellular copper levels were also assessed. Cells 
were pre-treated with 200 μM BCS or BCS and 10 mM metformin, followed by treatment 
with LC30 concentrations of DSF or DSF and 10 mM metformin combined with BCS for 24 
hrs. Cells were washed with cold 1x PBS three times, scraped and collected by centrifugation 
for 10 minutes at 8000 rpm at 4 °C.  A relative portion of cells was removed for protein 
quantification by the Bradford assay (Bradford 1976). Cell pellets were then incubated with 
65% nitric acid (Suprapure, Merck) at 65 °C for 2 hours. Samples were then diluted to a final 
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concentration of 5% nitric acid and analysed for copper on an Agilent 7700 ICP-MS with He 
collision gas. Copper levels were corrected for protein (μg) and compared to untreated cells 
(n=3 ± SD). 
4.2.6. Determining Proteasome Activity based on 
Amidomethylcoumarin Fluorescence 
Proteasome function was assessed in treated cells using the fluorogenic proteasome 
substrate N-Succinyl-Leu-Leu-Val-Tyr-7-Amido-4-Methylcoumarin (Suc-LLVY-AMC), which  
indicates levels of chymotrypsin-like activity, as previously described (Daniel et al., 2004). 
Cells were equally seeded in 100 mm dishes, allowed 24 hours to settle and treated 
accordingly. To assess the effects of metformin on DSF mediated proteasome inhibition, cells 
were treated with 10 mM metformin only for 24 hours, 24 hours with 10 mM metformin 
followed by 24 hours with the LC30 concentration of DSF and metformin for 24 hours, 24 
hours with 10 mM metformin followed by 24 hours with the LC30 concentration of Cu-DSF 
and metformin for 24 hours, 5 µM copper-8-hydroxyquinoline (Cu-8HQ), an established 
proteasome inhibitor, for 24 hours. In order to assess the involvement of DSF metabolites on 
proteasome function, cells were treated with LC30 concentrations of DSF, DPTD or TTD for 
24 hours. Following treatment, cells were washed in 1x PBS, collected by scraping and 
centrifugation, lysed in lysis buffer (25 mM Tris-HCl, pH 8.0; 75 mM NaCl; 0.05 % SDS; 0.5 % 
Triton X-100; 0.25 % Sodium deoxycholate), and lysates cleared by centrifugation. Protein 
was quantified by Bradford assay. Equal amounts of protein (40 µg) were added to assay 
buffer (50 mM Tris-HCl pH 7.5) to a final volume of 400 µl and Suc-LLVY-AMC (6 mM in 
DMSO) was added to a final concentration of 40 µM, the reaction mixture was incubated at 
37 °C for 1 hour, followed by the addition of trichloroacetic acid to a final concentration of 
4% to stop the reaction. Fluorescence was measured 360nmexcitation/460nmemission using 
an Ascent multi-well plate fluorimeter (Thermo Scientific) (n=3 ± SD). 
4.2.7. Acridine Orange Staining for Lysosomal Acidity Assessment  
Lysosomal acidity was visualised by staining cells with the pH sensitive dye, acridine orange 
(Paglin et al., 2001). OSCC cells were evenly seeded on glass coverslips in 6-well plates and 
after 48 hours, were treated with LC30 concentrations of DSF, Cu-DSF, DPTD or TTD, for 24 
 85 
 
 
hours, with or without 10 mM metformin or incubated with 1 mM chloroquine (CQ) for 1 
hour as a positive control. LC30 concentrations were chosen in order to observe the effects 
of these drugs prior to cell death. Cells were incubated with 3 µM acridine orange added to 
culture medium at 37 °C for 1 hour and immediately visualised using the Olympus BX41 
fluorescence microscope (100 W equipped with a camera and lamp using a 490 nm band-
pass blue excitation filter and a 515 nm long-pass barrier filter). Images captured and 
processed with CellSens Dimension software. 
4.2.8. Autophagosomes Visualised by Transmission Electron 
Microscopy 
Electron Microscopy (EM) was used to look for autophagosome formation (Yla-Antilla et al. 
2009). Cells were equally seeded in 10 cm culture dishes and after 24 hours, they were 
treated with 10 mM metformin for 24 hours, the LC30 concentration of DSF or DSF and 10 
mM metformin for 24 hours, the LC30 concentration of Cu-DSF or Cu-DSF and 10 mM 
metformin for 24 hours. Cells were then rinsed with cold with 1x PBS three times and fixed 
in EM fixative (2.5% gluteraldehyde in 0.1 M HEPES buffer pH 7.2) for 1 hour. Cells were then 
scraped into a microcentrifuge tube and collected by centrifugation at 1000 x g for 10 
minutes. Fixative was removed and cells were processed for EM as previously described (Yla-
Antilla et al. 2009). The following parts of the EM experiments were conducted by Dr. 
Monica Birkhead at the National Institute for Communicable Diseases (NICD).  Pelleted cells 
were fixed in EM fixative overnight, then rinsed several times in HEPES buffer followed by 
post-fixation in  1% buffered osmium tetroxide for 1 hour. Cells were then rinsed in HEPES 
buffer, then dehydrated in graded ethanol solutions for 30 minute intervals with three 
repeated changes of absolute ethanol. Cells were then infiltrated with low viscosity epoxy 
resin (Agar Scientific®) and polymerised in BEEM® capsules at 70 °C overnight. Sections (70 
nm) were cut with the Leica EM UC6 ultramicrotome, picked up on 0.25% formvar-coated 
copper slot grids, double stained with uranyl acetate and lead citrate and viewed at 80 kV on 
an FEI BioTwin Spirit transmission electron microscope fitted with an Olympus Quemesa CCD 
Camera.  
 86 
 
 
4.2.9. Western Blotting to Determine Autophagy Levels and Protein 
Degradation  
Autophagy and protein ubiquitination were assessed by western blotting to determine LC3-B 
and total ubiquitinated protein levels, respectively. Cells were treated with 10 mM 
metformin for 24 hours, 10 mM metformin for 24 hours followed by 24 hours with the LC30 
concentration of DSF and metformin for 24 hours, 10 mM metformin for 24 hours followed 
by 24 hours with the LC30 concentration of Cu-DSF and metformin for 24 hours or 50 µM CQ 
for 24 hours. Cells were harvested and quantified, and western blots were conducted as 
described in section 2.2.5, with the following exceptions. Proteins were separated on a 12% 
SDS-PAGE gel for LC3-B blots. Membranes were incubated in 5% bovine serum albumin in 
1xTBS-T with the primary antibodies (1 in 1000 dilution was used for all primary antibodies), 
rabbit anti-LC3B (#2775), rabbit anti-ubiquitin (#3933) or β-actin (Santa Cruz, sc-130656) 
overnight, following which, membranes were washed in 1xTBS-T and then incubated with a 
goat anti-rabbit IgG-horseradish peroxidase (Santa Cruz Biotechnologies). Densitometry was 
performed using QuantityOne software. 
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4.3. Results 
4.3.1. Metformin works in combination with drugs activated in 
reducing environments to exert cytotoxic effects against OSCC cell 
lines  
In chapter 3, we found that metformin increases the intracellular reducing environment in 
OSCC cell lines. Therefore, it is likely that metformin could work well in combination with 
drugs that are activated in reducing environments to offer a potentially new treatment 
option for OSCC. Copper bis(thiosemicarbazones) are activated in reducing environments 
and exert cytotoxic activity by promoting intracellular copper accumulation. Cu-ATSM and 
Cu-GTSM release their copper upon intracellular reduction and unlike normal cells which can 
readily re-oxidise the drug, copper accumulates in hypoxic tissues such as cancer. DSF is also 
a copper chelating drug that can act as copper delivery agents. DSF toxicity is mainly 
attributed to formation of the Cu-DSF complex. However, DSF also forms numerous 
metabolites that may also contribute to its anti-cancer effects. The effects of Cu-ATSM, Cu-
GTSM and DSF, with and without metformin, on OSCC cytotoxicity were evaluated.  
4.3.1.1. Copper bis(thiosemicarbazones) retain their toxicity in the presence 
of metformin  
Cu-ATSM and Cu-GTSM both displayed cytotoxic effects toward OSCC cell lines, whereas 
ATSM and GTSM not reacted with copper did not induce an effective cytotoxic response. The 
cytotoxic effects of Cu-ATSM and Cu-GTSM were retained in the presence of metformin, 
which indicates that metformin can be combined with Cu-ATSM or Cu-GTSM should they be 
used for cancer therapy. Figure 4.3 displays cytotoxicity curves for ATSM, Cu-ATSM, GTSM 
and Cu-GTSM in the absence and presence of metformin for each of the three OSCC cell lines 
used in this study. LC50 values determined from these curves (Table 4.1) for metformin in 
combination with Cu-ATSM or Cu-GTSM were not significantly different compared to Cu-
ATSM or Cu-GTSM alone. Although a slight increase in LC50 was observed in the case of the 
SNO cell line treated with Cu-ATSM and metformin, these agents exert cytotoxic effects at 
doses much smaller than conventional drugs such as cisplatin, which highlights that their 
potential as anti-cancer agents.   
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Figure 4.3: Cu-ATSM and Cu-GTSM are toxic toward OSCC cell lines alone and in 
the presence of metformin.  WHCO1, WHCO5 and SNO cell lines were pre-treated 
with 10 mM metformin for 24 hours, followed by co-treatment with A) ATSM or 
Cu-ATSM, or B) GTSM or Cu-GTSM, for 48 hours and cytotoxicity was evaluated by 
MTT assay. Absorbance values were taken as a percentage of the control and 
plotted against the Log transform of drug concentration. In the absence of reacted 
copper, ATSM and GTSM did not exert significant cytotoxic effects. Cu-ATSM and 
Cu-GTSM exerted cytotoxic effects toward all three OSCC cell lines alone and in 
the presence of metformin.  
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Table 4.1: Cu-ATSM and Cu-GTSM retain their toxicity in the presence of metformin.  LC50 
values obtained from cytotoxicity curves are tabulated below. Metformin did not 
significantly alter the cytotoxicity of Cu-ATSM and Cu-GTSM in all three OSCC cell lines. This 
indicates that Cu-ATSM and Cu-GTSM retain their toxicity in the presence of metformin.  
  LD50 (µM) 
Compounds WHCO1 WHCO5 SNO 
 Cu-ATSM 11.93 ± 0.47 13.51 ± 0.81 7.10 ± 0.57 
 Cu-ATSM + Met 12.54 ± 0.19 ns 12.05 ± 0.83 ns 10.90 ± 0.77 * 
 ATSM >200 >200 >200 
 ATSM + Met >200 >200 >200 
 Cu-GTSM 1.14 ± 0.16 5.39 ± 0.9 3.37 ± 0.23 
 Cu-GTSM + Met 1.16 ± 0.12 ns 6.24 ± 0.01 ns 4.23 ± 0.70 ns 
 GTSM >200 >200 >200 
 GTSM + Met >200 >200 >200 
 
Although the copper bis(thiosemicarbazones) are promising chemotherapeutic agents that 
can be combined with metformin, more studies are still required before these drugs can be 
approved for cancer therapy. Cu-ATSM is still undergoing phase I trials for use as a 
radiopharmaceutical. The copper bis(thiosemicarbazones) are not as well established as DSF. 
For these reasons, we chose to proceed with investigating the mechanisms of action of DSF 
rather than the copper bis(thiosemicarbazones). DSF has been used in the treatment of 
alcoholism for more than 50 years and is known to be tolerated at high doses in the absence 
of alcohol (Suh et al., 2006). Additionally, DSF is currently undergoing clinical trials for the 
treatment of various different cancer types. The effects of metformin and DSF on OSCC 
cytotoxicity is the area of focus for the remaining part of this chapter.  
4.3.1.2. Metformin enhances the cytotoxic effects of DSF toward OSCC cell 
lines and Cu-DSF toxicity is retained  
Cytotoxicity was assessed in OSCC cell lines treated with DSF or Cu-DSF in the absence or 
presence of metformin. MTT assay data (Figure 4.4 A) indicated that DSF and Cu-DSF both 
exert cytotoxic effects toward the three OSCC cell lines at doses as low as between 6 µM – 
12 µM. Metformin enhanced the effects of DSF by 28.5% in WHCO1, 25.9% in WHCO5 and 
43.1% in SNO. The effects of copper alone at the doses used during Cu-DSF therapy were 
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also assessed by MTT assay (Figure 4.4 B). The graphs do not form an S-shape as is typical for 
cytotoxicity curves, and cells are still viable at the highest concentrations of copper used (up 
to 200 µM). This indicates that the effects of Cu-DSF on OSCC cytotoxicity are not due to the 
effects of copper alone.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Cytotoxic effects of DSF are significantly enhanced in the presence of 
metformin and copper in OSCC cell lines but minimal cytotoxicity occurs in 
response to copper alone.  A) Cells were pre-treated with 10 mM metformin for 24 
hrs, followed by co-treatment with DSF or Cu-DSF for 48 hours. Cytotoxicity curves 
show that DSF and Cu-DSF exert toxic effects toward OSCC cell lines and metformin 
treatment increased the effects of DSF.  B) Cells were pre-treated with 10 mM 
metformin for 24 hours followed by combination therapy with metformin and copper 
for 48 hours. MTT assays were conducted and results for each cell line are depicted 
on the graph above. Low concentrations of copper (≤30 µM) did not induce any 
cytotoxic effects toward OSCC cell lines and mild cytotoxicity was observed at higher 
concentrations of copper (≥80 µM).    
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Table 4.2: Metformin and copper enhance the toxicity of DSF in OSCC cell lines.  LC50 
values were calculated from cytotoxicity curves for DSF and Cu-DSF with or without 
metformin. There was a significant reduction in LC50 values when metformin was added to 
DSF therapy, which indicates that metformin enhances the effect of DSF. There was a mild, 
yet insignificant reduction in LC50 values when metformin was added to Cu-DSF. This 
indicates that Cu-DSF toxicity is retained in the presence of metformin.  
 
  LD50 (µM DSF) 
Compounds WHCO1 WHCO5 SNO 
 DSF 6.04 ± 0.39 6.85 ± 0.32 11.89 ± 0.56 
 DSF + Met † 4.70 ± 0.14 * 5.44 ± 0.20 ** 8.31 ± 1.30  ** 
 Cu-DSF † 3.63 ± 0.31 ** 2.80 ± 0.23 *** 2.01 ± 0.08 *** 
 Cu-DSF + Met 3.44 ± 0.22 2.42 ± 0.10 1.95 ± 0.07 
† Significance stars represent P-values for DSF + Met or Cu-DSF compared to DSF alone in the 
corresponding cell line.  
 
To complement MTT assay data, images of cells with treatments corresponding to MTT 
assays were captured, in all cases, LC30 concentrations of DSF or Cu-DSF were used (Figure 
4.5). When comparing the effects of metformin to untreated cells, it is apparent that cells 
are less confluent and cell morphology is unaltered, as found previously. The cytotoxic 
effects of DSF are clearly depicted as there is a visible reduction in cell viability. Cytotoxicity 
of DSF is enhanced by metformin as cells appeared more rounded with severe alterations to 
membrane integrity for DSF-metformin treated samples. Cell morphology and viability was 
significantly altered by Cu-DSF and there was more cell debris in the regions surrounding 
cells. Whilst not seen with the MTT assays, it was observed that metformin also enhanced 
the effects of Cu-DSF on OSCC cell viability as very few cells were still attached after Cu-DSF-
metformin therapy. Surviving cells had significantly altered morphology with more rounded 
cells and higher amounts of cell debris.   
In vitro studies suggest that the effects of DSF in cancer are copper dependent, but DSF has 
also been shown to exert anti-cancer effects in vivo without additional copper (Chen et al., 
2001; Conticello et al., 2012; Rae et al., 2013). Although DSF has been prescribed for years in 
the treatment of alcoholism, its anti-cancer effects were only recently described. As such, a 
direct mechanism of action for this drug in cancer is still not known. There are various 
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actions of DSF that have been shown to contribute to its anti-cancer effects and most of 
these effects involve additional copper. The contribution of copper to DSF mediated toxicity 
was therefore investigated further.  
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Figure 4.5: Effects of DSF and Cu-DSF in the absence and presence of metformin on 
cell morphology observed by light microscopy. Images captured in brightfield (100x) 
demonstrate the cytotoxic effects of DSF and Cu-DSF exert cytotoxic effects toward 
WHCO1, WHCO5 and SNO cell lines which are enhanced by metformin. 
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4.3.2. Copper enhances, but is not exclusively required for the 
cytotoxic effects of DSF in OSCC cell lines  
4.3.2.1. Increasing levels of Cu-DSF complex enhances DSF toxicity 
Copper and DSF were reacted in 0.25:1, 0.5:1 and 1:1 ratios respectively, and the effects of 
these complexes on OSCC cytotoxicity were evaluated. As the copper:DSF ratio was 
increased, cytotoxicity toward OSCC cell lines also increased (Figure 4.6). This indicates that 
copper plays a significant role in DSF mediated cytotoxicity in OSCC cell lines.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: DSF toxicity is enhanced by increasing concentrations of copper.  OSCC 
cell lines were exposed to DSF alone or copper reacted with DSF in three molar ratios, 
0.25:1, 0.5:1 and 1:1 for 48 hours. A) There is a leftward shift in dose response curves 
as copper levels are increased. B) LC50 values expressed as a percent of DSF 
decreased as copper levels increased, which shows that DSF toxicity is enhanced by 
copper in OSCC cell lines.  
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4.3.2.2. DSF treatment leads to increased intracellular copper levels 
Intracellular copper levels were quantified after OSCC cells were treated with DSF or DSF and 
metformin in order to assess the contribution of copper to DSF-metformin mediated toxicity. 
DSF alone significantly increased intracellular copper levels in all three OSCC cell lines (Figure 
4.7). Interestingly, co-therapy with DSF and metformin resulted in a further increase in 
intracellular copper levels, which was significant in the WHCO1 and WHCO5 cell lines. This 
finding is not unusual as a recent study revealed that two molecules of metformin can act as 
a chelating agent with particularly high affinity for copper (Logie et al., 2012). Although 
metformin did not significantly alter copper uptake in these cell lines, studies have shown 
that two molecules of metformin can bind to copper, and thus alter copper homeostasis by 
transporting it into the cell or by altering its sub-cellular localisation.  
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Intracellular copper levels in OSCC cell lines are significantly higher in 
the presence of DSF, and further increased by metformin.  Cells were treated with 
10 mM metformin for 24 hrs, LC30 concentrations of DSF for 24 hrs, or pre-treated 
with metformin for 24 hrs followed by combination therapy with DSF and metformin 
for 24 hours. Intracellular copper levels assessed by ICP-MS, are expectedly higher in 
the presence of DSF. Metformin combined with DSF led to a further increase in 
intracellular copper levels compared to DSF alone in the WHCO1 and WHCO5 cell 
lines.  
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4.3.2.3. Copper depletion reduces but does not abolish the cytotoxic effects 
of DSF  
Based on the previous two experiments, it is evident that copper plays a significant role in 
DSF mediated toxicity toward OSCC cell lines. In order to fully assess the contribution of 
copper, the effects of copper depletion on DSF cytotoxicity were determined. Bathocuproine 
disulfonate (BCS), a cell impermeable copper chelator, was used to deplete intracellular 
copper levels by reducing copper uptake. DSF or DSF and metformin were combined with 
BCS and cytotoxicity was assessed by MTT assay. Additionally, we confirmed that this agent 
reduces intracellular copper levels by ICP-MS. Treatment with 200 µM BCS effectively 
reduced intracellular copper levels to those similar to untreated cells in all three OSCC cell 
lines (Figure 4.8). The percent reduction in intracellular copper levels for DSF-BCS compared 
to DSF treatment or DSF-BCS-Met compared to DSF-Met treatment respectively, was 62 ± 
2.9% and 59 ± 9.6% in WHCO1; 41 ± 1.6% and 43 ± 17.0% in WHCO5; and 32 ± 7.4% and 63 ± 
12.6% in SNO.  
 
 
 
 
 
 
 
Figure 4.8: Bathocuproine disulfonate (BCS) effectively reduces the DSF or DSF-
metformin induced increase in intracellular copper levels. Cells were pre-treated 
with 200 µM BCS, 10 mM metformin, or BCS and metformin for 24 hrs, followed by 
combination therapy with DSF for 48 hrs and compared to untreated cells. ICP-MS 
data indicated that BCS significantly reduced copper levels in OSCC cell lines as 
depicted in the graph.  
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As expected, copper depletion inhibited the cytotoxic effects of DSF in OSCC cell lines as 
higher LC50 values were observed when BCS was combined with DSF or DSF and metformin 
(Figure 4.9). The percent increase in LC50 for DSF and BCS compared to DSF alone was 42% 
for WHCO1; 58% for WHCO5 and 182% for SNO. This confirms that copper plays a significant 
role in DSF mediated cytotoxicity toward OSCC cell lines. However, DSF still induced cell 
death toward OSCC cell lines even in the presence of BCS, as can be seen by the 
characteristic S-shape of the dose response curves. This suggests that formation of DSF-
copper complexes may not be the only factor contributing to the cytotoxic effects of DSF. 
DSF toxicity has been attributed to general copper induced toxicity as well as proteasome 
inhibition caused by Cu-DSF. Accumulation of copper promotes DNA damage and oxidative 
stress which eventually leads to cell death. We therefore assessed the effects of DSF on 
copper-induced DNA damage and proteasome activity.  
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Figure 4.9: Copper depletion partially reduces DSF cytotoxicity in OSCC cell lines.  
Cells were pre-treated with 200 µM BCS, 10 mM metformin, or BCS and metformin 
for 24 hrs, followed by combination therapy with DSF for 48 hrs. A) MTT assay curves 
indicate that BCS reduces the toxicity of DSF. However, DSF still exerted potent 
cytotoxic effects during copper reduction, as can be deduced from the characteristic 
S-shaped dose response curves. B) LC50 values, represented as a percent of DSF 
alone, are higher in the presence of BCS. 
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4.3.2.4. Metformin interferes with copper and Cu-DSF induced DNA damage  
Copper toxicity can occur due to various reasons and one of these is its ability to cleave DNA 
in the presence of reducing agents such as ascorbic acid, GSH or H2O2. Formation of the 
Cu(I)-DNA complex results in DNA base modifications, whereas free Cu1+ causes random DNA 
strand breaks (Drouin et al., 1996). We determined the effects of DSF and Cu-DSF with or 
without metformin on plasmid DNA cleavage in the absence and presence of ascorbic acid. 
Results indicated that metformin completely blocked DNA damage induced by copper and 
inhibited Cu-DSF mediated DNA damage (Figure 4.10).  
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Metformin inhibits DNA damage caused by the reduction of copper and 
Cu-DSF.  The pBR322 plasmid was exposed to DSF or Cu-DSF in the absence or 
presence of metformin or ascorbic acid at 37°C for 1 hr. Bands are labelled based on 
various degrees of plasmid DNA supercoiling; I- Supercoiled, II- Circular, III- Linear. 
DNA damage was not induced in the absence of ascorbic acid. Reduction of Cu2+ ions 
to Cu1+ resulted in shearing of plasmid DNA, as can be seen in lane 14. Metformin 
acted to block Cu1+ induced DNA damage, lane 7. DSF alone did not alter plasmid 
DNA, whereas reduced Cu-DSF promoted DNA damage indicated by the absence of 
supercoiled and circular plasmid DNA in lane 11. Metformin also inhibited Cu-DSF 
induced DNA damage, as supercoiled plasmid DNA is still present in lane 18.   
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Plasmid DNA was cleaved upon the reduction of copper and Cu-DSF but not DSF. As this 
experiment was conducted in a cell-free system, the absence of copper explains why DSF 
does not induce any DNA damage. The reduction of Cu2+ ions from CuCl2 to form Cu
1+ 
resulted in extensive DNA damage, and interestingly, this effect was completely blocked with 
the addition of metformin. Metformin also inhibited Cu-DSF induced DNA damage, as more 
supercoiled and circular plasmid DNA were observed when metformin was combined with 
Cu-DSF and ascorbic acid compared to Cu-DSF and ascorbic acid alone which resulted in the 
formation of linear and cleaved DNA fragments.   
Although metformin inhibits copper and Cu-DSF induced DNA damage, it enhanced DSF 
cytotoxicity and also seemed to add to cytotoxic effects of Cu-DSF based on cell 
morphological features. This indicates that metformin induced inhibition of DNA damage by 
copper did not reduce the effects of DSF or Cu-DSF toward OSCC cell lines. This implies that 
there are other mechanisms, apart from copper induced DNA damage that may play a 
significant role in DSF mediated toxicity toward OSCC cell lines. Studies have shown that the 
Cu-DSF complex inhibits proteasomal chymotrypsin-like activity and that this is a major 
factor contributing to its cytotoxic effects (Chen et al., 2006). We therefore investigated the 
effects of DSF on proteasome activity in OSCC cell lines.  
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4.3.3. DSF alters multiple pathways involved in protein degradation 
and this contributes to DSF induced toxicity 
Protein degradation pathways are crucial for regular homeostasis. This process is tightly 
controlled as it is involved in regulating short-lived proteins, recognising and degrading 
damaged proteins and also provides amino acids required for nascent polypeptide synthesis. 
There are three major mechanisms by which proteins are degraded, these include 
proteasomal, endosomal and autophagic protein degradation (Clague & Urbé, 2010). The 
Ubiquitin-Proteasome system is responsible for the degradation of approximately 90% of 
intracellular proteins (Cvek & Dvorak, 2008). Ubiquitin ligases catalyse the binding of 
ubiquitin to proteins in an ATP dependent manner. Additional ubiquitin molecules then bind 
to this residue to form a polyubiquitin chain that can adopt various 3D conformations and 
may be recognised by the 26S proteasome and target the protein for degradation (Lecker, 
Goldberg & Mitch, 2006). Another mechanism of protein degradation is via lysosomal 
pathways. Lysosomes are membrane enclosed organelles containing hydrolytic enzymes that 
can degrade proteins, other major macromolecules and organelles. Lysosomes play an 
important role in both endosomal and autophagic pathways.  
The endosomal pathway is involved in the degradation of membrane proteins. Plasma 
membrane proteins are engulfed by endocytosis to form early endosomes, which fuse with 
lysosomes and lead to the degradation of membrane proteins (Cooper, 2000). Ubiquitin was 
also shown to play a role in the endosomal pathway as some receptors use 
monoubiquitination as a signal for endocytosis (Clague & Urbé, 2010). Autophagy involves 
sequestration of cytosolic proteins or organelles in a double membrane vesicle called the 
autophagosome. The autophagosome then fuses with lysosomes to form an autolysosome 
that is involved in the degradation of its contents. Numerous autophagy related proteins are 
involved in regulating the process. One of these proteins, LC3-I (microtubule-associated 
protein light chain 3) becomes conjugated to a phosphatidylethanolamine (PE) moiety to 
form LC3-II which is conjugated to the autophagosome. LC3-II acts as an adaptor protein that 
is involved in recognising protein aggregates and organelles that are to be engulfed by the 
autophagosome (Glick, Barth & Macleod, 2010). Monoubiquitination has also been linked to 
autophagic degradation of damaged mitochondria (Clague & Urbé, 2010).  
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4.3.3.1. Disulfiram inhibits proteasomal function 
Studies have suggested that the Cu-DSF complex can inhibit chymotrypsin-like activity of the 
proteasome  (Chen et al., 2006). The 26S proteasome complex contains two trypsin-like, two 
chymotrypsin-like and two caspase-like proteolytic sites. These sites each recognise and 
cleave proteins at specific amino acid sequences. The effects of DSF on overall protein 
degradation were assessed by western blotting for ubiquitin or ubiquitin-conjugated 
proteins. There was an accumulation of ubiquitinated proteins in samples treated with DSF 
or Cu-DSF compared to untreated samples which indicates that DSF inhibits protein 
degradation in OSCC cell lines (Figure 4.11 A). Metformin increased protein degradation as 
total ubiquitin levels were lower when cells were treated with metformin alone or 
metformin combined with DSF or Cu-DSF.  
The effects of DSF or Cu-DSF with or without metformin, or chloroquine, which is a known 
proteasome inhibitor, on chymotrypsin-like activity of the proteasome were assessed based 
on cleavage of Suc-LLVY-AMC. Suc-LLVY-AMC is a proteasome specific substrate and that is 
cleaved at the tyrosine residue by chymotrypsin-like activity, it then releases the AMC group 
which emits fluorescence. Fluorescence was lower in DSF and Cu-DSF treated samples 
indicating that DSF and Cu-DSF inhibit chymotrypsin-like activity (Figure 4.11 B). However, 
proteasomal chymotrypsin-like activity was only reduced by 15% to 20% for the three cell 
lines. Interestingly, metformin enhanced proteasomal inhibition as fluorescence was further 
reduced in cells treated with DSF and metformin or Cu-DSF and metformin. Although 
metformin enhanced DSF and Cu-DSF mediated inhibition of chymotrypsin-like proteasome 
activity, ubiquitin western blot data show that it increased overall protein degradation in the 
presence of DSF. This indicates that other protein degradative pathways are still active in the 
presence of metformin and proteasome inhibition. Since DSF and Cu-DSF were mild 
inhibitors of proteasomal activity in OSCC cell lines, this suggests that proteasome inhibition 
may not be sufficient for the cytotoxic effects of these drugs in OSCC cell lines. For this 
reason we compared the effects of DSF to two thiuram disulfide analogues, which are more 
potent proteasome inhibitors, on OSCC cytotoxicity.  
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Figure 4.11: Disulfiram inhibits proteasomal activity in OSCC cell lines.  Cells were 
treated with 10 mM metformin for 24 hrs, LC30 concentrations of DSF or Cu-DSF for 
24 hrs, or pre-treated with metformin for 24 hrs followed by combination therapy 
with DSF or Cu-DSF for 24 hrs. Positive control treatments were 50 µM chloroquine 
(CQ) for 24 hrs to assess ubiquitin accumulation and 5 µM copper 8-hydroxyquinoline 
(Cu-8HQ) for 24 hrs to assess inhibition of chymotrypsin-like activity. A) DSF and Cu-
DSF treatment led to an accumulation of ubiquitinated proteins, and therefore 
inhibited proteasomal function. Metformin was associated with reduced levels of 
ubiquitinated proteins.   B) DSF and Cu-DSF both inhibit chymotrypsin-like activity of 
the proteasome, and interestingly, this is enhanced by metformin as fluorescent 
signals are further reduced.   
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4.3.3.2. DSF analogues are more effective inhibitors of proteasomal 
chymotrypsin-like activity but are less toxic than DSF 
Various drugs capable of binding copper have been shown to inhibit proteasomal activity 
and the dithiocarbamate family of drugs fall in this category. As a members of this drug 
family, DSF and DDC are known to inhibit chymotrypsin-like proteasome activity when they 
are in complex with copper (Daniel et al., 2007). Since the Cu-DSF or Cu(DDC)2 complexes are 
implicated in proteasome inhibition, rather than their unconjugated counterparts, we 
investigated the effects of two DSF analogues that retain their copper to a better extent than 
DSF, on proteasome activity.  
The two DSF analogues used in this study, dipyrrolidine thiuram disulfide (DPTD) and 
tetrapropyl thiuram disulfide (TTD) were derived from their monomers, pyrrolidine 
dithiocarbamate and di-n-propyl dithiocarbamate, respectively. These analogues were 
chosen as they have lower decomposition rates and are therefore more stable than DSF. 
Second order decomposition rates for DSF, DPTD and TTD are 2.5 x 104, 0.1 and 500 L.mol-1. 
min-1, respectively (Topping & Jones, 1988). This means DPTD is the most stable and would 
retain copper better than DSF, which has a high decomposition rate and would easily release 
its copper. Pyrrolidine dithiocarbamate has been shown to inhibit 26S proteasome activity, 
and this was due to formation of a copper complex (Daniel et al., 2005). However, DSF 
analogues do not form DSF hydrolysis products such as diethylamine or modified 
diethyldithiocarbamates. DPTD and TTD were used to differentiate between the roles of Cu-
DSF or Cu(DDC)2 and the effect of DSF metabolites.  
We first determined the effects of DSF analogues on OSCC cytotoxicity with the MTT assay. 
DPTD, TTD and their copper conjugates were less toxic than DSF and Cu-DSF, respectively 
(Figure 4.12). DPTD reduced proteasome activity by 98%, 73% and 103% and TTD reduced 
proteasome activity by 49%, 52% and 115% in WHCO1, WHCO5 and SNO cell lines 
respectively. LC30 values for these treatments are recorded in Table 4.3. DPTD and TTD were 
also less toxic than DSF when all drugs were combined with metformin; however, metformin 
did not significantly alter the toxicity of DPTD and TTD in all cell lines.  
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Figure 4.12: DSF analogues with lower hydrolysis rates are less toxic than DSF.  Cells 
were treated with DSF, DPTD, TTD, Cu-DSF, Cu-DPTD or Cu-TTD either with or without 
10 mM metformin pre-treatment and combination therapy. Absorbance values were 
expressed as a percent of their respective control and represented on the graphs. 
DPTD and TTD were less toxic than DSF and Cu-DPTD and Cu-TTD were less toxic than 
Cu-DSF. This indicated that DSF hydrolysis products may play a significant role in its 
cytotoxic effects.  
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Table 4.3: LC50 values for DSF and DSF analogues.  DSF analogues displayed higher LC50 
values compared to DSF and this trend was maintained in the presence of metformin and 
when drugs were reacted with copper.  
 
LC50 (μM) 
 
WHCO1 WHCO5 SNO 
 DSF 7.35 ± 0.270 7.87 ± 0.139 10.20 ± 0.724 
 DSF + Met † 6.26 ± 0.176 * 7.04 ± 0.442 * 10.01 ± 1.118 ns 
 Cu-DSF † 0.37 ± 0.024 *** 0.67 ± 0.023 *** 0.56 ± 0.113 *** 
 Cu-DSF + Met ‡ 0.40 ± 0.026 ns 0.81 ± 0.026 * 0.57 ± 0.006 ns 
 DPTD ‽  14.52 ± 0.264 *** 13.64 ± 0.652 *** 20.68 ± 1.335 *** 
 DPTD + Met † 14.38 ± 0.702  ns 15.45 ± 0.888 ns 22.89 ± 0.484 ns 
 Cu-DPTD † 0.75 ± 0.055 *** 0.76 ± 0.099 *** 0.66 ± 0.131 * 
 Cu-DPTD + Met ‡ 0.82 ± 0.025 ns 0.80 ± 0.096 ns 0.85 ± 0.033 * 
 TTD ‽ 10.98 ± 0.605 ** 11.99 ± 0.284 *** 21.92 ± 1.637 *** 
 TTD + Met † 8.97 ± 1.275 * 13.65 ± 1.643 ns 23.48 ± 1.214 * 
 Cu-TTD † 0.64 ± 0.064 *** 1.56 ± 0.042 *** 0.83 ± 0.036 *** 
 Cu-TTD + Met ‡ 0.66 ± 0.04 ns 1.90 ± 0.057 ** 0.80 ± 0.023 ns 
‽ Significance stars for DPTD and TTD were calculated by comparing these treatments to DSF.  
† Significance stars were determined from P-values comparing DSF + Met or Cu-DSF with DSF alone, 
DPTD + Met and Cu-DPTD with DPTD alone and, TTD + Met or Cu-TTD with TTD alone.  
‡ Significance stars were determined from P-values comparing Cu-DSF + Met with Cu-DSF, Cu-DPTD + 
Met with Cu-DPTD and, Cu-TTD + Met with Cu-TTD.  
 
Next, we investigated the effects of DPTD and TTD on proteasomal chymotrypsin-like 
activity. DPTD and TTD inhibited proteasome activity to a greater extent than DSF alone 
(Figure 4.13). DPTD reduced proteasomal activity by 43%, 15% and 29% in WHCO1, WHCO5 
and SNO cell lines, respectively compared to DSF. TTD reduced proteasomal activity by 18% 
in WHCO1 and WHCO5 cell lines and 19% in the SNO cell line compared to DSF. DPTD was a 
more efficient proteasome inhibitor than TTD and DSF in WHCO1 and SNO cell lines. This is 
in line with decomposition rates of the compounds, as DPTD is the most stable, followed by 
TTD and DSF.  
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Figure 4.13: DPTD and TTD inhibit proteasomal chymotrypsin-like activity to a 
greater extent than DSF.  Cells were treated with LC30 concentrations of each drug 
for 24 hours and chymotrypsin-like activity was assessed. Fluorescence of AMC 
groups was expressed as a percent of DSF and represented on the graph. DSF 
analogues had lower fluorescence readings which indicate that DPTD and TTD are 
more effective proteasome inhibitors compared to DSF.  
The cytotoxic effects of DSF have been attributed to Cu-DSF or Cu(DDC)2 complex mediated 
proteasome inhibition (Chen et al., 2006). However, we show here that thiuram disulfide 
analogues, which inhibit proteasome activity to a greater extent than DSF, have reduced 
cytotoxicity toward OSCC cell lines. Cytotoxicity of DSF analogues also correlated with their 
hydrolysis rates, as thiuram disulfides with higher rates of hydrolysis were more toxic toward 
OSCC cell lines. This finding suggests that copper complexes of DSF are not solely responsible 
for its cytotoxic effects. Therefore, we hypothesised that the hydrolysis products of DSF also 
contribute to its cytotoxic effects and that diethylamine may accumulate in lysosomes and 
reduce lysosomal acidity, which could add to the cytotoxic effects of DSF.  
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4.3.3.3. DSF reduces lysosomal acidity 
We hypothesised that DSF could enter the lysosome, where it is reduced to its hydrolysis 
products, diethylamine and carbon disulfide, and reduce lysosomal acidity due to 
accumulation of diethylamine. DSF has been shown to bind to proteins and form mixed 
disulfides (Strömme, 1965) and may therefore enter lysosomes when bound to proteins. 
Alternatively, DSF could also enter lysosomes via diffusion. DSF is unstable in low pH 
environments and the hydrolytic enzymes of the lysosome will reduce DSF to its monomer, 
DDC, which will be further degraded to form diethylamine and carbon disulfide (Martin, 
1953; Johansson, 1992). Increased levels of diethylamine can promote lysosomal 
alkalinisation and block autophagosome maturation, thus inhibiting another pathway for 
protein degradation and this would add to DSF toxicity. In order to test this hypothesis, cells 
that were treated with DSF or DSF analogues were stained with acridine orange (AO) in 
order to assess the pH of acidic vesicular organelles (AVOs) which include lysosomes and 
autolysosomes.  
In untreated cells, lysosomes were orange in colour, which indicates that these 
compartments were still highly acidic (Figure 4.14). Chloroquine (CQ) is a weak base that can 
be trapped in lysosomes and therefore increase lysosomal pH. As expected, CQ treated cells 
had completely green lysosomes. DSF treatment reduced lysosomal acidity as can be 
deduced from the yellow to green appearance of lysosomes. Cu-DSF treated cells also 
exhibited yellow to green organelles, which indicates that lysosomal function is hampered in 
the presence of DSF and Cu-DSF. Although lysosomes appeared slightly more orange when 
DSF or Cu-DSF were combined with metformin compared to DSF or Cu-DSF, lysosomal acidity 
was significantly reduced compared to untreated cells. Metformin or metformin combined 
with copper did not significantly alter lysosomal acidity.  
Treatment with DPTD and TTD did not alter lysosomal acidity as organelles appeared orange 
and not much different compared to untreated cells. This confirms that it is a DSF metabolite 
and not the Cu-DSF complex that is involved in reducing lysosomal acidity. In order to 
confirm that DSF does alter lysosome function, autophagy was assessed by western blotting 
for LC3-B and also by transmission electron microscopy.  
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Figure 4.14: DSF reduces lysosomal acidity.  OSCC cells were treated with LC30 
concentrations of the drugs of interest, in the absence or presence of 10 mM 
metformin. Cells were treated with 1 mM CQ for 1 hr as a positive control. Lysosomal 
acidity was visualised by staining cells with 2.7 µM AO for 1 hr and observing cells 
with the Olympus BX41 microscope (400x). AO is a dye that appears orange in acidic 
environments and green in alkali environments. Lysosomes appeared yellow to green 
in cells treated with DSF or DSF + Met, compared to untreated cells where lysosomes 
were orange. This indicates that lysosomal acidity was significantly reduced in the 
presence of DSF. A similar trend was observed in Cu-DSF and Cu-DSF + Met treated 
cells. As expected, lysosomal vesicles were completely green in the presence of CQ. 
The DSF analogues, DPTD and TTD did not significantly alter lysosomal acidity as 
indicated by the orange colour of lysosomes.  
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4.3.3.4. DSF inhibits autophagy 
We found that there was a significant increase in ubiquitinated proteins in the presence of 
DSF, but DSF was only a partial inhibitor of proteasome activity. DSF and Cu-DSF treatment 
led to reduced lysosomal acidity and this effect was maintained in the presence of 
metformin.  We therefore hypothesised that DSF may inhibit the autophagic pathway, which 
is also involved in protein degradation. In order to test this hypothesis, autophagosomes 
were viewed using EM and LC3B levels were evaluated by western blotting. WHCO1 was 
chosen as a representative cell line for EM experiments.  
There was an increase in the number of enlarged autolysosomes in metformin treated cells 
(Figure 4.15), compared to untreated cells which displayed smaller autophagosomes. There 
was an accumulation of protein aggregates in AVOs after DSF treatment, as indicated by 
dark spots within the autolysosomes, which suggests that DSF treatment blocks lysosome 
mediated protein degradation. Metformin exacerbated the effects of DSF, as there were 
numerous autolysosomes containing non-degraded protein aggregates in cells treated with 
DSF and metformin. This suggests that DSF blocked the degradation of components within 
autolysosomes, which is likely due to reduced lysosomal acidity.  
The effects of Cu-DSF were slightly different, protein aggregates were not as common as 
seen in DSF or DSF + Met treated cells. AVO’s were much larger and characteristic of 
autophagic cell death. Treatment with Cu-DSF combined with metformin resulted in a more 
toxic response as there was a severe loss in cell membrane integrity and hardly any 
organelles, apart from the nucleus, could be seen in the cytoplasm. These results confirm 
our findings which indicate that Cu-DSF is more toxic than DSF alone. However, DSF alone 
was still able to exert an effective cytotoxic response in OSCC cell lines. Due to the observed 
accumulation of lysosomes containing non-degraded protein aggregates, we hypothesised 
that DSF also interferes with autophagy. To test whether DSF inhibits autophagy in OSCC cell 
lines, we determined the levels of LC3B-II by western blotting.  
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Figure 4.15: DSF inhibits autolysosome maturation.  Cells were treated with LC30 
concentrations of DSF for 24 hrs, or pre-treated with 10 mM metformin for 24 hrs 
followed by combination with DSF for a further 24 hrs. Fixed cells were osmicated 
and evaluated by EM (1x106 x). Untreated cells had few lysosomes ( ), but 
autolysosmes were not observed. Autolysosomes (   ) were observed in the presence 
of metformin. Many uncleared autolysosmes containing protein aggregates (  ) were 
observed in cells treated with DSF or DSF + Met. Few autolysomes containing protein 
aggregates were observed in cells treated with Cu-DSF. Cells treated with Cu-DSF or 
Cu-DSF and metformin showed evidence of vacuolisation (  ). N-nucleus; C-cytoplasm.    
Autophagy initiation leads to cleavage of proLC3 at the C terminus to the soluble form, LC3-I. 
Autophagy related proteins are involved in conjugating LC3-I to the lipid PE moiety so it can 
associate with the autophagic membrane both internally and externally (Mizushima, 2004). 
Internal LC3-II is degraded by hydrolytic enzymes of the lysosome upon maturation, whereas 
external LC3-II dissociates and is re-converted to LC3-I. Rapid degradation of LC3B-II is 
indicative of high levels of autophagy. On the other hand, inhibition of autophagy is 
associated with reduced degradation and increased accumulation of LC3B-II (He & Klionsky, 
2009).  
DSF and Cu-DSF both inhibited autophagy in OSCC cell lines as indicated by higher LC3B-II 
levels compared to untreated cells (Figure 4.16). Chloroquine treatment, which inhibits 
autophagy due to its effects on increasing lysosomal pH, resulted in a large increase in LC3B-
II levels as expected. DSF treatment lead to a slight increase in LC3B-II which was further 
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improved by metformin in WHCO1 and WHCO5 cell lines. This effect was more pronounced 
in the SNO cell line. Cu-DSF and Cu-DSF with metformin lead to even larger increases in 
LC3B-II levels in all three cell lines. This indicated that DSF and Cu-DSF both inhibit autophagy 
in OSCC cell lines. 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: DSF increases LC3B-II accumulation and therefore inhibits autophagy.  
Cells were treated with LC30 concentrations of DSF or Cu-DSF for 24 hrs, or pre-
treated with 10 mM metformin for 24 hrs followed by combination with DSF or Cu-
DSF for a further 24 hrs. Cells were treated with 50 µM CQ for 24 hrs as a positive 
control for autophagy inhibition. The bar graph represents the relative optical 
densities of LC3-B II with respect to β-actin (n = 1). As expected, CQ treatment 
resulted in an accumulation of LC3B-II (16 kDa), indicative of autophagy inhibition.  
DSF and Cu-DSF treatment resulted in increased levels of LC3B-II in all three cell lines, 
which indicates that these drugs and inhibit autophagy. LC3B-II levels were slightly 
reduced in WHCO1 and WHCO5 cells treated with metformin only, but elevated in 
SNO cells treated with metformin, suggesting that metformin does not alter 
autophagy in these cell lines. Metformin did not hamper autophagy inhibition by DSF 
or Cu-DSF.  
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4.4. Discussion 
The effects of Cu-ATSM and Cu-GTSM toward OSCC cell lines were retained in the presence 
of metformin. Metformin enhanced the effects of DSF and did not significantly alter the 
cytotoxic effects of Cu-DSF. The addition of metformin did seem to reduce cell number and 
morphology when observed under the microscope when combined with Cu-DSF, which 
suggests that the difference in LC50 value for Cu-DSF compared to Cu-DSF and metformin 
could be insignificant due to approaching saturating levels of toxicity induced by Cu-DSF. 
Based on these findings, we concluded that metformin worked well in combination with 
drugs that are activated in reducing environments and therefore, we suggest that it can be 
combined with either of these agents for cancer therapy. However, of the three drugs, DSF is 
the most promising agent for a cancer treatment option that can be implemented relatively 
sooner than the copper bis(thiosemicarbazones). This is because DSF is already prescribed 
for the treatment of alcoholism and has passed phase I clinical trials for the treatment of 
alcohol abuse, if DSF is prescribed at similar doses for cancer therapy, it may easily move to 
phase II trials for cancer therapy. For this reason, we investigated the mechanistic effects of 
DSF toward OSCC cell lines.  
Our findings clearly indicate that copper plays a major role in DSF mediated toxicity, as an 
increase in the amount of copper bound DSF enhanced the toxicity toward OSCC cell lines. 
Treatment with DSF also led to increased intracellular copper levels, which suggests that DSF 
can bind to copper in cell culture medium and transport it into the cell. Intracellular copper 
levels were even higher when cells were treated with metformin combined with DSF, which 
explains the effects of metformin in enhancing DSF toxicity. Although the evidence 
presented here largely points at copper being the distinguishing factor in DSF mediated 
toxicity, we also showed that DSF can exert cytotoxic effects during copper depletion. 
Therefore, although copper plays a major role in enhancing the effects of DSF, DSF may also 
exert significant cytotoxic effects toward OSCC cell lines in a copper independent manner.  
Studies have indicated that DSF promotes apoptosis by inhibiting chymotrypsin-like activity 
of the proteasome in the presence of copper (Chen et al., 2006). Therefore, we assessed 
chymotrypsin-like proteasome activity in response to DSF in OSCC cell lines and found that 
DSF is a mild inhibitor of proteasome function in OSCC cell lines. Metformin enhanced the 
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effects of DSF and Cu-DSF on proteasome inhibition. Since it is the Cu-DSF complex or 
Cu(DDC)2 that has been credited with the effects of DSF on proteasome inhibition and the 
1:1 Cu-DSF complex had the highest toxicity, we expected that Cu-DSF would be a more 
effective inhibitor of proteasomal activity than DSF alone. However, inhibition of 
proteasome activity was not much lower with Cu-DSF compared to DSF treatment, with a 
difference of 1.5% in WHCO1, 14.9% in WHCO5 and 1.5% in SNO between the two 
treatments. Therefore, these results indicate that inhibition of proteasomal chymotrypsin-
like activity is only a partial contributor to DSF mediated toxicity in OSCC cell lines.   
An accumulation in ubiquitinated proteins suggests that DSF and Cu-DSF inhibit protein 
degradation in OSCC cell lines. However, we showed that there was reduced accumulation 
or increased clearance of ubiquitinated proteins when metformin was combined with DSF or 
Cu-DSF, most apparent in the WHCO1 and WHCO5 cell lines. DSF and Cu-DSF were mild 
inhibitors of proteasomal chymotrypsin-like activity, which explains the observed increase in 
ubiquitinated proteins. Although there was a reduction in the accumulation of ubiquitinated 
proteins in the presence of metformin, we found that it improved DSF and Cu-DSF mediated 
inhibition of chymotrypsin-like activity. This result may seem counter-intuitive at first, 
however, mono-ubiquitination can be utilized as a signal in other protein degradative 
pathways such as autophagy (Clague & Urbé, 2010). Which indicates that metformin may 
promote the degradation of ubiquitin by other protein degradative pathways which are still 
to be explored. Metformin did improve proteasome inhibition by DSF and Cu-DSF and this 
corresponds with its ability to enhance the cytotoxicity of these drugs. However, DSF 
analogues with lower hydrolysis rates were more effective proteasome inhibitors, but were 
less toxic toward OSCC cell lines. For these reasons, we deduced that DSF may be involved in 
inhibiting other protein degradative pathways and that this process may involve one or more 
of its metabolites.  
In addition to binding copper, DSF has a high affinity for protein thiols and is involved in the 
formation of mixed disulfides (Strömme, 1965). DSF-protein binding would inhibit the 
regular function of these proteins and lead to an accumulation of damaged or unused 
proteins. We hypothesised that DSF can enter lysosomal compartments, perhaps when 
when bound to these proteins or by passive diffusion, and alter lysosomal function. DSF is 
highly unstable in a low pH environment, and would readily degrade to its hydrolysis 
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products, diethylamine and carbon disulfide (Martin, 1953). The accumulation of 
diethylamine in lysosomal compartments would reduce lysosomal acidity and thus inhibit 
the regular function of these acidic organelles. As expected, we saw that both DSF and Cu-
DSF significantly reduced lysosomal acidity as acridine orange stained lysosomes were green 
in the presence of DSF and Cu-DSF in all OSCC cell lines tested. DSF hampered lysosomal 
function with a concomitant reduction in autophagy based on reduced clearance of LC3B-II. 
We therefore conclude that DSF exerts its cytotoxic effects by inhibiting multiple protein 
degradative pathways. The combination of metformin and DSF is a promising new strategy 
for the treatment of OSCC as it is both effective and affordable.  
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Chapter 5: Conclusion and Future Prospects 
 
OSCC is among the top 10 most prevalent cancers in South Africa and has a high mortality 
rate (National Health Laboratory Service, 2008). High mortality rates arise from late 
detection and lack of cost-effective treatment options. Drugs that are currently prescribed 
for OSCC lack in their ability to target late stage cancers and harmful side effects of these 
drugs often lead to discontinuation of the therapy. New drugs that are currently being 
developed for oesophageal cancer offer a more targeted approach to cancer therapy, 
however, most of these drugs are unlikely to be implemented in developing or moderately 
developed countries like South Africa as they are unaffordable. Furthermore, introduction of 
these drugs in the clinical setting may still be many years away. This highlights the need for 
more cost effective chemotherapeutic options for OSCC that can be rapidly implemented.  
Metformin is a cost effective and frequently prescribed drug, which is known to have a low 
toxicity profile. Studies have shown that metformin has anti-proliferative effects toward 
various cancer types in vitro and in mouse models (Zakikhani et al., 2006; Gotlieb et al., 
2008). In this study we demonstrate metformin also inhibits the growth of OSCC cell lines. 
The chemostatic effects of metformin are promising as metformin will be useful as a pre-
surgical therapy for OSCC. Studies have shown that metformin can target and selectively kill 
cancer stem cells (Hirsch et al., 2009). The tumour microenvironment consists of multiple 
cell types, and different parts of the tumour have different levels of access to nutrients, 
depending on their proximity to blood vessels. Therefore, tumours may contain cancer cells 
of various levels of differentiation in their microenvironment. Metformin slowed down the 
proliferation of the moderately differentiated OSCC cell lines and was able to kill cancer 
initiating stem cells. If combined with other drugs that are cytotoxic toward cancer cell lines, 
metformin may offer a novel chemotherapeutic option that is both cost-effective and has 
fewer side effects.  
The most commonly prescribed drugs for OSCC are cisplatin, mitomycin C and 5-fluorouracil. 
We have shown that metformin inhibits the effects of cisplatin and also mildly inhibited the 
effects of mitomycin C (Damelin et al., 2014). Preliminary data in our lab indicates that 
 118 
 
 
metformin also inhibits the effects of 5-fluorouracil toward OSCC cell lines. Therefore, 
metformin should not be used in combination with these commonly prescribed 
chemotherapeutic drugs. Should metformin reach the stage where it can be prescribed for 
OSCC, caution must be used when treating diabetic patients with these chemotherapeutic 
drugs.  
Metformin increased the intracellular reducing environment and also enhanced the effects 
of anti-cancer drugs that are reductively activated. DSF is approved for the treatment of 
alcoholism, and also has a low toxicity profile. DSF exerted cytotoxic effects toward OSCC cell 
lines which were enhanced in the presence of metformin. This drug combination is a very 
promising chemotherapeutic approach for OSCC as these drugs are both affordable and 
individually, they both have a low toxicity profile. DSF was effective against cancer at 
particularly low doses and may be more effective toward tumours that have elevated copper 
levels.  
We have therefore identified a novel treatment option for OSCC that may be superior to 
currently prescribed chemotherapeutic drugs as this novel combination is cost effective and 
less harmful. For this reason, this study has been extended to include an in vivo component. 
Future work that will be conducted in this laboratory will involve studies on nude mice. The 
effects of DSF, Cu-DSF, Cu-ATSM and Cu-GTSM in combination with metformin will be 
assessed in nude mice. This will allow us to determine drug dosage that is tolerated and 
acceptable for cancer therapy. Copper content and redox state of the xenografts will be 
determined in order to identify whether the effects of these drugs in vitro match its in vivo 
effects. We will also investigate whether OSCC tumours will be susceptible to reductively 
activated drugs such as DSF, Cu-ATSM or Cu-GTSM using immunohistochemistry to detect 
biomarkers of redox state in human tumour biopsies.  
This study holds promise for a novel treatment option for OSCC that is likely to move to 
clinical trials should mouse trials be successful. Rather than investigating new drugs, drug 
repurposing may be a more effective approach in the identification of novel 
chemotherapeutic drugs. This study may be the first step toward the implementation of a 
new treatment option for OSCC patients in this country and other developing countries. 
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Background: Oesophageal squamous cell carcinoma (OSCC) is a highly aggressive carcinoma with a poor survival
rate. One of the most commonly used chemotherapeutic drugs, cisplatin, displays varied and often poor efficacy
in vivo. Therefore, alternative, cost-effective and more efficacious treatments are required. Metformin has been
previously shown to reduce proliferative rates in various carcinoma cell lines. We report for the first time, the
effect of metformin on OSCC cell proliferation and show that it antagonises cisplatin-induced but not copper-bis
(thiosemicarbazone)-induced cytotoxicity in OSCC cells.
Methods: Cell proliferation and stage of the cell cycle were quantified by trypan blue counts and flow cytometry,
respectively. All cytotoxicity measurements were made using the tetrazolium based MTT assay. Metabolic
alterations to cells were determined as follows: glycolysis via a lactate dehydrogenase assay, reducing equivalents
by MTT reduction and reduced intracellular thiols by monobromobimane-thiol fluorescence, and glutathione
depletion using buthionine sulfoximine. Inductively coupled plasma mass spectrometry was used to quantify
cisplatin-DNA adduct formation.
Results: Metformin was found to reduce cell proliferation significantly in all OSCC cell lines, with an accumulation
of cells in G0/G1 phase of the cell cycle. However, metformin significantly protected OSCC cells against cisplatin
toxicity. Our results indicate that a major mechanism of metformin-induced cisplatin resistance results from a
significant increase in glycolysis, intracellular NAD(P)H levels with a concomitant increase in reduced intracellular
thiols, leading to decreased cisplatin-DNA adduct formation. The glutathione synthesis inhibitor buthionine
sulfoximine significantly ablated the protective effect of metformin. We subsequently show that the copper-bis
(thiosemicarbazones), Cu-ATSM and Cu-GTSM, which are trapped in cells under reducing conditions, cause significant
OSCC cytotoxicity, both alone and in combination with metformin.
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Conclusions: This is the first study showing that metformin can be used to decrease cell proliferation in OSCC cells.
However, metformin protects against cisplatin cytotoxicity by inducing a reducing intracellular environment
leading to lower cisplatin-DNA adduct formation. As such, we advise that caution be used when administering
cisplatin to diabetic patients treated with metformin. Furthermore, we propose a novel combination therapy
approach for OSCC that utilises metformin with metformin-compatible cytotoxic agents, such as the copper-bis
(thiosemicarbazones), Cu-ATSM and Cu-GTSM.
Keywords: Oesophageal squamous cell carcinoma, Metformin, Copper bis(thiosemicarbazones), Metabolism,
Cisplatin, Thiol, GlutathioneBackground
Oesophageal carcinoma, of which there are two sub-
types, adenocarcinoma and squamous cell carcinoma, is
the sixth most common cause of cancer-related death
[1]. Oesophageal squamous cell carcinoma (OSCC) is a
highly aggressive carcinoma with a very poor survival
rate that occurs with particularly high frequency in de-
veloping countries including Iran, China, South Africa,
and Brazil, where mortality rates can exceed 100 per
100,000 population. In developed countries, incidence
rarely exceeds 10 per 100,000 population [2,3], with the
exceptions of certain regions in North-West France and
Northern Italy where incidence may reach 30 and 2 per
100,000 in males and females, respectively [4]. The causes
of OSCC are multiple and varied, probably reflecting re-
peated exposure to dietary components, such as N-nitroso
compounds, excessive smoking and alcohol consumption,
chronic inflammation and possibly, genetic predisposition
[5]. Current commonly used therapies for OSCC include
5-fluorouracil and cisplatin, which show poor efficacy and
often display both chemotoxicity and chemoresistance [6].
Cisplatin has multiple mechanisms of cytotoxicity in-
cluding the formation of DNA and protein adducts,
as well as via oxidative stress. Many resistance mecha-
nisms for cisplatin have been identified, including, pertin-
ent to this study, sequestering of cisplatin by glutathione
(a major species of intracellular thiols). This results in
export of cisplatin-glutathione adducts leading to a
reduction in cisplatin-mediated DNA damage [7-9]. In-
vestigations into more effective targeted treatment op-
tions for OSCC using monoclonal antibody therapies
are very promising [10] however, access to such therap-
ies in developing countries is extremely limited, primar-
ily due to cost. Therefore, there is a continued and
urgent requirement for alternative, effective and eco-
nomical treatment options.
Recently, the well characterized and tolerated anti-
diabetic drug, metformin has been the subject of intense
investigations in cancer research. Population studies
have shown that this biguanide, conventionally used to
decrease peripheral glucose levels and increase insulin
sensitivity in diabetic and pre-diabetic patients [11,12],reduced breast cancer occurrence in female patients
with type 2 diabetes [13]. Since then, metformin has
been observed to reduce the proliferation of many types
of carcinoma cell lines and diabetic patients taking met-
formin have been found to have better recovery rates
from breast cancer [14-17]. Furthermore, metformin has
been shown to target cancer stem cells [18]. However,
whilst metformin reduces cell proliferation in most cancer
types, it rarely causes apoptosis, and is therefore being
combined with conventional chemotherapeutic drugs, in-
cluding cisplatin. This treatment combination has mixed
results, with some studies showing that metformin can en-
hance the effectiveness of chemotherapeutic drugs whilst
others have shown increased chemoresistance in the
presence of metformin [19,20]. With regards to cisplatin,
metformin has been shown to reduce cisplatin sensitivity
through the AMPK-independent upregulation of the Akt
survival pathway [20]. A search on clinicaltrials.gov found
over 40 clinical trials investigating metformin and a variety
of chemotherapeutic drugs, for breast, ovarian and pros-
tate cancer amongst a number of others.
In this study, we investigated the effect of metformin
on OSCC cell proliferation and on the cytotoxicity of
cisplatin for OSCC cells. We show that whilst metformin
markedly reduces OSCC cell proliferation and causes
cells to accumulate in the G0/G1 phase of the cell cycle,
it also significantly protects against cisplatin cytotoxicity.
The protective effect is not solely due to reduced cell-
proliferation, as the biguanide minimally to partially pro-
tects against the DNA-crosslinker, mitomycin C, but is
dependent on a metformin-induced increase in glycolysis
and intracellular NAD(P)H levels with a concomitant in-
crease in reduced intracellular thiols, which coincides
with decreased cisplatin-DNA adduct formation. The
glutathione synthesis inhibitor buthionine sulfoximine
(BSO) significantly reverses this protective effect, con-
firming the role of reduced glutathione in cisplatin
detoxification by metformin-treated cells. In light of
these findings, we investigated the copper-bis(thiosemi-
carbazones), copper diacetyl-bis(4-methylthiosemicar-
bazonato)copper(II) (Cu-ATSM) and copper glyoxal-bis
(4-methylthiosemicarbazonato)copper(II) (Cu-GTSM).
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a number of mechanisms, including inhibition of DNA
synthesis [21]. Importantly, as these compounds are
known to be trapped in cells under reducing conditions,
they are therefore compatible with a reducing intra-
cellular state [22]. We show that both Cu-ATSM and
Cu-GTSM display significant levels of cytotoxicity at
LD50 values comparable to or lower than cisplatin, both
alone or in combination with metformin, highlighting
the use of metformin and reduction-compatible cyto-
toxic drugs as a novel combination therapy strategy for
the treatment of OSCC.
Methods
Reagents
Reagents for flow cytometry were purchased from
Beckman Coulter. All other reagents were purchased
from Sigma Aldrich unless otherwise specified.
Synthesis of bis(thiosemicarbazones)
The bis(thiosemicarbazones), ATSM and GTSM, were
synthesised from 4-methyl thiosemicarbazide and butane-
dione or glyoxal, respectively, according to the method of
French et al. [23].
ATSM: 1H NMR (500 MHz, DMSO) 11.74 (2H, s, 2 ×
CH =N), 8.48 (2H, d, J = 4.2, 2 × NH), 7.72 (2H, s, 2 ×
NH), 2.96 (6H, d, J = 4.4, 2 × CH3);
13C NMR (126 MHz,
DMSO) 177.55 (2 × C = S), 140.02 (2 × C = N), 30.89
(2 × CH3).
GTSM: 1H NMR (500 MHz, DMSO) 10.20 (2H, s, 2 ×
NH), 8.36 (2H, d, J = 4.1, 2 × NH), 3.02 (6H, d, J = 4.5,
2 × CH3), 2.20 (6H, s, 2 × CH3);
13C NMR (126 MHz,
DMSO) 178.47 (2 × C = S), 147.95 (2 × C = N), 31.18
(2 × CH3), 11.64 (2 × CH3).
Cu-ATSM and Cu-GTSM were synthesized from
ATSM and GTSM and cupric chloride as previously
described [24].
Cell culture
The human OSCC cell lines were a kind gift from Pro-
fessor Robin Veale. These cells, WHCO1, WHCO5 [25]
and SNO [26] were maintained in Dulbecco’s Modified
Eagles Medium/Hams F12 (DMEM/Hams F12, 3:1) sup-
plemented with 10% FCS at 37°C and 5% CO2.
Cell proliferation
Cell proliferation was assessed by cell counts using try-
pan blue exclusion. Cells were seeded in 48-well plates
at 1×104 cells per well. After 24 hours, cells were in-
cubated with or without 10 mM metformin for an
additional 24 hours. Cells were then trypsinized, re-
suspended in 1×PBS and incubated in 2% trypan blue
for 2 minutes and counted using a haemocytometer
(n = 5 ± SD).Cell cycle analysis
Cell cycle analysis was by flow cytometry as previously
described [27]. Cells were seeded equally in 10 cm dishes
and cultured for 48 hours (~60% confluent). At this
time, the medium was replaced and cells incubated with
or without 10 mM metformin for 24 hours. Control cells
were serum-deprived for 8 hours. Cells were then har-
vested and prepared for analysis using the DNA Prep
Reagent kit according to manufacturers’ instructions
(Beckman Coulter). Briefly, cells were treated with DNA
prep LPR (lysis) solution in order to facilitate propidium
iodide (PI) entry and samples vortexed for 10 seconds
followed by the addition of DNA prep stain (PI and RNAse)
and additional vortexing. Samples were then immediately
analysed on an LSRFortessa™ cell analyser, BD Biosciences.
DNA histograms were analysed using FlowJo v10 software
and the percentage of cells in the G0/G1, S, and G2/M
phase of the cell cycle calculated (n = 3 ± SD).
Cytotoxicity assays
Cytotoxicity was assessed using the 3-(4,5-dimethylthiazol-
2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay. Cells
(8500 cells per well) were seeded into 96-well plates and
after 24 hours exposed to cytotoxic agents for varying
times. After treatment, the medium was replaced with
100 μl of MTT solution (0.5 mg/ml in cell culture medium)
and incubated at 37°C for 2 hours. MTT solution was then
removed, and MTT formazan dissolved in 100 μl dimethyl
sulfoxide (DMSO). Absorbance was measured at 570 nm
using the Bio-Rad iMark microplate reader (n = 3 ± SD).
ICP-MS analysis of platinum-DNA adducts
Inductively-coupled plasma mass spectrometry (ICP-
MS) was performed as previously described [28]. Briefly,
cells were treated with cisplatin (LD30 concentrations)
for 48 hours with or without 24 hour prior exposure to
10 mM metformin. Total genomic DNA was extracted,
resuspended in water and quantified using a NanoDrop
ND-1000 spectrophotometer (Thermo Scientific). DNA
samples were hydrolysed in a final concentration of 1%
HNO3 at 70°C for 24 hours and analysed for platinum
(n = 3 ± SD) on an Agilent 7700 ICP-MS. The instru-
ment was optimised for sensitivity and low oxides. Ana-
lysis was done in no-gas mode, and the instrument was
calibrated for platinum analysis using National Institute
of Standards and Technology traceable standards.
Determination of glycolysis via lactate production
As an indicator of levels of glycolysis, lactate levels in
culture medium were quantified using a lactate dehydro-
genase assay [29] where the production of NADH from
NAD via the conversion of lactate to pyruvate is directly
proportional to lactate concentration. Cells were seeded
and treated as for cell cycle analysis and both conditioned
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were counted using trypan blue exclusion as described
above. For lactate quantification, 50 μl of medium was
added to 950 μl glycine-hydrazine buffer (0.64 M glycine,
0.64 M hydrazine, 4.8 mM NAD+, 16 U/ml lactate de-
hydrogenase, pH 9.2) and incubated at 37°C for 2 minutes.
NADH was then quantified spectrophotometrically at
340 nm and values corrected for cell number (n = 3 ± SD).Figure 1 Anti-proliferative effects of metformin on OSCC cells. A, Cells
number in comparison to untreated controls across all cell lines, n = 4, mea
cytometry analysis (from SNO cells) for untreated cells (Untreated), FCS dep
24 hours (Metformin). Metformin treated cells exhibited an accumulation a
of cells in phase of cell cycle (n = 3, mean ± SD), where for all cells there w
treated cells relative to untreated controls with WHCO1 p = 0.05, WHCO5 pQuantification of reducing equivalents
Total cellular reducing equivalents were quantified by tetra-
zolium (MTT) assay as previously described [30]. An equal
number of cells were seeded into 96-well plates (8500 cells
per well) and after 24 hours cells were incubated for
24 hours with or without 10 mM metformin and MTT
assay performed. Values were corrected for cell number
using trypan blue exclusion as described above (n = 3 ± SD).exposed to 10 mM metformin for 24 hours showed a decrease in cell
n ± SD. B, Quantification and C,representative figures of flow
rived control (FCS Control) and cells exposed to 10 mM metformin for
t the G0/G1 stage of the cell cycle across all cell lines, expressed as %
as a statistically significant increase in cells in G0/G1 in metformin
= 0.04 and SNO p = 0.01.
Figure 2 Effect of metformin on cisplatin and mitomycin C cytotoxicity for OSCC cells. OSCC cells, untreated or treated with 10 mM
metformin for 24 hours and then treated with (A) cisplatin or (B) mitomycin C for a further 48 hours, were assessed by MTT assay. All
metformin-cisplatin treated cells displayed a trend for higher LD50 values, with WHCO1 and SNO cells statistically higher (n = 3, mean ± SD).
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Total low-molecular weight thiols were quantified using
monobromobimane, which forms fluorescent thiol con-
jugates [31]. Cells were seeded and treated as for cell
cycle analysis with or without 10 mM metformin for
24 hours. Cells were subsequently washed three times
with 1×PBS and incubated in 1 ml of 1×PBS with 18 μl
monobromobimane solution (stock 5 mg/ml in DMSO)
for 10 minutes. Cells were then lysed in 1 ml of triple
detergent lysis buffer (50 mM Tris–HCl, 150 mM NaCl,
0.1% SDS, 1% Triton ×-100, 0.5% sodium deoxycholate),
the lysate centrifuged at 10000 g and 100 μl of the re-
sultant supernatant fluorescently analysed at 360nmexcita-
tion/460nmemission using an Ascent multi-well plate
fluorimeter (Thermo Scientific). Cells seeded in parallel
dishes were counted using trypan blue exclusion asTable 1 Cytotoxicity in OSCC cells treated with or without me
Compounds
WHCO1
Cisplatin 70.88 ± 13.8
p = 0.009
11
Met + Cisplatin 126.02 ± 26.57 28
Mitomycin C 32.73 ± 2.49
p = 0.003
32
Met + Mitomycin C 37.15 ± 0.79 30
OSCC cells were treated with 10 mM metformin (Met) and either cisplatin or mitom
(n = 3, mean ± SD).above and fluorescence values were corrected for cell
number (n = 3 ± SD).
Glutathione depletion assay
The glutathione synthesis inhibitor BSO was used in
order to deplete intracellular glutathione levels and
thereby assess the involvement of thiols (glutathione)
in the cytoprotective effects of metformin on cisplatin
toxicity [32]. Cytotoxicity assays were performed as above
with the following modifications, cells were seeded at
7500 cells per well in 96-well plates and allowed to settle
for 18 hours. Cells were then treated with 0.4 mM of BSO
for 18 hours, followed by the addition of 10 mM metfor-
min (or metformin diluent for control cells) and subse-
quently cisplatin, and cytotoxicity determined by MTT
assay as above (n = 3 ± SD).tformin and cisplatin or mitomycin C
LD50 (μM)
WHCO5 SNO
.68 ± 3.62 p = 0.075 11.01 ± 1.62
p = 0.0001
.03 ± 15.81 28.16 ± 3.37
.87 ± 3.03 p = 0.25 9.92 ± 1.80
p = 0.011
.19 ± 4.36 16.64 ± 2.77
ycin C and MTT assays performed. LD50 (μM) was calculated on replicates
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Comparisons were by two-tailed Student’s t-tests and
p < 0.05 was considered statistically significant. LD50
and LD30 values were calculated using GraphPad Prism
version 6.
Results
OSCC cells exhibit decreased cell proliferation and cell
cycle arrest in response to metformin
We investigated the effect of metformin on three OSCC
cell lines (WHCO1, WHCO5 and SNO), previously de-
rived from South African OSCC patients [25,26]. All
cell lines exhibited a significant reduction in cell prolifera-
tion in response to 10 mM metformin after 24 hour treat-
ment, in comparison to untreated controls. There was 50%,
32% and 39% reduction in cell proliferation in WHCO1,
WHCO5 and SNO cells, respectively (Figure 1A). In
addition, we assessed cell cycle progression using flow
cytometry with propidium iodide staining of cellular
DNA content. Cells deprived of foetal calf serum (FCS)
for 8 hours were used as the control, which as expected,
showed an increase in the number of cells in G0/G1
phase of the cell cycle. Metformin treatment (10 mM
for 24 hours), as anticipated, caused an increase in the
number of cells in G0/G1 phase relative to untreated
controls (Figure 1B and C).
Metformin protects cells from cisplatin cytotoxicity
Next, we assessed the effect of metformin on cisplatin
cytotoxicity by MTT assay. Cells pre-treated with
10 mM metformin for 24 hours and then treated with
10 mM metformin and cisplatin for 48 hours (Figure 2A),
exhibited significantly lower cytotoxicity than cellsFigure 3 Decreased platinum-DNA adduct formation in
cisplatin-metformin treated OSCC cells. OSCC cells were treated
with LD30 concentrations of cisplatin, either alone or in combination
with 10 mM metformin. Genomic DNA was extracted and platinum
quantified by ICP-MS which showed a decrease in platinum in
cisplatin-metformin treated cells in comparison to cells treated with
cisplatin alone (values expressed per μg of DNA) (n = 3, mean ± SD).
Figure 4 Metformin increases lactate production, intracellular
NAD(P)H and low molecular weight reduced thiols in OSCC
cells. A, Increased secretion of lactate (per 104 cells) indicated
increased glycolysis levels in OSCC cells treated with 10 mM metformin
for 24 hours in comparison to untreated cells (n = 3, mean ± SD). B,
Elevated total reducing equivalents (per 104cells) in OSCC cells treated
with 10 mM metformin for 24 hours in comparison to untreated cells
(n = 3, mean ± SD). C, Low molecular weight thiols levels (per 104 cells)
is higher in OSCC cells treated with 10 mM metformin for 24 hours, in
comparison to untreated cells (n = 3, mean ± SD).
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LD50 values for cisplatin in the presence of metformin,
with a 78% increase for WHCO1, 140% increase for
WHCO5 and 156% increase for SNO cells (Table 1).
We assessed the effects of metformin on the formation
of cisplatin-DNA adducts, by treating cells as above
but using the calculated LD30 of cisplatin. DNA-bound
platinum, as quantified by ICP-MS, showed a signifi-
cant reduction in metformin treated cells by 19.3% in
WHCO1, 14.1% in WHCO5 and 18.4% in SNO cells
(Figure 3). To determine whether reduced cytotoxicity
and cisplatin-DNA adduct levels was principally due to
the observed metformin-induced reduction in cell pro-
liferation, cells were treated with an alternative DNA
crosslinker, mitomycin C with or without metformin as
above (Figure 2B). Partial to no protection from mito-
mycin C was observed after metformin pre-treatment
across the cell lines (Table 1), indicating that factors
other than decreased proliferation were the major con-
tributors to metformin-dependent cisplatin resistance.
Metformin treatment increases lactate production,
intracellular NAD(P)H and low molecular weight reduced
thiols in OSCC cells
Metformin has been shown to increase cellular glucose
transport and glycolytic rates [33]. We hypothesized that
such an occurrence in OSCC cells could result in an
enhanced intracellular reducing environment (increased
NAD(P)H levels) and the potential for increased intra-
cellular reduced thiol levels, thus contributing to the
observed metformin-induced protection against cis-
platin. Cisplatin cytotoxicity has been previously shown
to be antagonized by low-molecular-weight reduced
thiols via cisplatin-thiol adduct formation, specifically
with glutathione. Glutathione is the major contributor
to intracellular thiols, existing in millimolar amounts in
the cytosol [7,8,34]. We found that glycolysis (as measured
by lactate output), and indirectly, glucose utilization, was
indeed significantly increased for all OSCC cell lines afterFigure 5 Increased intracellular thiols causes cisplatin resistance in O
confirm the role of thiols in cisplatin resistance in OSCC cells. Cells were eit
treated with a concentration range of cisplatin for a further 48. Cytotoxicity
higher LD50 values than cisplatin treated cells alone (n = 3, mean ± SD).treatment with 10 mM metformin for 24 hours relative to
untreated controls (Figure 4A). As predicted, total intra-
cellular NAD(P)H levels (quantified by tetrazolium
(MTT) reduction) (Figure 4B) and low-molecular
weight thiol levels (monobromobimane-thiol adduct
fluorescence) (Figure 4C) were significantly elevated
for all OSCC cell lines following metformin treatment
relative to untreated controls.
Intracellular thiols mediate metformin induced cisplatin
protection in OSCC cells
To confirm that increased thiol levels can protect OSCC
cells against cisplatin, cells were treated with the cell per-
meable thiol derivative, N-acetyl cysteine (NAC) (10 mM)
prior to cisplatin exposure [35]. Predictably, all OSCC
cell lines were significantly protected against cisplatin
cytotoxicity by NAC pre-treatment (Figure 5). Therefore,
our hypothesis, that a metformin-dependent increase in
intracellular thiols is primarily responsible for the ob-
served protection against cisplatin, seemed highly plaus-
ible. Since glutathione is the major thiol species within the
cells, we confirmed its role in metformin-induced cisplatin
resistance using the glutathione synthase inhibitor, BSO
[32], to deplete intracellular glutathione pools. Cells were
treated with metformin in the presence of BSO, prior to
cisplatin exposure. Glutathione depletion by BSO almost
completely reversed the protective effect of metformin
for all OSCC cell lines, confirming the role of reduced-
glutathione in metformin-induced cisplatin resistance
(Figure 6). We also observed that BSO increased cis-
platin cytotoxicity, with lower LD50 values, and this was
anticipated as decreased intracellular glutathione levels
would result in less cisplatin-thiol sequestration and an
increase in cisplatin-DNA adduct formation.
OSCC cells are highly susceptible to copper-bis
(thiosemicarbazones)
Given the above observations, we considered the role of
cytotoxic molecules that are compatible with increasedSCC cells. The cell permeable thiol derivative NAC was used to
her untreated or treated with 10 mM NAC for 24 hours and then
was assessed by MTT assay. All NAC-cisplatin treated cells displayed
Figure 6 Metformin-induced cisplatin resistance is reversed by
glutathione depletion in OSCC cells. The glutathione synthesis
inhibitor, BSO was used to confirm the involvement of elevated
glutathione levels in metformin induced cisplatin resistance in OSCC
cells. MTT assays for cytotoxicity were performed as described, with
cells treated with cisplatin alone (C), or in the presence 0.4 mM BSO
(CB), or metformin and cisplatin (CM), or metformin and cisplatin in
the presence of 0.4 mM BSO (CMB). Data is expressed as the
percentage difference of LD50 values for each treatment relative to
cisplatin alone (n = 3, mean ± SD). Predictably, the inhibition of
glutathione synthesis increased cisplatin toxicity as LD50 values for
cisplatin-BSO treated cells were significantly lower than cisplatin
alone. Importantly, the presence of the inhibitor ablates the protective
effect of metformin, with LD50 values for cisplatin-metfomin-BSO
treated cells approaching those of cisplatin alone.
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used in conjunction with metformin. In this way, the
cytostatic effects of metformin could be utilised when
combined as an adjuvant in chemotherapy regimens;
since there is also evidence that metformin targets can-
cer stem cells, this would offer a considerable added
advantage [18]. The copper bis(thiosemicarbazone) de-
rivatives ATSM and GTSM have been previously shown
to be trapped intracellularly under reducing conditions
[22]. We therefore tested their efficacy as cytotoxic
agents against OSCC cell lines with or without met-
formin. OSCC cells were pre-treated with or without
10 mM metformin for 24 hours and then treated with
copper-bis(thiosemicarbazones) and 10 mM metformin
for 48 hours (Figure 7). Interestingly, we found that
both Cu-ATSM and Cu-GTSM displayed significant
cytotoxicity for all cell lines, both in the presence and
absence of metformin treatment, with LD50 values
lower than or comparable to cisplatin alone. Cu-GTSM
displayed lower LD50 levels than Cu-ATSM (Table 2).
Statistically there was no difference between untreated
and metformin treated samples (p > 0.05). Non-cop
per-conjugated bis(thiosemicarbazone) compounds dis-
played far lower levels of cytotoxicity than their copper-
conjugated counterparts, with LD50 concentrations over
200 μM; copper alone had minimal effect on cells at the
concentrations used in this study.
Discussion
We have established that metformin significantly re-
duces the proliferation of OSCC cells. However, we ob-
served that metabolic alterations caused by metformin
rendered cells less sensitive to the commonly used che-
motherapeutic agent, cisplatin. Previous studies have
shown that metformin can reduce sensitivity to cisplatin
through the activation of pro-survival signals via Akt
[20] and hyperactivation of Akt has been linked to in-
creased glycolysis [36]. Those studies therefore support
our findings, which show that metformin increases
glycolysis with a subsequent increase in intracellular
reducing equivalents and a concomitant increase in
intracellular reduced thiols.
Since cisplatin is ineffective in a reducing intracellular
environment, our findings also support observations re-
garding cisplatin chemoresistance in tumours; cancer
cells within the tumour are known to display a highly
reducing phenotype and resist cisplatin chemotherapy
[37]. However, in recent years, the observation that
tumours consist of cells in differing metabolic states to
surrounding normal tissue [38] has encouraged the con-
cept of cancer-cell specific metabolic targeting as an in-
creasingly popular strategy in cancer therapy [39]. Our
study highlights the use of metformin with cytotoxic
agents that are compatible with or remain active under
Figure 7 Copper bis(thiosemicarbazones) are highly toxic to OSCC cells in the presence of metformin. OSSC cells, untreated or treated
with 10 mM metformin for 24 hours and then treated with (A) GTSM or Cu-GTSM, or (B) ATSM or Cu-ATSM for a further 48 hours were assessed
by MTT assay. The non-copper-conjugated bis(thiosemicarbazones) showed relatively little toxicity with LD50 values greater than 200 μM in both
the presence and absence of metformin. The copper-conjugated compounds however displayed considerable toxicity to OSCC cells with similar
LD50 values for metformin treated-and untreated compounds for WHCO1, WHCO5, and SNO cells.
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therapy combinations for the treatment of this highly
aggressive malignancy.
Mitomycin C, which must be reductively activated to
exert its biological effects [40], is one potential candidate
for this strategy as partial to no protection from this
drug was observed after metformin pre-treatment. How-
ever, an obvious concern with the use of mitomycin C
and related DNA crosslinkers in combination with metfor-
min would be the potential for decreased drug effective-
ness or the emergence of drug resistance in vivo, due toTable 2 Cytotoxicity in OSCC cells treated with or without
metformin and with Cu-GTSM or Cu-ATSM
Compounds LD50 (μM)
WHCO1 WHCO5 SNO
Cu-GTSM 1.14 ± 0.16 5.39 ± 0.9 3.37 ± 0.23
Metformin + Cu-GTSM 1.16 ± 0.12 6.24 ± 0.01 4.23 ± 0.7
GTSM >200 >200 >200
Metformin + GTSM >200 >200 >200
Cu-ATSM 11.93 ± 0.47 13.51 ± 0.81 7.099 ± 0.57
Metformin + Cu-ATSM 12.54 ± 0.19 12.05 ± 0.83 10.90 ± 0.77
ATSM >200 >200 >200
Metformin + ATSM >200 >200 >200
OSCC cells were treated with 10 mM metformin and either GTSM, Cu-GTSM,
ATSM or Cu-ATSM and the MTT assay performed. LD50 (μM) was calculated on
replicates (n = 3, mean ± SD).the anti-proliferative effects of the biguanide. Therefore,
agents that are either reductively activated or tolerant, and
that target proliferating and non-proliferating tumour
cells, would be a more logical choice for use in combin-
ation with metformin in OSCC. We have established
that a potential highly efficacious combination strategy
of this kind, could be metformin and the copper-bis
(thiosemicarbazones), Cu-GTSM or Cu-ATSM. Bis
(thiosemicarbazones) have been considered for cancer
treatment since the 1950’s [23], whilst the copper-bis
(thiosemicarbazones) have been shown to possess po-
tent anti-cancer activities and are attractive candidates
for use as chemotherapeutics as they often preferen-
tially accumulate in tumour tissue and are retained in
cells under reducing conditions [22]. We have shown that
Cu-ATSM and Cu-GTSM, in contrast to non-copper con-
jugated bis(thiosemicarbazones), are highly cytotoxic to
OSCC cells, both in the presence and absence of metfor-
min, and are thus metformin-compatible. The fact that an
increase in toxicity was not observed for Cu-ATSM or
Cu-GTSM in the presence of metformin suggests that: (1)
there already exists a sufficiently high intracellular redu-
cing environment in the OSCC cell lines used (a common
observation in cancer cells [37]) to allow for the intracellu-
lar accumulation of these compounds to toxic levels, and
(2) that the mechanisms of toxicity of these compounds,
are compatible with, but not necessarily dependent on a
intracellular reducing environment.
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LD50 values than Cu-ATSM as Cu-GTSM is known to
be rapidly reduced by intracellular thiols resulting in cell
retention, copper release and ultimately apoptosis via
oxidative stress, and/or the inhibition of DNA synthesis
and oxidative phosphorylation [41,42]; Cu-ATSM on the
other hand has been shown to be poorly reduced by
intracellular thiols and thought to be maintained in a
reduced state (and thus retained intracellularly) only
under hypoxic conditions [41]. Recently, however,
Donnelly et al. have shown that Cu-ATSM can be
retained in cells under normoxic conditions when the
intracellular reducing environment is increased due to
factors such as impaired mitochondrial electron trans-
port chain function [22]. These findings appear to
agree with the findings of our study as SNO cells,
which exhibit the greatest intracellular reducing envir-
onment (in the absence of metformin) of all the OSCC
cell lines tested (Figure 4B), exhibit the greatest sensi-
tivity to Cu-ATSM (Table 2). Nonetheless, the fact that
all OSCC cell lines were highly sensitive to Cu-ATSM
alone or in combination with metformin, at LD50
values comparable to or lower than those for cisplatin
for all OSCC cell lines used, is extremely promising
given its increased stability over Cu-GTSM and inves-
tigatory Food and Drug Administration approval of
64Cu-ATSM for use as a hypoxia contrast agent [43].
Conclusions
Metformin, which has an extensive track record and is
well tolerated by individuals, has been shown to sup-
press cancer cell proliferation. We have established that
metformin significantly reduces cell proliferation in
OSCC cell lines. However, we found metformin causes
resistance to cisplatin in OSCC cell lines and as such
we advise that caution be used when administering
cisplatin to diabetic patients treated with metformin
and in the use of metformin as an adjuvant to cisplatin
chemotherapy. Furthermore, we have shown that two
copper-conjugated bis(thiosemicarbazones), Cu-ATSM
and Cu-GTSM, exhibit marked cytotoxicity in OSCC
cells in the presence of metformin. The preliminary
data presented in this study justifies further investiga-
tions into the therapeutic effects of copper-bis(thiose-
micarbazones) in both the presence and absence of
metformin, for OSCC. In addition metformin lends
itself to combination therapy with reduction compat-
ible or activated compounds (unlike cisplatin) for both
OSCC and potentially other cancers where similar
metabolic changes are observed.
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ABSTRACT 
Disulfiram (DSF), used since the 1950s in the treatment of alcoholism, is reductively activated to 
diethyldithiocarbamate and both compounds are thiol-reactive and readily complex copper. More recently DSF 
and copper- DSF (Cu-DSF) have been found to exhibit potent anticancer activity.  We have previously shown that 
the anti-diabetic drug metformin is anti-proliferative and induces an intracellular reducing environment in 
oesophageal squamous cell carcinoma (OSCC) cell lines. Based on these observations, we investigated the 
effects of Cu-DSF and DSF, with and without metformin, in this present study. We found that Cu-DSF and DSF 
caused considerable cytotoxicity across a panel of OSCC cells, and metformin significantly enhanced the effects 
of DSF.  Elevated copper transport contributes to DSF and metformin-DSF-induced cytotoxicity since the cell-
impermeable copper chelator, bathocuproinedisulfonic acid, partially reversed the cytotoxic effects of these 
drugs, and interestingly, metformin-treated OSCC cells contained higher intracellular copper levels. 
Furthermore, DSF may target cancer cells preferentially due to their high dependence on protein 
degradation/turnover pathways, and we found that metformin further enhances the role of DSF as a 
proteasome inhibitor. We hypothesized that the lysosome could be an additional, novel, target of DSF. Indeed, 
this acid-labile compound decreased lysosomal acidification, and DSF-metformin co-treatment interfered with 
the progression of autophagy in these cells. In summary, this is the first such report identifying the lysosome as a 
target of DSF and based on the considerable cytotoxic effects of DSF either alone or in the presence of 
metformin, in vitro, we propose these as novel potential chemotherapeutic approaches for OSCC. This article is 
protected by copyright. All rights reserved 
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   Disulfiram (DSF) (tetraethylthiuram disulfide) has been used since the 1950’s to treat alcohol abuse (Johansson 
1992). In vivo, DSF is rapidly converted to its monomer, diethyldithiocarbamate (DDC), which is then methylated 
and subsequently oxidised to methyl diethylthiocarbamoyl sulfoxide (MeDTC-SO) (Ververka et al., 1997). Both 
DSF and MeDTC-SO can irreversibly inhibit aldehyde dehydrogenase, which leads to an accumulation of 
acetaldehyde in the blood upon alcohol intake, causing, amongst other effects, severe nausea, vomiting and 
tachycardia (Johansson 1992; Ververka et al., 1997).  
   DSF was shown to have anticancer activity in the 1970’s (Wattenberg 1974) and in recent years, there has 
been renewed interest in DSF for cancer therapy primarily because DSF is an attractive candidate for drug 
‘repurposing’ given its well characterised toxicity profile and good safety track record (Cvek 2011; Johansson 
1992).  DSF and DDC are thiol-reactive and can react with the free thiol groups on proteins and glutathione; they 
also have high affinity for, and form stable complexes with, heavy metals such as copper and zinc (Johansson 
1992).  Much of the anticancer activity of DSF has been attributed to its copper complex, which has been found 
to exhibit highly efficacious and specific toxicity both in vitro and in vivo through a variety of mechanisms, 
including acting as an inhibitor of activating transcription factor/cyclic AMP-responsive element binding protein 
(ATF/CREB), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), P-glycoprotein, DNA 
topoisomerases, DNA methyltransferases, as a potent inhibitor of the proteasome and of invasion and 
angiogenesis (Cen et al., 2004; Brar et al., 2004; Wang et al., 2003; Loo et al., 2004; Yakisich et al., 2001; Lin et 
al., 2011; Lovberg et al. 2006; Chen et al., 2006). 
  In a previous study, in which we investigated the effects of metformin on cisplatin cytotoxicity in oesophageal 
squamous cell carcinoma (OSCC) cell lines, we established that metformin induces a reducing intracellular 
environment, which whilst protective against cisplatin toxicity, allows cells to be targeted by compounds that 
are activated under reducing conditions. As a case in point, we showed that two copper-bis(thiosemicarbazone) 
compounds, copper diacetyl-bis(4-methylthiosemicarbazonato)copper(II) (Cu-ATSM) and copper glyoxal-bis(4-
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methylthiosemicarbazonato)copper(II) (Cu-GTSM), which are understood to be reductively activated, are highly 
cytotoxic to OSCC cells in the presence of metformin (Damelin et al. 2014). Given these promising results, we 
decided to investigate the effect of the reductively activated DSF and Cu-DSF on OSCC cells in combination with 
metformin; we and others have shown that metformin exhibits excellent antiproliferative effects on carcinoma 
cell lines (Damelin et al. 2014; Quinn et al. 2013).  
In this study, we show that Cu-DSF and interestingly, DSF alone, display considerable cytotoxic activity 
towards OSCC cell lines, and that this cytotoxicity is enhanced by metformin co-treatment.  In addition, we show 
that DSF toxicity is only partially copper-dependent and, for the first time, we identify that a major contributing 
mechanism of DSF toxicity (in OSCC cells) is perturbed lysosomal acidification and autophagic activity, which in 
combination with proteasomal inhibition, confer damage to multiple protein degradation/ turnover pathways in 
these cells.  This study therefore identifies a novel mechanism of action for DSF and highlights the potential use 
of DSF, with or without metformin as a potential chemotherapy strategy for the treatment of OSCC. 
 
 
MATERIALS AND METHODS 
 
REAGENTS 
All reagents were purchased from Sigma Aldrich unless otherwise specified.  
 
SYNTHESIS OF CU-DSF AND DSF ANALOGUES  
Cu-DSF was synthesized by adding equimolar amounts of DSF and cupric chloride in DMSO.  Analogues of DSF 
were synthesized, as previously described (Cramer 1935). 
Dipyrrolidine thiuram disulphide (DPTD) 
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1H NMR (500 MHz, DMSO-d6) δ 3.86 (dt, J = 61.6, 7.0 Hz, 1H), 2.03 (dt, J = 73.0, 6.9 Hz, 1H); 
13C NMR (126 MHz, 
DMSO-d6) δ 187.71, 57.43, 51.40, 26.63, 24.21. 
Tetrapropyl thiuram disulphide (TTD) 
1H NMR (500 MHz, DMSO-d6) δ 3.89 (dt, J = 10.1, 4.9 Hz, 1H), 1.78 (dq, J = 87.4, 7.6 Hz, 1H), 0.92 (dt, J = 57.1, 7.4 
Hz, 2H); 13C NMR (126 MHz, DMSO-d6) δ 192.10, 58.88, 54.89, 21.73, 19.49, 11.42. 
 
CELL CULTURE 
The human oesophageal squamous carcinoma cell (OSCC) lines, WHCO1, WHCO5, (Veale and Thornley, 1989) 
and SNO (Bey et al., 1976) were cultured in DMEM/F12 (3:1) with 10% foetal bovine serum (Lonza) and 100 
U/ml penicillin/0.1 mg/ml of streptomycin, in a humidified atmosphere at 37°C with 5% CO2. OSCC cell lines 
were isolated from moderately differentiated tumours from South African OSCC patients. The SNO cell line 
harbours an p53-R175H mutation (Fanucchi and Veale, 2009).   
 
CYTOTOXICITY ASSAYS 
Cytotoxicity was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay.  
Briefly, 7500 cells per well were seeded into 96-well plates and after 24 hours, exposed to cytotoxic agents DSF, 
Cu-DSF or the DSF analogues DPTD or TTD for a further 48 hours. To determine the effect of metformin on 
cytotoxicity, cells were pre-treated with 10 mM metformin for 24 hours then co-treated with metformin and 
DSF, Cu-DSF or the DSF analogues DPTD or TTD for a further 48 hours.  To investigate the role of copper in DSF 
mediated cytotoxicity, cells were treated as described but with the addition of the cell impermeable copper 
chelator, bathocuproinedisulfonic acid (BCS) (200 µM) (Furuta et al., 2002).  After treatments, the medium was 
replaced with 100 µl of MTT solution (0.5 mg/ml MTT in cell culture medium) and incubated at 37°C for 1.5 
hours. MTT solution was then removed, and MTT formazan dissolved in 100 µl dimethyl sulfoxide (DMSO). 
Absorbance was measured at 570 nm using a Thermo Scientific Multiskan GO microplate reader (n=3±SD).  Cells 
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were also visualized microscopically and images captured on an Olympus BX63 microscope at 40x magnification 
and images processed using CellSense Dimension software. 
 
INDUCTIVELY COUPLED PLASMA MASS SPECTOMETRY FOR COPPER QUANTIFICATION 
Inductively Coupled Plasma - Mass Spectometry (ICP-MS) was used to quantify total intracellular copper levels as 
previously described (Price et al., 2011). Cells were seeded in 100 mm dishes and treated with metformin, DSF 
or metformin and DSF, as previously indicated. Cells were washed with cold 1x Phosphate Buffered Saline (PBS) 
three times, scraped and collected by centrifugation for 10 minutes at 8000 rpm at 4 °C.  A relative portion of 
cells was removed for protein quantification by the Bradford assay (Bradford 1976).  Cell pellets were then 
incubated with 65% nitric acid (Suprapure, Merck) at 65 °C for 2 hours. Samples were then diluted to a final 
concentration of 5% nitric acid and analysed for copper on an Agilent 7700 ICP-MS with He collision gas 
(n=3±SD).  
 
WESTERN BLOTTING FOR AUTOPHAGY AND PROTEIN UBIQUITINATION 
Autophagy and protein ubiquitination were assessed by western blotting by LC3B and total ubiquitinated 
protein levels, respectively. Cells were treated as described above (the positive control was 50 μM chloroquine 
(CQ) for 24 hrs) and harvested in triple detergent cell lysis buffer. Protein was quantified (Bradford assay), 40 µg 
electrophoresed on 5-10% polyacrylamide gels at 25 mA for 45 minutes and protein was subsequently 
electroblotted for 2 hours at 200 mA onto nitrocellulose (Bradford 1976). Membranes were blocked in 5% fat-
free milk powder  in 1xTris Buffered Saline with 0.1% Tween (TBS-T) then incubated with the primary antibodies, 
rabbit anti-LC3B or rabbit anti-ubiquitin (Cell Signalling Technology) in 5% bovine serum albumin in 1xTBS-T 
overnight, following which, membranes were washed in 1xTBS-T and then incubated with a goat anti-rabbit IgG-
horseradish peroxidase (Santa Cruz Biotechnologies). Chemiluminescent signal was obtained with SuperSignal® 
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West Pico Chemiluminescent substrate (Thermo Scientific) and detected using x-ray film.  Densitometry was 
performed using QuantityOne software. 
 
PROTEASOME FUNCTION 
Proteasome function was assessed in treated cells using the fluorogenic proteasome substrate N-Succinyl-Leu-
Leu-Val-Tyr-7-Amido-4-Methylcoumarin (Suc-LLVY-AMC), which indicates levels of chymotrypsin-like activity, as 
previously described (Daniel et al. 2004). Cells seeded at equal density in 100mm dishes were left to settle for 24 
hours then treated with LD30 concentrations of DSF, Cu-DSF or the DSF analogues DPTD and TTD, as for the MTT 
assays, or with the positive control copper-8-hydroxyquinoline (5 μM for 24 hours) (Cu-8HQ), which is a 
previously established inhibitor of proteasomal function (Daniel et al., 2004). Cells were then washed in 1xPBS, 
collected by scraping and centrifugation, lysed in 25 mM Tris-HCl, pH 8.0; 75 mM NaCl; 0.05 % SDS; 0.5 % Triton 
X-100; 0.25 % Sodium deoxycholate, and lysates cleared by centrifugation. Protein was quantified by Bradford 
assay and 40 µg added to assay buffer (50 mM Tris-HCl pH 7.5) to a final volume of 400 µl. Suc-LLVY-AMC in 
DMSO was added to a final concentration of 40 µM and the reaction mixture incubated at 37 oC for 1 hour, 
followed by the addition of trichloroacetic acid to a final concentration of 4% to stop the reaction. Fluorescence 
was measured 360nmexcitation/460nmemission using an Ascent multi-well plate fluorimeter (Thermo Scientific) 
(n=3±SD). 
 
FLUORESCENCE MICROSCOPY FOR ACIDIC VESICULAR ORGANELLE ACIDIFICATION 
Acidic vesicular organelles (AVO), including lysosomes, were visualised using the pH sensitive dye acridine 
orange (AO), which displays a clear shift from red to yellow to green fluorescence, with increasing pH, unlike 
other commercially available dyes (Paglin et al., 2001; Pierzynska-Mach et al., 2014). OSCC cells were grown on 
glass coverslips until 50% confluent then treated with LD30 concentrations of DSF, Cu-DSF, DPTD or TTD, for 24 
hours, with or without 10 mM metformin.  Chloroquine was used as the positive control (1 mM for 1 hour). Cells 
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were then incubated with 3 µM AO added to culture medium for 1 hour at 37 °C. Cells were visualised using the 
Olympus BX41 fluorescence microscope (100 W equipped with a camera and lamp using a 490 nm band-pass 
blue excitation filter and a 515 nm long-pass barrier filter) and images captured and processed with CellSense 
Dimensions software.  
 
ELECTRON MICROSCOPY FOR AUTOPHAGY 
Electron microscopy (EM) was used to look for autophagosome formation (Yla-Antilla et al. 2009). Cells were 
cultured as previously described in 100 mm dishes and when 60% confluent were incubated with 10 mM 
metformin for 24 hours, or LD30 dose of DSF,  metformin plus DSF, Cu-DSF or CuDSF plus metformin. Cells were 
then rinsed with cold 1x PBS three times and then fixed with 2.5% glutaraldehyde in 0.1 M HEPES buffer pH 7.2 
for 1 hour. Cells were then scraped into a microfuge tube and collected by centrifugation at 1000 xg for 10 
minutes. Pelleted cells were routinely prepared for transmission electron microscopy as previously described 
(Hayat 2000). Briefly, pelleted cells were fixed overnight in 2.5% glutaraldehyde in 0.1M HEPES buffer (pH 7.2), 
rinsed several times in HEPES buffer followed by post-fixation in 1% buffered osmium tetroxide for 1 hour, 
repeatedly rinsed, dehydrated in a graded ethanol series (30 minute intervals, absolute ethanol thrice), 
infiltrated with a low viscosity epoxy resin (Agar Scientific®) and polymerised in BEEM® capsules at 70°C 
overnight. 70nm sections were cut on a Leica EM UC6, picked up on 0.25% formvar-coated copper slot grids, 
double stained with uranyl acetate and lead citrate, and viewed at 80kV on an FEI BioTwin Spirit transmission 
electron microscope fitted with an Olympus Quemesa CCD camera. 
 
STATISTICAL ANALYSIS 
All experiments were performed a minimum of three times as indicated. Comparisons were made by Student’s 
t-tests and p < 0.05 was considered statistically significant. LD50 and LD30 values were calculated using GraphPad 
Prism version 6. 
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RESULTS 
 
OSCC CELLS ARE HIGHLY SUSCEPTIBLE TO CU-DSF AND DSF ALONE AND METFORMIN ENHANCES DSF 
CYTOTOXICTY 
MTT cytotoxicity assays indicated that Cu-DSF was highly toxic to all OSCC cell lines (IC50 values: WHCO1 3.6±0.3 
µM, WHCO5 2.8±0.2 µM and SNO 2±0.08 µM) (Fig. 1A and 1B).  Interestingly, DSF alone was also highly cytotoxic 
to OSCC cells with IC50 values of 6±0.4 µM for WHCO1, 6.8±0.3 µM for WHCO5 and 11.9±0.6 µM for SNO cells 
(Fig. 1A and 1B).  The addition of metformin significantly enhanced the cytotoxicity of DSF alone (by 25-40% 
across the three cell lines), but not of Cu-DSF (Fig. 1A and 1B). Cell morphology following treatments reflected 
the findings of the MTT assays (Fig. 1C). 
 
PERTURBED COPPER HOMEOSTASIS IS PARTIALLY RESPOSNSIBLE FOR DSF AND METFORMIN-ENHANCED DSF 
CYTOTOXICTY  
The treatment of OSCC cell lines with DSF and doubling cupric chloride concentrations, with or without 
metformin, indicated that DSF-induced cytotoxicity increased with increasing cupric chloride concentrations (Fig. 
2A), but interestingly, metformin-enhanced cytotoxicity was only observed at low and not at high levels of cupric 
chloride concentrations. This suggested that metformin-enhanced DSF-cytotoxicity was due to increased copper 
transport (leading to increased intracellular Cu-DSF and/or Cu-dithiocarbamate formation), and that this effect is 
saturating at high copper concentrations. To confirm this, intracellular copper levels for DSF treated cells, with 
or without metformin co-treatment, were quantified using ICP-MS analysis. Predictably, DSF-treated cells 
exhibited a significant increase in intracellular copper levels vs. untreated controls; DSF facilitates increased 
copper import via the formation of stable, neutral lipophilic copper complexes (Fig. 2B).  Metformin treated cells 
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exhibited higher intracellular copper levels overall vs. untreated controls while DSF-metformin co-treated cells 
exhibited an additive increase in intracellular copper levels (Fig. 2B), confirming that metformin treatment did 
indeed facilitate increased copper transport and this was most likely responsible for the observed increase in 
cytotoxicity for DSF/metformin co-treatment vs DSF alone. These findings agree with previous investigations, 
which have established that metformin can indeed bind copper and alter intracellular copper levels (Zhu et al, 
2002; Logie et al., 2012).   
   Whilst copper-enhanced DSF toxicity in all OSCC cell lines was significant, we also determined the contribution 
of copper–independent mechanisms of DSF cytotoxicity using the cell impermeable copper chelator, BCS (200 
µM), which was in considerable excess to medium copper levels (range 1.4-4 µM). ICP-MS on cells treated with 
BCS confirmed the reduction in intracellular copper levels (Figure 2B). Interestingly, a significant but only partial 
(approximately 50% for WHCO1 and WHCO5 cells) increase in the LD50 value was observed for DSF-treated cells 
in the presence of BCS vs. DSF alone  (Fig. 2C), indicating that while copper significantly contributed to DSF-
cytotoxicity, copper-independent mechanisms were also involved in DSF-mediated cytotoxicity in OSCC cell 
lines.  
 
DSF PERTURBS MULTIPLE PROTEIN DEGRADATION AND TURNOVER PATHWAYS: 
1. DSF INHIBITS PROTEASOME FUNCTION 
The above observation that DSF alone was cytotoxic to OSCC cells was interesting as previous investigations 
have indicated that cytotoxicity occurs largely through proteasome inhibition by Cu-DSF, and is the primary 
contributor to DSF-cytotoxicity (Cvek and Dvorak 2008). To confirm that DSF treatment inhibited proteasome 
function in OSCC cell lines, we quantified levels of ubiquitinated proteins as a gross indicator of protein turnover 
and observed an increase in total ubiquitinated proteins for DSF and Cu-DSF treated cells, (WHCO1 cells shown 
in Fig. 3A, WHCO5 and SNO cells in supplementary data). Next, proteasome chymotrypsin-like activity was 
fluorescently quantified for DSF-treated cells using the fluorogenic substrate Suc-LLVY-AMC.  This assay 
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indicated that DSF and Cu-DSF markedly reduced proteasome function, with metformin co-treatment 
exacerbating this effect. Cu-8HQ served as an effective positive control for proteasome inhibition (WHCO1 cells 
shown in Fig. 3B, WHCO5 and SNO cells in supplementary data). In order to gain further insight into the 
contribution of proteasome inhibition to DSF-cytotoxicity in OSCC cell lines, two DSF analogues, dipyrrolidine 
thiuram disulphide (DPTD) and tetrapropyl thiuram disulphide (TTD) were synthesized and their effect on 
proteasome activity in OSCC cells tested.  The monomers of DPTD and TTD, namely pyrrolidine dithiocarbamate 
and dipropyl dithiocarbamate, respectively, have significantly smaller decomposition rates than the diethyl 
dithiocarbamate monomer of DSF:  second order decomposition rate constants for pyrrolidine dithiocarbamate, 
dipropyl dithiocarbamate  and diethyl dithiocarbamate are 0.1, 500 and 2.5x104 L mol-1 min-1, respectively 
(Topping and Jones, 1998), but their copper complexes are still expected to exhibit proteasome inhibition, as 
previously established for Cu-(DPTD).  We found that, DPTD and TTD were significantly better at inhibiting 
proteasome function in OSCC cells in comparison to DSF (40% and 20% more effective, respectively) (WHCO1 
cells shown in Fig. 3C, WHCO5 and SNO cells in supplementary data), but importantly, MTT assays revealed 
DPTD and TTD to be far less toxic than DSF for all OSCC cell lines (approximately a log fold and half a log fold less 
toxic, respectively) (WHCO1 cells shown in Fig. 3D, WHCO5 and SNO cells in supplementary data).  
   Collectively, these results suggested that: (1) proteasome inhibition by Cu-DSF was only a partial contributor to 
DSF-induced cytotoxicity in OSCC cell lines and (2), that the intracellular decomposition of the DSF monomer, 
DDC, may be important for DSF-induced cytotoxicity.           
 
2. DSF ALTERS LYSOSOMAL ACIDIFICATION  
Dithiocarbamates are acid labile and rapidly break down at low pH to their parent amine and carbon disulfide. 
We therefore hypothesized that since the decomposition rates of the monomers (dithiocarbamates) for DSF, 
TTD and DPTD were found to be proportional to their cytotoxicities, a potential novel mechanism of toxicity for 
DSF could be via its diffusion into lysosomes, its conversion to acid labile DSF and subsequent decomposition of 
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DSF within the low pH (~4) lysosomal environment to diethylamine and carbon disulfide, resulting  in amine 
accumulation within lysosomes,  amine-dependent lysosomal alkalinisation,  and ultimately, reduced lysosomal 
function.  Therefore to investigate the effect of DSF and DSF analogues on lysosomal pH, cells were treated with 
LD30 levels of DSF, DPTD and TTD with or without cupric chloride and then stained with AO and examined by 
fluorescent microscopy. AO is a weekly basic, lysomsomotropic fluorescent dye, which upon accumulation in 
AVOs, including lysosomes, exhibits a red shift in fluorescence. Therefore acidic lysosomes stained with AO 
display orange/red fluorescence while lysosomes with reduced acidity display a progressive shift to yellow then 
green fluorescence with increasing alkalinisation.  DSF treated cells displayed a marked increase in AVO 
(lysosomal) pH and this effect was exacerbated by the presence of copper, where overall fluorescence was both 
shifted towards green (DSF alone) and also reduced in intensity (Cu-DSF) in comparison to untreated controls, as 
seen across all OSCC cell lines (Fig. 4).  DPTD had a minimal effect on lysosomal pH, with and without copper, 
while TTD treatment alone had a minimal effect on lysosomal pH while some reduction in overall fluorescence 
was observed in the presence of copper (Fig. 4). Chloroquine, a standard lysosomal alkaliniser, which served as a 
positive control, completely dissipated lysosomal pH as expected, as evidenced by bright green lysosomes (Fig. 
4). These results strongly indicated that DSF did indeed perturb lysosomal pH/function and supported the above 
hypothesis that diethyl dithiocarbamate decomposition within lysosomes and subsequent diethylamine-
dependent lysosomal alkalinisation may be responsible for this effect.  DPTD and TTD, that have monomers with 
significantly smaller decomposition rates than the monomer of DSF (diethyl dithiocarbamate), exhibited a 
minimal effect on lysosomal pH, as would be expected for this model to be valid.  
       
3. DSF INHIBITS AUTOPHAGY  
Damaged lysosomal function leads to perturbed autophagy (Yang et al. 2011). We observed, by electron 
microscopy, that a representative OSCC cell line (WHCO1) exhibited numerous autophagic vesicles, which 
increased in number and size after metformin treatment (Fig. 5A), indicating a highly autophagic phenotype for 
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OSCC cells and potentially, as with many other cancer cell lines, a high susceptibility to autophagic perturbation. 
We therefore investigated the effect of DSF on autophagic activity by assessing LC3B levels in OSCC cell lines. 
Cells treated with DSF exhibited a significant increase in LC3B-II relative to -actin in response to DSF treatment 
and this effect was highly exacerbated by metformin, copper and copper/metformin co-treatment (Fig. 5B), 
suggesting that both perturbed lysosomal function and copper-DSF mediated oxidative effects acted in concert 
to severely damage autophagic function in Cu-DSF treated cells, and this is not surprising given the sensitivity of 
the autophagic cascade to altered redox state (Filomeni et al., 2010).  Electron microscopy further supported the 
above findings in that DSF-treated cells contained large irregular autophagosomes while DSF-metformin treated 
cells exhibited a considerable accumulation of autophagosomes with poorly cleared autolysosomes. This 
suggested an inhibition in the maturation of autophagosomes to autolysosomes, which occurs upon fusion of 
the autophagosome with the lysosome, and is a potential consequence of perturbed lysosomal function (Fig. 
5A).  Cu-DSF and Cu-DSF-metformin treated cells exhibited vacuolization (Fig. 5A) along with a significant 
increase in LC3B-II (Fig. 5B), which is likely to be indicative of cell death with autophagy (Kroemer et al 2009). 
 
 
DISCUSSION 
 
Cancer cells have a higher dependence on protein degradation and turnover pathways than normal cells, in 
order to accommodate for their elevated metabolic rates (Mancias and Kimmelman, 2011; Molineaux 2012). 
These pathways comprise the ubiquitin-proteasome system, where proteins are targeted by polyubiquitination 
for degradation by the proteasome; and lysosomal proteolysis, which involves the degradation of proteins by 
proteases in this acidic organelle.  This latter pathway also includes autophagy since autophagosomes, 
containing cellular material for degradation, fuse with lysosomes to form autolysosomes, in which organelles 
and proteins are degraded (Yang et al. 2011).  Cancer cells are therefore very sensitive to inhibition of these 
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pathways and this has led to the identification and development of new classes of inhibitors that have a greater 
effect on cancer cells over normal cells; proteasome inhibitors and modifiers of autophagy such as bortezomib 
and hydroxychloroquine, respectively, are under extensive clinical trial evaluation (Molineaux 2012). 
   In recent years, DSF (and Cu-DSF), has been shown to exhibit anticancer properties both in vitro and in vivo 
(Cvek, 2011).  We have found in this study that both Cu-DSF and DSF are highly cytotoxic to OSCC cells lines. 
OSCC is a particularly aggressive carcinoma and there are very few treatment options, especially in the resource 
poor countries in which OSCC is prevalent (Ilson 2008; Ferlay et al., 2010), and as such, drug ‘repurposing’ is an 
attractive prospect.  DSF displays a high specificity in its toxicity towards cancer cells. We show that in addition 
to proteasome inhibition, which is evidenced in this study and has been previously documented (Cvek and 
Dvorak 2008), DSF also perturbs AVO (lysosomal) acidification and subsequently autophagy (an effect greatly 
enhanced by copper) in OSCC cells. This simultaneous inhibition of multiple protein degradation/turnover 
pathways in cells that are so highly dependent on these processes, may additionally explain the cancer-cell 
specific toxicity of DSF over normal cells.   
   In this study we also show that metformin, which is highly anti-proliferative in OSCC cells (Damelin et al., 
2014), significantly increases DSF cytotoxicity. We have shown that a major reason for this is a metformin-
dependent increase in copper transport but as metformin also induces a reductive phenotype in OSCC cells 
(Damelin et al., 2014), metformin treatment may increase the rate of reduction of DSF to its monomer, diethyl 
dithiocarbamate, the decomposition of which is likely responsible for lysosomal alkalinisation. Electron 
microscopy in this study, and in previous studies, also indicate that metformin may increase autophagy (Tomic 
et al., 2011), therefore also potentially increasing cell susceptibility to DSF-dependent autophagic perturbation.  
   Our findings therefore highlight the potential use of DSF in OSCC therapy and the use of metformin/DSF as a 
highly efficacious and economical drug therapy combination in the treatment of this highly aggressive 
malignancy. Such ‘repurposing’ of existing drugs that are already very well characterised could be particularly 
beneficial in resource poor settings where OSCC is prevalent.   
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FIGURE LEGENDS 
Fig. 1. Cu-DSF and DSF are highly cytotoxic to OSCC cells and DSF cytotoxicity is enhanced by metformin. 1A. 
Cells exposed to Cu-DSF and DSF for 48 hours show considerable cytotoxicity across all three OSCC cell lines with 
a significant leftward shift in toxicity curves for Cu-DSF  (n=3, mean±SD). 1B. The addition of 10mM metformin 
further enhanced DSF cytotoxicity and whilst Cu-DSF was considerably more toxic than DSF alone, the addition 
of metformin to Cu-DSF did not significantly change cytotoxicity (n=3, mean±SD). 1C. Cell morphology mirrored 
the observations of the MTT assays.  
 
Fig. 2. Copper is partially responsible for DSF toxicity and metformin causes increased copper uptake by OSCC 
cells  
2A. The role of copper in DSF toxicity was observed by increasing copper concentrations to equimolar molar 
levels of copper and DSF, which had an increasing effect on cytotoxicity as seen by the significant leftward shift 
in toxicity curves with increasing copper concentration (n=3, mean±SD). 2B. Measurement of intracellular 
copper by ICP-MS showed that as expected DSF treated cells had significantly higher copper levels than 
untreated cells. Interestingly OSCC cells treated with 10 mM metformin had, overall, higher intracellular levels of 
copper in comparison to untreated controls. The effect of metformin compounded that of DSF, with DSF-
metformin co-treated cells displaying higher copper levels than DSF alone (values expressed per µg of protein), 
(n=3, mean±SD. 1D).  Copper content of cells was also assessed in the presence of a cell impermeable copper 
chelator bathocuproinedisulfonic acid (BCS) to confirm the reduction in intracellular copper, as anticipated. 2C. 
The contribution of copper to cell cytotoxicity was further assessed by the addition of BCS (100 µm), which 
partially reversed the cytotoxic effects of DSF. All values are expressed as % change in LD50 relative to DSF alone 
(n=3, mean±SD). 
 
This article is protected by copyright. All rights reserved 24 
Fig. 3. DSF inhibits proteasomal function.  
3A. OSCC cells treated with LD30 concentrations of DSF for 48 hours had higher amounts of total ubiquitinated 
proteins in comparison to untreated controls. Metformin (Met) treated cells (10 mM for 24 hours) had slightly 
lower levels, as did cells treated with both DSF and metformin; as expected, chloroquine treated cells showed 
high levels of total ubiquitinated proteins. 3B. Proteasomal function for chymotrypsin-like activity using the 
fluorogenic peptide LLVY-AMC showed that, as expected, DSF decreased proteasome function.  Interestingly, 
metformin also had an inhibitory effect with slightly decreased fluorescence exhibited, and when combined with 
DSF or copper-DSF, proteasome activity was even further diminished. The positive control, Cu-8HQ, caused a 
considerable reduction in fluorescence as expected, (n=3, mean±SD). 3C. DPTD and TTD, two analogues of DSF 
that have lower rates of decomposition and thiol exchange, inhibited proteasome function more effectively in 
comparison to disulfiram. 3D. DPTD and TTD displayed lower levels of OSCC cell toxicity in comparison to their 
respective controls (n=3, mean±SD) (all data shown for WHCO1 cells).  
 
Fig. 4. DSF decreases AVO (lysosomal) acidification. 
Lysosomal acidification as visualised by AO staining shows a shift from red (low pH) to yellow to green (higher 
pH).  DSF treated and metformin-DSF (DSF + Met) co-treated cells clearly had yellow lysosomes, in comparison 
the red lysosomes in untreated cells, clearly indicating an increase in pH of these organelles upon DSF 
treatment. Cu-DSF and metformin-Cu-DSF (Cu-DSF + Met) treatment was highly cytotoxic to cells. Cells treated 
with the known lysosomal inhibitor chloroquine (CQ) (1 mM for 1 hour) as the positive control, had only green 
lysosomes, as expected. The DSF analogues DPTD and TTD did not show the same extent of perturbation of 
lysosomal acidification as DSF. 
 
Fig. 5. DSF inhibits autophagy. 
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5A. Electron microscopy showed a small increase in the numbers of autophagosomes and autolysosomes in 
metformin (Met) only treated cells. DSF only treated cells also exhibited increased numbers of autophagosomes, 
in comparison to untreated control. Interestingly, metformin-DSF (DSF+Met) co-treated cells, showed a 
considerable accumulation of autophagosomes (single arrow) with protein aggregates and far fewer cleared 
autolysosomes (double arrow).  Cu-DSF and metformin-CU-DSF (Cu-DSF+Met) treated cells show considerable 
vacuolization (dashed arrow).  5B. Autophagy by LC3B western blot showed that metformin (Met) alone did not 
significantly alter autophagy but that DSF alone treated cells had slightly higher LC3B-II levels relative to β-actin 
in comparison to untreated controls (Un), but that for metformin-DSF (DM), Cu-DSF (CuD) and metformin-CuDSF 
(CuDM) treated cells this increase in LC3B-II was significant. The positive control chloroquine (CQ) displayed a 
large proportion of the LC3B-II form as expected. 
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